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1. Background 
 
 
This volume contains the research methodology used in the first General Population Drug 
Prevalence Survey in Ireland and Northern Ireland, conducted by MORI MRC on behalf of the 
National Advisory Committee on Drugs (NACD) in Ireland and the Drug and Alcohol Information 
Research Unit (DAIRU) at the Department of Health, Social Services and Public Safety (DHSSPS) in 
Northern Ireland.   
 
1.1 Background 
 
As part of the EU Action Plan on Drugs 2000-2004 the relevant national bodies were asked to co-
operate in measuring the prevalence of drug use in their jurisdiction according to a common set of 
measures. This study is intended to fit into this EU-wide framework.  
There are five key indicators of drug misuse identified by the European Monitoring Centre for Drugs 
and Drug Addiction (EMCDDA) which each member state is expected to measure: 
1. Extent and pattern of drug use in the general population 
2. Prevalence of problem drug use 
3. Demand for treatment by drug users 
4. Drug-related deaths and mortality of drug users 
5. Drug-related infectious diseases (HIV, Hepatitis)  
 
Consequently, the data produced in any given member state can be comparable and consistent 
with that produced for other countries to enable the cross analysis and benchmarking of data 
between member states.  To ensure this, clear guidelines1 have being put in place by the EMCDDA 
in relation to the methodology and the outputs of the research. 
 
On the island of Ireland, the NACD and the DAIRU worked together in commissioning this research 
into the prevalence of drug use in Ireland and Northern Ireland respectively.    Their collaboration 
brings an all island perspective to drug prevalence whilst maintaining individual responsibility to 
provide information to their respective Governments. 
 
The goal of the NACD is, in its own words, “… to advise the Government on problem drug use in 
Ireland in relation to prevalence, prevention, consequences and treatment based on our analysis 
and interpretation of research findings”.  The committee was founded in response to the increasing 
drug problem in Ireland and its role is an advisory one to the Government.  It has five areas of 
interest– prevalence, prevention, treatment/rehabilitation, consequences and early warning 
emerging trends.  For the purposes of this research the focus was on the area of prevalence – how 
many people take drugs, what types of drugs, how frequently, at what age, and in what areas. 
 
The DAIRU was established in May 2001 to develop and manage a programme of information and 
research work in support of the joint implementation of the Northern Ireland Executive’s Drug and 
Alcohol Strategies.  Similar to the NACD, its role is the development of a programme of drug and 
alcohol information. 
                                                           
1 EMCDDA PROJECT CT.99.EP.08 B  Handbook for Surveys on Drug Use Among the General Population  Final 
Report  August 2002   
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In examining available data sources relating to prevalence in Ireland, the NACD identified a gap in 
knowledge existed relating to drug use in the general population.  The Drug Misuse Research 
Division (DMRD) of the Health Research Board, a member of the NACD, presented a paper to the 
committee in March 2001 highlighting the action to be taken.  Discussions ensued at subsequent 
NACD and Prevalence sub committee meetings culminating in agreement to commission a general 
population survey.  It was decided to seek a partner(s).  Communication issued to various 
Government Departments and to Northern Ireland.   
 
At a meeting in March 2002 in Dublin, DAIRU agreed to consider the possibility of collaborating 
with NACD in conducting an all island study subject to sourcing funding and agreeing on survey 
details.  A letter was dispatched on 28th March 2002 to Ms Jo Daykin, Head of the Drug Strategy in 
Northern Ireland to formally seek their collaboration in this project and to commit to joint funding 
an all island survey (Appendix A).  As DAIRU had already been discussing how they might obtain 
information about drug use in the population this was a timely communication. 
 
The NACD sought additional funding partners in the Health Promotion Unit of the Department of 
Health and Children as they provide funding for a health and lifestyle national survey, which is 
carried out every five years.  The Health Promotion Unit agreed to provide financial support for the 
detailed analysis of the survey data at a later stage in the project. 
 
Both Governments released a statement (Appendix B) announcing the collaboration and intention 
to commission a general population survey of drug use among those aged 15-64 years, using a 
face-to-face survey technique to be carried out in respondents’ homes, using a random sampling 
methodology and based on a tailored model of the EMCDDA questionnaire based on EMCDDA 
guidelines. 
 
PLANNING AND COMMISSIONING PROCESS 
 
A Research Advisory Group (RAG) was formed to oversee the commissioning process and to 
support the implementation of the survey to the EMCDDA standard.   The membership comprised 
of representatives (in alphabetical order) from DAIRU and the NACD: 
Buchanan, Mr Damian, Statistician, DAIRU and DHSSPS, (2002-2003) 
Corrigan, Dr Des, Chairperson, NACD and School of Pharmacy, Trinity College, Dublin  
Kelly, Mr John, NACD and Department of Community Rural & Gaeltacht Affairs  
Lyons, Ms Mairéad, Director, NACD 
Moore, Mr Kieron, Principal Statistician, DAIRU and DHSSPS 
McWilliams, Mr Brian, Statistician, DAIRU and DHSSPS, (2004 - 2006) 
O’Gorman, Dr Aileen, Research Officer, NACD, (2002 - 2005) 
Rogers, Mr Dave, Principal Statistician, DAIRU and DHSSPS, (2002 -2004) 
Sinclair, Dr Hamish NACD and Drug Misuse Research Division of the Health Research Board  
Stack, Ms Kathleen, NACD and Department of Community Rural & Gaeltacht Affairs (2002 -2004) 
 
The RAG set about agreeing the structure of the survey and whether changes should be made to 
the EU standard questionnaire.  It was important to have considered these issues in order to issue 
a tender notice.  The public procurement process according to EU Directives is a lengthy one, 
allowing 37 days for the Contract notice (Appendix C) and 40 days for the submission of tenders.  
All these days must be working days and the notices of the expressions of interest and the request 
for tender were put in the Official Journal of the European Union.   
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Between March 2002 and December 2003 the RAG met on 25 occasions, alternating meetings 
between Belfast and Dublin where possible.  On at least six of these occasions the RAG met with 
MORI MRC.  Members of the RAG also participated in the five briefing sessions to field workers 
conducted by MORI MRC. 
 
During this time between May and August 2002 the RAG continued to meet to draft the 
questionnaire, which included agreeing the following issues: 
• Determining quitters; 
• Using a filter question; 
• Including Nubain®  and steroids;  
• Need to get street names for the drugs under investigation; 
• Separate or combine sedatives and tranquillisers; 
• Whether to ask if named drugs have been used on the same occasion; 
• What type of cannabis is used; 
• What method is used to consume cannabis; 
• Drug market questions; 
• Positioning of drugs in a particular order; 
• Need to distinguish between cocaine and crack; 
• Mode of use for cannabis and heroin is important; 
• Drop relevin from the questionnaire; 
• Include magic mushrooms;  
• Include or drop methadone; 
• Include knowledge attitudes questions. 
 
1.2 Research Objectives 
 
The core objective of the research was to provide robust data regarding the prevalence of (licit and 
illicit) drug use amongst the general population.  The provision of estimates for both jurisdictions 
and on an all island basis was the priority of the research.  
 
The tender brief stated that the survey would be based on the guidelines produced by the EMCDDA 
which states its main aims as follows: 
(1) to report prevalence and continuation rates of the most common illicit drugs in the 
general population by gender and age groups; 
(2) To allow cross country assessment of relationships between general patterns of use of 
illicit and licit drugs; 
(3) To allow the assessment of relationships between particular population attributes and 
the use of illicit drugs. 
 
There were, however, a number of requirements in terms of the study’s results, which made it 
comparatively difficult to conduct.  In some respects the study would be judged on the degree to 
which its results would: 
• be reliable, in that overall results are statistically reliable estimates of the prevalence of drug 
use in each jurisdiction and on the island as a whole 
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• be comparable between both jurisdictions and as far as possible with similar studies being 
conducted throughout the European Union 
• allow analysis of results in terms of a variety demographic factors 
• be simple for staff at the NACD, the DAIRU, for policymakers and others in Ireland and across 
the EU to use 
 
To meet the objectives of the study, a target of 7,600 interviews (4,100 in Ireland and 3,500 in 
Northern Ireland) was set and a final sample size of 8,434 interviews was achieved (4,918 in 
Ireland and 3,516 in Northern Ireland).   
 
The survey was carried out using the EMCDDA Model Questionnaire with some modification and 
face to face interviewing method amongst 15 to 64 year olds.  Information on lifetime use, last 
year use, last month use was to be gathered using a random sampling method.  
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2. Survey Design 
 
2.1 Target Population 
 
It is important in any research study to carefully define the universe.  For this study, it was defined 
in the RAG’s brief to MORI MRC as “a household survey of all aged between 15 and 64 years old, 
living in private households in Ireland and Northern Ireland.   
 
RESIDENCY 
 
As the EMCDDA Handbook observes surveys of this nature are typically conducted in the 
respondent’s home for methodological and practical reasons2.  Among the reasons in this particular 
instance was the length of the questionnaire.  The 20 minutes interviewing time dictated that the 
interview needed to be conducted in the respondent’s home and not on the street; moreover the 
sensitive nature of the subject matter lent itself better to the more confidential surroundings of the 
person’s home.  It was felt that respondents would feel uncomfortable being approached in a 
street setting to discuss their licit and illicit drug intake and more practically respondents would not 
be willing to partake in such a relatively long survey “on-street”.  Also the home provides a more 
focussed environment for conducting research, with little disturbance or interruptions that would 
distract respondent attention, whilst interruptions can occur in such a setting they can be kept to a 
minimum, thus providing the interviewer with the respondents complete and full attention.  The 
home also provides a more relaxed and less hurried background, allowing respondents the 
opportunity to think about and consider their answer as opposed to giving a hurried response.   
 
Since this survey was conducted in the home, it follows that the target population for this study 
included all those usually resident within each jurisdiction and within the Health Board3 to which 
their responses are assigned.  With a few exceptions (e.g. prisons, the homeless etc.), this covered 
the population of both jurisdictions. 
 
In practice, this meant that all residential addresses could be contacted as part of this survey.  
Lodgers and boarders living at an address were included in the target population.  If a selected 
person was away from home at the time of the initial contact, they were to be included in the 
selection process and contacted later.  On the other hand, separated spouses, students and those 
working away from home were excluded if their usual residence was elsewhere.  Due to the 
practicalities of conducting research within a finite timeframe, persons who were usually resident at 
an address but who were away for six months or more were excluded. 
 
AGE 
 
In terms of age there were two sections of the population, which have been deliberately excluded.  
The first of these are the under 15s who have been excluded in line with EMCDDA guidelines and 
to be comparable with similar studies elsewhere in the European Union.  Under Market Research 
                                                           
2 EMCDDA Handbook for Surveys on Drug Use Among The General Population (2002), P.80 
3 Since January 2005 the Health Boards in Ireland have undergone restructuring and are merged under one authority – 
the Health Service Executive (www.hse.ie). The above reference relates to the Health Board structure as detailed in 
Bulletin 2: Drug Use in Ireland and Northern Ireland 2002/2003 Drug Prevalence Survey: Health Board (Ireland) & 
Health and Social Services Board (Northern Ireland) Results (Revised)  
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Society guidelines, it is only permissible to interview 15 year olds and under with the written 
consent of their parents or guardian.  Therefore, in order to include 15 year olds in this study, the 
written consent of their parents or guardians was obtained. It should be noted that the 
parent/guardian has the right to sit in on the interview, if they so wish.  As this may influence the 
responses given by the respondent, interviewers were instructed to explain the importance of 
conducting the interview in private.  The table below outlines the numbers of 15-year-old 
respondents, who conducted the interview in the presence of a parent/guardian. 
 
 Ireland Northern Ireland Total 
Parent present 30 36 66 
Parent not present 52 17 69 
Not stated 1 - 1 
 
The second age group which was excluded were people aged 65 and over.  This group was 
excluded because, as the EMCDDA points out, responses from respondents in this group may be 
less reliable (due to effects of memory) and in any case the prevalence of (lifetime) drug use 
amongst this group is not expected to be very high4. 
 
AUDIENCES OUTSIDE THE SCOPE OF THIS STUDY 
 
For practical reasons, it was decided not to set out to deliberately achieve interviews with the 
homeless, those in residential care and those in institutions, such as prisons.  Although it was 
recognised that these were, indeed, potentially important audiences, it was felt that research with 
these groups would be best treated as part of a separate research exercise.   
 
SIZE OF TARGET POPULATION 
 
The chart overleaf provides the latest known population figures at the time of commencing 
fieldwork. For Northern Ireland, these were taken from the 2001 Census. As data for Ireland had 
not yet being released by detailed age breakdown, population estimates for 2002 for the 
population aged 15-64 was used based on data from the 1996 Census.  As detailed in subsequent 
sections, 2001 Census figures for Northern Ireland and 2002 Census figures for Ireland were used 
for the purposes of re-weighting results. 
 
                                                           
4 EMCDDA Handbook for Surveys on Drug Use Among The General Population (2002) p.79 
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 Total % Sample Sizes 
Ireland Eastern 876,617 37.26% 1,580
 Midland 128,625 5.47% 315
 Midwestern 203,709 8.66% 424
 Northeastern 193,667 8.23% 433
 Northwestern 129,523 5.51% 332
 Southeastern 249,334 10.60% 604
 Southern 352,507 14.98% 746
 Western 218,799 9.30% 484
  
 2,352,781 100.00% 4,918
  
Northern  EHSSB 430,909 39.50% 1,393
Ireland NHSSB 278,371 25.52% 877
 SHSSB 199,438 18.28% 655
 WHSSB 182,272 16.71% 591
  
 1,090,990 100.00% 3,516
  
 Total 3,443,771 200.00% 
  
2.2 Mode of Interviewing 
 
The nature of the project demanded quantitative research as the study entailed producing robust 
statistical information on drug use on an all island basis, and for both Ireland and Northern Ireland.  
In line with the EMCDDA’s “preferred method”, the research was conducted on a face-to-face 
basis.  As noted in the preceding section, the subject matter and length of the questionnaire, lent 
themselves to interviewing in the home.  However, in deciding on a methodology it also had to be 
considered whether the questionnaire should be completed by the interviewer or by the respondent 
(self completion); and whether the data should be recorded electronically using Computer Assisted 
Personal Interviewing (CAPI) or by a pen and paper method. 
 
SELF-COMPLETION VERSUS INTERVIEWER-COMPLETION 
 
In choosing the means of completing interviews the project team were guided by the EMCDDA’s 
Handbook for Surveys on Drug Use Among The General Population, which recommended that 
questionnaires be completed by interviewers and not by the respondent themselves.  One reason 
for this, the handbook notes, was that “illiterate people either will not respond or will give 
unreliable answers (to mail)”5. If respondents deselected themselves because of reading difficulties 
this would have had serious implications with regards to undermining the validity of the research.  
This is particularly true, since both drug use and illiteracy problems may be more prevalent within 
the marginalized communities and amongst the more disadvantaged members of society. 
                                                           
5 EMCDDA, Handbook for Surveys on Drug Use Among The General Population, (2002), P.82  
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The latest figure from the OECD6 suggests that for almost a quarter (23%) of the population in the 
Ireland, aged between 25 to 64, their highest educational achievement was pre-primary or primary 
education. This, placed alongside illiteracy figures of 25%7, reinforced the expert views of the 
EMCDDA that a “self-completion” format would alienate a sizeable section of the population, who 
may have difficulty reading and understanding fully the questionnaire.  Moreover, estimated 
dyslexia figures of between 1 in 8 and 1 in 108 of the population in both Ireland and Northern 
Ireland further support the soundness of conducting an “interviewer-completion” survey.   
 
As part of the Interview Quality Control Scheme (IQCS), all interviewers had undertaken a rigorous 
training schedule which was ongoing so interviewers did not become complacent in their work.  At 
all stages during the interviewing process, it was impressed upon the fieldforce the necessity of 
keeping to the script as outlined.  Given this, little variation in putting questions to respondents 
was expected. 
 
It was not foreseen that the subject matter in itself would be a source of embarrassment or 
discomfort for respondents.  Indeed certain illicit drug taking no longer has the social stigma 
previously attached to it (although it may still have in certain age categories), though of course, it 
was not asserted that it was socially acceptable.  Nevertheless, as the EMCDDA point out there is 
the possibility that respondents may consciously or unconsciously give what they consider to be the 
socially or politically correct answer to any given question.  It was felt that this could be reduced 
through the judicious use of show cards, which interviewers read out (to aid those with illiteracy 
problems/partially sighted).  These had a letter pre-fix for each response in order to lessen the 
discomfort of respondents, as they only needed to call out the letter accompanying each 
statement/answer.  It should also be borne in mind that the presence of an interviewer in a face-
to-face interview “provides the best context for stimulating respondents to answer”9. 
 
COMPUTER ASSISTED PERSONAL INTERVIEWING VERSUS PEN AND PAPER 
 
When looking at how the data would be gathered by the interview, the project team was once 
again guided by the EMCDDA Handbook, which suggested that the choice should be determined as 
much by the practicalities of conducting a survey in a given country as by purely methodological 
considerations10.  The choice of how interviewers were to physically record responses is one 
example of this.  Although recording answers directly onto laptop or notebook computers is 
commonplace in other countries, at the time that this survey took place, no research agency could 
offer a Computer Assisted Personal Interviewing (CAPI) service for the entire island of Ireland.   
 
As part of the quality control procedures for this project, respondent details were taken so that 
interviews could be back-checked and responses verified11. This was critical for any quality 
guarantees attributed to the data collected, and for such an important piece of research it was 
                                                           
6 Organisation for Economic Co-operation and Development – Education at a Glance 
7 Education Research Centre – Department of Education Ireland (1997) 
8 Irish Dyslexia Association / British Dyslexia Association 
9 EMCDDA, Handbook for Surveys on Drug Use Among The General Population, (2002), P.84 
10 EMCDDA, Handbook for Surveys on Drug Use Among The General Population, (2002), P.79 
11 As part of our MORI MRC’s IQCS procedures, 22% of interviews and contacts were back-checked to ensure 
their accuracy (ie 23% of interviews/contacts in Ireland, 21% of interviews/contacts in Northern Ireland). 
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essential.  For anonymity, and to reassure respondents, any personal details were noted on a 
separate sheet as opposed to details being recorded directly on to the questionnaire.   
   
In summary, the RAG and MORI MRC decided that, the project should be an interviewer-completed 
questionnaire, in the respondent’s place of residence, with data recorded using pen and paper. 
Although this does offer some advantages, as detailed above, the main reason this approach was 
taken was largely because no contractor could demonstrate they possessed a sufficiently 
established CAPI capability covering the entire Island of Ireland. 
 
2.3 Sampling 
 
Population surveys on drug use, in common with most other surveys, are usually conducted among 
a sample of the entire target population because it is not practical, nor cost or time-efficient to 
interview every single individual in the population. 
 
A survey is only as good as its sample.  This is especially true of a population survey such as this, 
where the key objective is to provide for reliable national estimates of the prevalence of drug use 
in Ireland to feed into public policy making.  
 
QUOTA VERSUS RANDOM SAMPLING 
 
The EMCDDA Handbook suggests that “in prevalence studies, as in social studies in general, it is 
usually not possible to make assumptions (about the distribution of survey variables in the 
population) and, as a consequence probability sampling should almost be considered mandatory”12.  
Given that collecting accurate, up-to-date profile data was a key aim of the survey, the RAG and 
project team felt that a similar approach should be used here, despite it being more expensive in 
comparison to equivalent commercial market research surveys.   
In most commercial surveys, quota sampling is generally used.  This approach takes data from the 
most recent Census to set fixed quotas of people to be interviewed in each sampling point (in this 
case it would be EDs in Northern Ireland and DED/Electoral Wards in Ireland).  Using this method, 
quotas are set to reflect the socio-demographic profile of residents, on characteristics such as sex, 
age, work status, and where relevant ethnicity.  The critical drawback to this approach for this 
particular survey is that the profile of residents would effectively have to be set by the Census 
data, which at the time of starting fieldwork was over ten years old in Northern Ireland and six 
years old in Ireland.  In the particular context of a prevalence survey, the use of quotas may also 
exaggerate the impact of clusters of population who may or may not use drugs.  As drug use is 
known to take place in clusters this would either over- or under-represent the true prevalence.  
The drawbacks of adopting a quota sampling approach clearly made this approach inappropriate 
for this survey, given the high standards of accuracy sought by the RAG.  
 
Rather than using quota sampling the project team opted for stratified random sampling and the 
RAG agreed.  This avoided the problems mentioned above, as actual addresses were drawn at 
random and allocated to the interviewers.  As the selection of addresses lies at the heart of a 
stratified random survey, interviewers made many call-backs to specific addresses until there was 
an outcome (for example, interview achieved, refused, no contact after a minimum of five calls, 
                                                           
12 EMCDDA Handbook for Surveys on Drug Use Among The General Population, (2002), p.97 
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etc).  In order to maximise the opportunity of achieving an interview, callbacks took place at 
different times of the day including evenings, and on different days of the week including 
weekends.  Not only were interviewers sent to specific individual addresses, but they were also 
given strict procedures to follow for selecting the respondent within each household.  While this 
made the stratified random sampling approach more complicated, it also helped provide a more 
accurate reflection of the population and followed the EMCDDA’s suggestion that such an approach 
be followed.13 
To ensure confidentiality and anonymity, no interviewers were to conduct the research in their 
immediate locality, thus reducing the likelihood that interviewers would speak to an acquaintance, 
relation, friend or relative.  Needless to say, when such a situation arose a replacement interviewer 
was found to conduct the interview. 
 
2.4 Sample Frame 
 
As a randomly drawn sample, this survey was one in which every member of the defined 
population (in this case, those aged 15-64) had a calculable chance of being included in the 
sample.  If every member of the defined population was to have a chance of being included in the 
sample, it follows that every member of the defined population must be known in order to have 
that chance.  Therefore, the first step in drawing a random sample was to make a list of all the 
members of the population, and this became the “sampling frame”.   
 
It was important that the sampling procedures for both Northern Ireland and Ireland be as similar 
as possible.  A number of different approaches for drawing the sample frames were possible and 
each had its limitations.  The solution, therefore, was to find the approach, which minimises these 
limitations.   
 
ELECTORAL REGISTERS 
 
One obvious approach would have been the use of electoral registers in both Northern Ireland and 
Ireland.  However, based on the experience of the project team, the electoral registers have a 
number of shortcomings.  The biggest of these was their well-known tendency to under-represent 
certain households, such as the more mobile and disadvantaged or marginalised communities, 
where voter registration was considered to be low.  It was the understanding of the project that 
the use of the electoral register for non-electoral purposes could have caused problems under the 
Data Protection Acts in Northern Ireland14.  
 
VALUATION AND LANDS AGENCY 
 
An alternative approach might have been to use the Valuation and Lands Agency (VLA) list in 
Northern Ireland.  However, in common with the electoral register this list is also far from complete 
and its use may also have raised similar data protection issues.  In any event, a sufficiently similar 
list does not exist in Ireland, which could have made comparing the two jurisdictions more difficult.   
                                                           
13 Details of interviewer callbacks are dealt with in the Response Rates section 
14 The ruling in the case of R -v- City of Wakefield Metropolitan Council & another ex parte Robertson (16 November 
2001) suggests that purchase of the electoral register by commercial concerns may be unlawful under the UK’s Data 
Protection Act 1998. 
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POSTAL ADDRESS FILE (NORTHERN IRELAND) & AN POST/ORDINANCE SURVEY IRELAND GEO-DIRECTORY 
 
The Postal Address File (PAF) smaller user file, maintained by the Post Office, was used as the 
primary sampling frame for this study in Northern Ireland and the An Post/Ordinance Survey 
Ireland Geo-Directory, as the primary sampling frame in Ireland.  Both of these files are 
comprehensive, regularly updated, and provide both a high degree of accuracy and the 
comparability of approach between the two, which was required in this study.  As these lists are 
based on buildings and not electoral lists, they do not under-represent any groups in the 
community, nor does their use contravene the provisions of the Data Protection Act. 
 
SAMPLING FRAME – NORTHERN IRELAND 
 
The “Robertson judgement” (see footnote 14) which prohibited the use of the electoral register for 
market research is of particular relevance to Northern Ireland, as part of the United Kingdom.  As a 
result, the Post Office’s PAF listing was used.  This is an extremely reliable and up-to-date sampling 
frame.  It is based on addresses, which the Post Office uses to deliver mail in Northern Ireland (and 
the rest of the UK) and is derived from information collected for each postal round.  Consequently, it is 
both comprehensive and up-to-date.  It was restricted to “small user residential” addresses, thereby 
omitting many businesses which would not have been appropriate for this study.  
 
As with all approaches, however, there were a number of limitations with using the PAF for the sample 
frame.  In particular, the PAF contains: 
• “extra dwellings” at the sampled address. Sometimes an address listed as a single 
dwelling actually contains more than one dwelling, frequently because of conversion 
into flats;  
•  combined addresses. It is possible to find that two dwellings had combined since the 
PAF was compiled (updates of PAF are released quarterly but major reviews of its 
content are comparatively infrequent), with two addresses listed but where actually 
there is only one dwelling; 
•  addresses without dwellings (for example small businesses, workshops, community 
halls or other properties receiving small amounts of mail). 
A 1987 study estimated an average number of households at PAF addresses at around 1.02.  
However, since then the Royal Mail has made efforts to ensure each separate dwelling is separately 
listed on the PAF, with Households in Multiple Occupation accounting for much of the discrepancy 
between households and PAF addresses.  The project team’s experience of similar surveys, 
suggested that around 8% of PAF addresses were ineligible.  In addition to the reasons outlined 
above, a proportion of all properties may be vacant or demolished.  To counteract this, the 
interviewer’s contact sheet15 for each address was used to record details of this nature, which 
provided essential information for analysis purposes. 
 
Please see www.royalmail.com/paf for further information on the Postal Address File. 
 
                                                           
15 See Questionnaire section for further details 
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SAMPLING FRAME – IRELAND 
The sampling frame used in Northern Ireland was replicated for sampling in Ireland by using the 
GeoDirectory.  This is developed and continuously updated by An Post and Ordinance Survey 
Ireland, and is the most accurate and up-to-date database in Ireland.  It is very similar in design to 
the PAF, which was used in Northern Ireland (except that the GeoDirectory contains additional 
spatial information).  Again, it contains accurate information on every home and building in Ireland, 
from which it was possible to exclude all but residential addresses, in much the same way as using 
the PAF smaller address file.  In particular the GeoDirectory address lists were chosen for Ireland 
because: 
• It contained every address point in Ireland and is designed for use for market research and by 
all kinds of businesses; 
• It is updated on a quarterly basis, which is more often than the PAF small user list is updated.  
This resulted in lower frame errors for the survey south of the border (see Response Rates 
section); 
• It avoids double counting as buildings, which have alternative names (e.g. No.15, Any Street 
and Rose Cottage, Any Street), would be counted only once; 
• GeoDirectory provide separate lists for businesses and residential addresses. 
• It links every address to its electoral division, allowing for the separation of data from both 
large (e.g. health boards) and small geographic areas (e.g. DEDs) alike; 
• Demographic data from the CSO can be easily obtained at a DED level and incorporated into 
databases provided by GeoDirectory; 
• In common with the PAF in Northern Ireland, the address lists provided by GeoDirectory would 
also include those who may not be on the electoral register for one reason or another. 
 
Since it is more regularly updated and excludes commercial premises (large or small), the 
Geodirectory is a better listing to use as a sample frame than the PAF small user file.  As a result, it 
was expected that there would be a lower proportion of vacant, derelict or non-residential 
properties on the Geodirectory list.  Indeed, this was borne out by the actual proportions for these 
properties in this study.16   
 
Despite these obvious advantages, using the Geodirectory list still had the same potential for 
limitations described above (“extra dwellings”, combined dwellings and addresses without 
dwellings).  Again, interviewers’ contact sheets2 were used to gather information on the addresses 
that were excluded. 
 
Please see www.anpost.ie/business/geodirectory for further information on the GeoDirectory. 
 
2.5 Selection of Sample 
 
A three-stage process was used to construct the sample for this survey: 
                                                           
16 See Response Rates section (4.12) 
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SELECTION OF PRIMARY SAMPLING UNITS (PSUS) 
 
In the first instance, a series of Primary Sampling Units (PSUs) was randomly selected. These were 
Enumeration Districts (EDs) in Northern Ireland and District Electoral Divisions (DEDs) and Electoral 
Wards in Ireland.  These PSUs were initially ranked by socio-demographic indicators, from census 
data, to ensure that a representative cross-section of areas was included, and the likelihood of 
selecting an individual PSU would be proportional to the population of that PSU.  In this way, PSUs 
of all sizes and compositions would have an equal chance of selection. 
 
The decision on the number of PSUs used represented an appropriate compromise between 
allowing for sufficient range of coverage and the need to be practical from a data collection and 
field management point of view.  With this in mind, a total of 565 PSUs were selected (314 in 
Ireland and 251 in Northern Ireland).  
 
Health Board Number of Sampling Points 
Ireland  
Eastern  115 
Midland 18 
Midwestern 27 
Northeastern 26 
Northwestern 18 
Southeastern 35 
Southern 47 
Western 28 
Total 314 
Northern Ireland  
EHSSB 99 
NHSSB 64 
SHSSB 46 
WHSSB 42 
Total 251 
 
On average, 27 addresses were chosen at each of the sampling points. 
 
 
SUBSTITUTE SAMPLE POINTS 
 
In a few exceptional instances, the sample point originally selected was replaced with a new 
sample point.  This, for instance, was done where a point was found to be unsuitable for use 
because of a high proportion of business premises or vacant buildings.  Great care was taken when 
selecting a substitute sample point to ensure that it was geographically similar to the original 
sample point.  The substitution of sample points occurred on five occasions (twice in Northern 
Ireland and three times in Ireland), as the table below demonstrates. 
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Original Sample Point Substitute Sample Point 
Ireland 
Carrigeen, Co. Kildare Dun Laoghaire-Glenageary, Co. Dublin 
Kildare, Co. Kildare Garristown, Co. Dublin 
Narraghmore, Co. Kildare Athy (Urban East), Co. Kildare 
Northern Ireland 
Shaftesbury, Belfast Shankill, Belfast 
Newtown Stewart, Strabane Drumragh, Omagh 
 
SELECTION OF ADDRESSES 
 
A sample of addresses was then drawn at random, from each of the randomly selected PSUs, using 
the information provided in An Post/Ordnance Survey’s GeoDirectory and the Post Office’s PAF 
data.  These addresses were then issued to the team of interviewers and formed the basis for the 
survey sample.   
 
A number of reserve addresses were selected during the main sampling phase.  This was to ensure 
that additional addresses were readily available, in reserve, without the need for further sampling, 
if needed.  In all 4,789 reserve addresses were selected for sample points in Ireland, of which 32 
had to be used.  Meanwhile, in Northern Ireland, 3,863 reserve addresses were selected, with 513 
of these used during fieldwork.  Additional addresses were only issued for a given assignment point 
when an interviewer had encountered 10 or more ineligible properties.  These were, non-
residential, derelict, and demolished properties, and where no one in a particular household was 
eligible to take part in the survey, for example because of age. 
 
To ensure confidentiality and anonymity, no interviewers conducted the research in their 
immediate locality, thus reducing the likelihood of interviewers having to speak to an acquaintance, 
friend or relative.  
 
PROPERTY AND HOUSEHOLD SELECTION 
 
When an interviewer called at an address, their initial task was to establish whether the address 
was residential and occupied.  If it was, they next had to establish the number of properties or self-
contained dwelling units it comprised, defined as self-contained dwelling behind its own front door.  
If there was more than one property at an address, the interviewer was instructed to inform a 
member of the field management team and to tell them the number of dwellings.  The field 
manager then selected one of the dwellings by listing each in a systematic way (i.e. by flat room or 
number) and then randomly selecting one using a random table select grid.   
 
Once the interviewer had selected the correct property they then needed to determine whether it 
was occupied by one or more households, with a household being defined as a person, or group of 
people who normally live at the same property, who share a living room or at least one meal a day.  
If there was more than one household, the same random procedure as above was used. 
 
RESPONDENT SELECTION 
 
Individuals (aged 15-64) within each randomly selected household were randomly selected to take 
part in the survey, using a “last birthday rule”.  The person answering the door at any given 
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residential address was asked to list the birthdays of all residents in the target age group.  The 
person with the most recent birthday was selected to participate.  This random selection procedure 
took place during an initial screening interview, with an adult member of the household.  If the 
individual selected was not present at that time an appointment was arranged for a later date. 
 
 
2.6 Stratification 
 
The sample was stratified to ensure that it accurately reflected the population within each 
individual Health Board region.  As the key objective of this study was to provide for reliable 
estimates of prevalence at the national level, it was decided not to over-represent or boost the 
number of interviews in any one Health Board region to achieve a more even number of interviews 
in each.  The effects of such an approach and the subsequent post-survey weighting required 
would have introduced significant design effects into the survey. Consequently, it would have 
significantly reduced the effective sample size for the national data.  Instead, the number of 
interviews was in proportion to the population, accepting the possibility that the sample sizes in 
some Health Boards would be larger than in others.   
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3. Questionnaire Design 
 
 
The questionnaire used on this study followed the EMCDDA model questionnaire with modifications 
appropriate to the Irish context and without prejudice to the purpose of the questionnaire. 
 
The questionnaire was designed with the full involvement of the RAG.  The group made minor 
adaptations and refinements to tailor the questionnaire to Ireland and Northern Ireland, whilst 
ensuring full comparability with other surveys conducted with the model questionnaire.  It was also 
made suitable for face-to-face interviewing. The questionnaire did not go into field until it had been 
finally approved by all of the members of the RAG. 
 
3.1 Questionnaire Development 
 
Since the survey was conducted simultaneously in both jurisdictions, it was necessary to have two 
versions of the questionnaire.  This was necessary to account for differences in question categories 
for health boards and education levels (i.e. ‘O’ Level vs. Junior Cert.).  It also allowed for additional 
questions relating to respondents’ religious background (a standard question in all government 
surveys in Northern Ireland) in the Northern Ireland version of the questionnaire.  There were also 
three differences between the Northern Ireland and Ireland questionnaires relating to some drugs, 
these were:   
 
! The inclusion of a question on nubain® in the Northern Ireland version of the questionnaire. 
! The inclusion of a question on anabolic steroids in the Northern Ireland version of the 
questionnaire. 
! For one question relating to “other opiates” the description of other opiates differed in 
Ireland and Northern Ireland. While this made the questionnaires more appropriate to the 
relevant jurisdiction, it also meant that responses for Ireland and Northern Ireland cannot be 
compared.   
 
These variations were made to make the questionnaires more closely attuned to conditions in both 
jurisdictions. 
 
The NACD and DAIRU developed the initial questionnaire on the Population Survey in accordance 
with EMCDDA guidelines.  The EMCDDA provided methodological guidelines and a model 
questionnaire, which would allow the cross analysis of data amongst various EU member states.  
This questionnaire was then formatted with supplementary questions added by the RAG.  The 
changes made to the original EMCDDA questionnaire are outlined in the three sub-sections, which 
follow. 
 
3.2 Adaptation for a Face-to-Face Methodology 
 
These were necessary to adapt the formulation of questions so that wording and phrasing would 
be unambiguous when read aloud by interviewers.  Lead-ins and joining texts between different 
sections of the survey were also added, in addition to interviewer and routing instructions.  These 
were intended to give the interview a more conversational feel, thereby putting the respondent at 
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ease.  In the instance where lists of drugs were to be read aloud, ‘show’ cards were provided to 
respondents, which they could look at while they answered.  This prevented the respondent or 
interviewer from omitting or misinterpreting any option. 
 
In constructing the questionnaire great care was taken to ensure that the order of questions 
replicated that used in the EMCDDA’S Model questionnaire, even if some of the question formats 
were altered to allow for a face-to-face interview and cultural appropriateness.  The list of 
questions relating to cannabis (the terms ‘hashish’ or ‘marijuana’ are not generally used in Ireland) 
from the Model questionnaire and from the actual questionnaire used are displayed below, as an 
example.  The questionnaires and showcards for both the Ireland and Northern Ireland surveys are 
displayed in the appendices (G - J) of this document. 
 
 
Model Questionnaire 
 
13. Do you personally know people who take hashish or marijuana? 
1 yes 
2 no 
14. Have you ever taken hashish or marijuana yourself? 
1 yes 
2 no 
15. At what age did you take hashish or marijuana for the first time? 
......... 
16. During the last 12 months, have you taken hashish or marijuana? 
1 yes 
2 no 
17. During the last 30 days, have you taken hashish or marijuana? 
1 yes 
2 no 
18. During the last 30 days, on how many days did you take hashish or marijuana? 
(NEW CATEGORIES 2002) 
On ......... days 
OR 
1 20 days or more 
2 10-19 days 
3 4-9 days 
4 1-3 days 
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Actual Questionnaire 
 
SHOW CARD 24 
Q24 Yes 1 CONTINUE 
 No 2 GO TO Q33 
 
Have you ever heard of any of these …………..? 
SHOW CARD, IF YES TO ANY LISTED ON CARD 
CODE YES AND CONTINUE    
     
Q25 Yes 1  
 
Do you personally know people who take cannabis? 
No 2  
     
Q26 Yes 1 CONTINUE 
 
Have you ever taken cannabis? 
No 2 GO TO Q33 
    
Q27  # INSERT 
AGE 
 
At what age did you first take cannabis? 
Don’t know -1  
     
Q28 Yes 1 CONTINUE 
 
During the last 12 months have you taken cannabis? 
No 2 GO TO Q33 
     
Q29 Yes 1 CONTINUE 
 
During the last 30 days have you taken cannabis? 
No 2 GO TO Q33 
    
Q30  # INSERT 
FIGURE 
 
During the last 30 days, on how many days 
have you taken cannabis? 
Don’t know -1  
 
In addition to the above questions, the RAG also recommended the inclusion of additional 
questions on cannabis relating to the type of cannabis most commonly used and what method is 
most used to take cannabis.  These questions were asked of people who answered ‘yes’ to using 
cannabis in the last 30 days.  The questions were phrased as follows: 
 
SHOW CARD 31 
Q 31 What type of cannabis do you most commonly use? 
Just call me out the numbers from the card – MULTI CODE 
Grass 1 Hash 6 
Weed 2 Resin 7 
Skunk 3 Other (specify) 8 
Hash Oil 4   
Herb 5 Don’t Know 9 
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SHOW CARD 32 
Q32 Joint 1  
 Pipe 2  
 Bong 3  
 Eat 4  
 Other (specify) 
__________________ 
5  
 
What method do you most 
commonly use to take cannabis? 
 
Just call me out the numbers 
from the card – MULTI CODE 
Don’t know 6  
 
The above question was also asked of those who answered yes to ‘current use’ (last 30 days) for 
cocaine and heroin.  In addition, those people who answered yes to ‘current use’ of methadone 
and other opiates were asked “The last occasion you took other opiates how had you obtained 
them? (Just call me out the number from the card)” – Show Cards 104b and 118b. 
 
3.3 Opening Statements of Questionnaire 
 
Communicating the study objectives effectively is the most important means of ensuring a high 
response rate and accurate findings.  As a result, the opening statements of the questionnaire 
were designed with careful consideration for a number of reasons.  Firstly, it was designed to 
introduce the interviewer and research agency to the respondent while letting them know how 
much of their time would be needed to complete the survey.   
 
Secondly, it put the study in context and added validity to the exercise, which in turn enabled the 
respondent to be confident that his or her participation mattered for a cause of public interest.  In 
accordance with EMCDDA guidelines, the questionnaire was introduced as a study on lifestyles 
such as alcohol, tobacco and drugs.   
 
Consequently the questionnaire began with a very carefully thought out and worded preamble 
introducing the survey in the right context, to reassure respondents and to encourage them to take 
part.  This was agreed in close co-operation with the RAG.   
 
In addition to this, interviewers were able to mention who the survey was on behalf of, if asked i.e. 
the Department of Community, Rural & Gaeltacht Affairs in Ireland and the Department of Health, 
Social Services and Public Safety in Northern Ireland.  
 
3.4 Socio-economic Groups 
 
The RAG required comparable social class/socio-economic questions in both the Ireland and 
Northern Ireland questionnaires.  Socio-economic questions used in the census of both jurisdictions 
were examined but were ruled out as the questions were not comparable across both jurisdictions. 
Comparability was ensured by using a standard social classification that is widely used in Ireland 
and Northern Ireland. This is based on the employment status of the chief income earner within a 
household, as well as level of responsibility and qualifications (if employed). This enabled the 
coding of households into the following social grades; A, B, C1, C2, D, E. 
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In Northern Ireland a more detailed set of questions was also asked.  This allowed for respondents 
to be categorised according to the SOC 2000 system of social grading. Respondents were coded 
into the following social grades:  
A. (Professionals, senior management and top civil servants)  
B. (Middle management, senior civil servants, managements and owners of businesses)  
C1. (Junior management and owners of small business)  
C2. (Skilled manual workers and manual workers responsible for other workers)  
D. (Semi-skilled and unskilled manual workers, trainees and apprentices)  
E. (All those dependant on the State long-term)  
 
3.5 Additional Questions 
 
The RAG added the following question areas in order to gather further information on drug use in 
Ireland/Northern Ireland.  However, in adding questions the integrity of the survey was priority.  
Thus it was decided that most additional questions would appear at the end of the survey so that if 
someone chose not to continue when asking sensitive drug market type questions the prevalence 
aspect of the survey was not lost. 
 
• Everyone was asked if they had ever been offered illegal drugs in the particular jurisdiction in 
which the survey was conducted; 
• If people had ever used the drug regularly, this question was addressed to those who had 
answered yes earlier in the questionnaire for either or all of alcohol, cannabis, ecstasy, cocaine 
and heroin; 
• The age of first regular use of alcohol, cannabis, ecstasy, cocaine and heroin; 
• People were asked if they had ever tried to stop using alcohol, cannabis, ecstasy, cocaine and 
heroin and what were their reasons for stopping; 
• Source of cannabis, ecstasy, cocaine & heroin (location, family/friend/stranger, ease/difficulty in 
24hr period); 
• Use of other drugs not already covered in the questionnaire; 
• Use of a substance for which the name was not known to the individual. 
 
3.6 Contact Sheets 
 
As well as the questionnaires, interviewers also filled in contact sheets for each address visited, 
documenting each attempt to contact or interview the selected individual (following the “last 
birthday rule” methodology as detailed in the Sample Design section). They also established some 
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basic details about them (i.e. type of house).  The final outcomes of the attempts to interview the 
selected respondent were noted, as were any reasons for not taking part.  
 
Contact sheets were kept separate from the questionnaires in order to reassure respondents about 
confidentiality.  However, if needed, it was still possible to link each contact sheet to each 
completed questionnaire via a numbering process. 
 
3.7 Pilot Exercise 
 
In line with the EMCDDA guidelines, once the two questionnaires had been developed, they were 
pilot-tested in their respective jurisdictions.  Eight interviewers in total, four in each jurisdiction, 
plus a supervisor in Northern Ireland, conducted the pilot interviews.  Interviewer briefings were 
conducted, in MORI MRC’s offices, on 17th September 2002 in Dublin and 18th September 2002 in 
Belfast.  
 
Pilot interviews were conducted between 20th-24th September 2002 and a total of 51 completed 
interviews with a broad range of people were achieved; 25 in Ireland and 26 in Northern Ireland.  
The pilot interviews were conducted in a range of locations in order to ensure that the 
questionnaire was understood by respondents from a variety of backgrounds.  The locations for the 
pilot interviews were as follows: 
 
Ireland Northern Ireland 
• Dublin (North) • Newtownabbey 
• Dundalk • North Belfast 
• Roscrea • Derry 
 • Bangor/Newtownards 
 
Once piloting was completed, interviewers reconvened in Belfast (24 September 2002) and Dublin 
(25 September 2002) and a comprehensive debriefing exercise was undertaken.  Within this 
format, interviewers shared their experiences and discussed the general interviewing process and 
any areas of confusion for respondents, within the questionnaire.  Feedback was compared 
between interviewers and jurisdictions. 
 
3.8 Pilot Feedback 
 
The feedback from the interviewers regarding the questionnaire was overwhelmingly positive. 
Interviewers enjoyed the process and commented that the questionnaire flowed well with little 
overall difficulty encountered.  Moreover, respondents were happy to participate in the study and 
to the best of the interviewers’ knowledge, answered honestly and frankly, no problems were 
encountered regarding the subject matter under discussion and no respondents viewed the 
material as sensitive or were inhibited by the questions posed.  Indeed, respondents commented 
that they enjoyed the experience and found the subject matter and the questions posed 
“interesting”. 
 
The mean length of the pilot questionnaire interviews was 20 minutes, in line with the project team 
and the RAG’s original estimation, with individual interview lengths ranging from 15 to 31 minutes.  
Consequently the original timeframe and target number of interviews (7,600) remained possible. 
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Interviewers found naming the client was an excellent way of enhancing respondent participation, 
adding credibility and authenticity to the research and giving the respondents the sense that their 
contribution was an important and useful exercise.  Moreover, the respondents were also reassured 
of the independence and confidentiality of the research, ensuring honest feedback. 
 
The pilot exercise identified a few minor issues with the questionnaire and raised a few particular 
queries and areas of respondent confusion.  The findings of the pilot exercise were discussed in 
detail with the RAG. While it was agreed that changes needed to be made, these were principally 
cosmetic in nature. Consequently it was felt that a further pilot exercise was not needed. 
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4. Fieldwork 
 
 
4.1 Overview 
 
As noted earlier, there were a variety of possible ways of undertaking this research but for this 
study, fieldwork was conducted by means of face-to-face interviews conducted in the respondents’ 
homes as per EMCDDA guidelines.  There were a number of reasons for this decision, as follows:  
• The length of the questionnaire dictated that the interview needed to be conducted “in-home” 
and not “on street”; 
• The sensitive nature of the subject matter lent itself better to the more confidential 
surroundings of the person’s home; 
• “Interviewer completion” was a better means of collecting information from respondents who 
had finished education ‘early’ (pre-primary, primary), were illiterate or had difficulty reading; 
• Any potential bias which may have arisen from the way an interviewer asked a question were 
largely removed through the use of a straightforward questionnaire, and the high level of 
interviewer training and supervision. 
 
 
4.2 Timing and Context 
 
The survey was treated as an ad-hoc research study.  Although it was designed as a one-off study, 
the need for the sampling and questionnaire design to allow for comparison with other studies in 
the EU as per EMCDDA guidelines was an important consideration.  So too was the need to be 
compatible with any future studies to update this benchmark study in Ireland and Northern Ireland.  
These concerns, however, were secondary to the ultimate aim of achieving accurate and robust 
data on the prevalence of drug use. 
 
Fieldwork was conducted in two phases, namely from October 2002 to December 2002 and from 
January 2003 to April 2003, in both jurisdictions and spread across all Health Board areas.  This 
was to allow a spread of interviews before and after Christmas 2002.  There were no differences in 
the questionnaires used or in sampling and interviewing techniques used during either period. 
 
4.3 Interviewer Briefings & Instructions 
 
One of the factors most correlated with high response rate is the experience interviewers already 
have with that particular survey and the extent to which they feel an attachment to it.  Prior to 
conducting the fieldwork, seven comprehensive half-day briefings (five in Ireland and two in 
Northern Ireland) were held, giving interviewers plenty of time to absorb all the information they 
needed.  The meetings included opportunities for discussion, practice sessions, and role-play 
exercises.  Senior members of the study teams led the briefings, which each and every interviewer 
working on the study attended.  In line with EMCDDA guidelines, the briefings were attended by 
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members of the RAG, who were able to give the interviewers the benefit of their specialist 
expertise. 
 
In addition to the verbal briefings with project executives and members of the RAG, all interviewers 
received full written instructions on all aspects of the survey.  The full instructions for interviewers 
in both jurisdictions are outlined in Appendix K. 
 
4.4 Field Management 
 
Following the sample selection MORI MRC’s Fieldwork Management System was used to control 
and monitor progress on the study, as follows: 
• The allocation of interviews was made to interviewers on a rolling basis to ensure an even 
spread of interviews by region by week.  This ensured that any seasonal variations in results 
would be evenly spread out across the country. 
• Every two to three days, supervisors and field staff were given an update on interviewers’ 
progress and this report on progress was substantiated by booking-in records. 
• Assignments of interviews were returned daily by the interviewers in the post. 
• Upon receipt, packages were opened and sorted and questionnaires and contact sheets 
counted and entered on to the booking-in system. 
• Contact sheets for each address bore a unique serial number so that it was possible to 
complete a response analysis for every household.  Not only was there a record of all calls 
made to each household detailing the dates and times of day but the interviewers also 
recorded the final outcome information.  This included as many details about the household as 
an interviewer could gather, for example if contact was made with the selected respondent who 
then refused to take part, the interviewer would record gender and estimate age.  A full set of 
contact sheets has been retained for any inspection of records.  A sample contact sheet is 
included in Appendix F of this document. 
• In order to maintain anonymity of the respondent the contact sheets were despatched and 
stored separately from the questionnaires themselves.  
• As questionnaires and contact sheets were returned they were passed to the supervisors for a 
full manual edit and then for validation (back checking).  It is their job to ensure that a 
minimum of 10% validation of all completed questionnaires and at least 5% validation of 
contact sheets showing that no successful interview had taken place.  It also confirmed vacant 
and commercial properties. 
• Only after these quality control procedures had taken place were questionnaires dispatched for 
data entry. 
• Each week an interim field report was compiled for each Health Board region showing 
addresses issued, successful interviews undertaken, pending interviews, refusals etc.  This was 
passed to the Executive staff Study Manager. 
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• At the end of each phase of interviewing a full fieldwork report was compiled showing not only 
full details of the interviews completed but also the results of all quality control procedures. 
• Interviewers had the support of their local regional supervisors who were always available to 
help them with difficulties in the field or problems of any nature.  All supervisors attended the 
briefings with project executives and RAG members and were kept informed of developments 
across the whole fieldwork period. 
• In addition to the support from supervisors, all interviewers had all Field staffs’ telephone 
numbers and knew that they could call on any member of the Field department for support at 
any time. 
 
4.5 Enhancing Response Rates 
 
If the interviewer had visited a household, which was occupied, there were nevertheless a number 
of reasons why an interview may not have been completed at that location.  This may have an 
impact on the accuracy of the sample. During the fieldwork considerable effort was taken to avoid 
such a situation occurring.   
 
Below are some approaches used to enhance the response rate for the survey.   
I INTERVIEWER CALLS 
In accordance with EMCDDA guidelines multiple calls were made to selected addresses. 
Interviewers were instructed to call up to five calls – an initial call, plus four call-backs – at each 
address, at different times (including evenings) and on different days (including weekends – 
Saturdays for initial calls and Sundays by prior appointment).  In practice, many addresses received 
significantly more calls, as all non-contacts and “soft refusals” were re-issued to Regional Field 
Supervisors for further calls.   
 
II TRAINED INTERVIEWERS 
The effectiveness of interviewers depends, more than anything, on the training they receive – and 
the encouragement they are offered throughout the fieldwork period.  This is especially true for 
random pre-selected surveys.  In this regard, only fully trained interviewers worked on the study.  
Many of these interviewers had extensive experience of pre-selected survey work. 
 
III HELP-LINE 
A telephone help-line was set-up for interviewers and respondents to handle queries, refusals, and 
requests for information or appointments from respondents.  A thoroughly briefed member of the 
support team at MORI MRC’s offices in Dublin and Belfast handled all the calls.  Written procedures 
outlined the action to be taken in response to different types of calls.  
  
IV NAMING THE CLIENT  
In the experience of the project team, response rates can be significantly enhanced by interviewers 
being able to name the sponsoring client, and this was especially true for a survey which some 
respondents might find sensitive or intrusive, such as this.  If contacts asked about whom the 
research was for, the interviewers were able to name the relevant government department (Dept. 
of Community, Rural & Gaeltacht Affairs in Ireland and the Dept. of Health, Social Services & Public 
Safety in Northern Ireland) as sponsoring the study.  This helped provide reassurance and establish 
the credibility of the survey in the respondent’s eyes. 
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V THE PROMISE OF CONFIDENTIALITY 
Response rates can also be enhanced by providing a visual reassurance of confidentiality to 
respondents.  As a matter of course, respondents in all MORI MRC surveys receive a leaflet 
reassuring them that the research has been conducted within the Code of Conduct of the Market 
Research Society (MRS). This also provides telephone contact numbers for both the MRS (free-
phone in Northern Ireland and lo-call in Ireland) and MORI MRC. 
 
Usually this is provided after completion of interviewing but in this instance, this reassurance was 
provided before the interview actually took place, with a visual display of the MORI MRC promise of 
confidentiality. This provided a contact number for respondents to call, on the spot, if they had any 
reservations about taking part. An example of how this looked is provided in Appendix E of this 
document.   
 
For this particular study it was also possible to provide potential respondents with a letter from the 
NACD in Ireland or DAIRU in Northern Ireland.  Police (ie Garda Síochána and PSNI) at 
headquarters in both jurisdictions were informed that the survey was taking place in order to 
reassure people that the survey was a bona fide research exercise.  This is standard procedure for 
all face-to-face surveys conducted by reputable research agencies and is designed to prevent 
undue anxiety on the part of the respondent. 
 
VI APPOINTMENT CARDS 
In an attempt to increase response rates carefully designed appointment cards were left with other 
members of the household where the randomly selected respondent is not at home.  This card 
provided brief details of the study and a name and telephone number to call to arrange an 
interview at a time most convenient to them.  This was particularly effective in converting some 
interviews with busy young professionals and those who work in shift work.   
 
VII APARTMENT COMPLEXES 
In any apartment complexes where access had to be gained through a gate or entry phone, 
interviewers were encouraged to make arrangements with caretakers and other staff to gain access 
to the block.  In this way, respondents from these locations were also included in the survey. 
 
VIII MONITORING AND SUPERVISION 
Significant resources were allocated to monitoring progress in the Field, with weekly reports being 
sent to the dedicated Field Study Manager working on the study.  
 
IX THE “MORI MRC” NAME 
Finally, people were generally more likely to be receptive to an approach from an organisation they 
have heard of.  As with other studies, interviewers found that the reputation and high profile of 
MORI as a trusted and independent research company – in both Ireland and Northern Ireland - 
also helped encourage responses. 
 
 
4.6 Dealing with Better than Anticipated Response Rates 
 
At the outset of this study, both MORI MRC and the RAG anticipated that the response rate would 
be around 60% in Ireland and 65% in Northern Ireland.  It was on this basis that it was 
anticipated that a total of around 7,600 interviews would be completed.   
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During fieldwork it became clear that final response rates in Northern Ireland were in line with 
expectations (a final response rate of 63% was achieved), while the final response rates in Ireland 
were considerably better than expectations (a final response rate of 70% was achieved; a full ten 
percentage points above the anticipated level).  This better than anticipated response rate was 
welcomed in terms of providing for robust data.  This is reflected in the greater number of total 
interviews achieved (a final sample size of 8,434 was achieved, against a target of 7,600).   
 
However, MORI MRC and the RAG had budgeted for a total of around 7,600 interviews and 
allowing the total number to increase substantially had budget implications (in terms of interviewer 
pay, field project management, quality control, and data entry and processing).  Following detailed 
discussions with the RAG it was decided to allow the survey to continue uncontrolled, as before 
until all addresses allocated were contacted a minimum of 5 times, with MORI MRC bearing the 
additional cost.   
 
4.7 Number of Contacts  
 
The process of re-contacting a selected household a number of times in order to achieve an 
interview with the person chosen is a critical part of the stratified random sampling approach, since 
the random selection of the initial list of addresses is maintained.  Inevitably, the number of calls, 
which were necessary to achieve each interview, varied.  The following table outlines the number 
of calls required to achieve interviews in each health board area. 
 
Number of Calls 
Health Board One to Three 
Calls (%) 
Four to Five 
Calls (%) 
Six or More 
Calls (%) 
Average 
Ireland 86 11 2 2.1 
Eastern 74 21 5 2.6 
Midland 95 4 * 1.5 
Mid-Western 93 7 * 1.7 
North-Eastern 94 6 1 1.5 
North-Western 100 - * 1.3 
South-Eastern 84 13 3 2.3 
Southern 89 9 2 2.1 
Western 94 5 * 1.6 
Northern Ireland 77 18 5 2.5 
EHSSB 74 22 5 2.6 
NHSSB 78 16 6 2.4 
SHSSB 75 20 6 2.6 
WHSSB 79 16 5 2.4 
TOTAL 82 14 4 2.2 
*<1% of interviews 
 
Overall interviews were achieved after about two contacts on average, with interviewers tending to 
require more visits in Northern Ireland than in Ireland (2.5 contacts vs. 2.1 contacts). The two 
jurisdictions also differed in terms of the degree to which there were variations in the average 
number of calls per interview.  While there was little variation between health board areas in 
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Northern Ireland (where contacts per interview ranged from 2.4 to 2.6), there was considerably 
more variation in Ireland.  At one end of the spectrum, interviewers in the North-Western Health 
Board area had the least difficulty, achieving all of their interviews within three contacts.  In the 
ERHA area, the number of contacts per interview was closer to the levels recorded in Northern 
Ireland, with 5% of all interviews requiring more than six calls to be completed. 
 
4.8 Age & Gender 
 
The following table compares the profile of the sample for the Ireland and Northern Ireland 
surveys with the profile of the target population as a whole.   
 
 Population % population Sample % sample
Ireland 2,653,774 100.0% 4,918 100.0% 
Gender     
Male 1,332,965 50.2% 2,147 43.7% 
Female 1,320,809 49.8% 2,771 56.3% 
Age     
15-24 641,522 24.2% 893 18.2% 
25-34 617,369 23.3% 1,102 22.4% 
35-44 562,890 21.2% 1,248 25.4% 
45-54 480,447 18.1% 900 18.3% 
55-64 351,546 13.2% 775 15.8% 
Health Board     
Eastern 985,185 37.1% 1,580 32.1% 
Midland 147,288 5.6% 315 6.4% 
Mid-Western 228,130 8.6% 424 8.6% 
North-East 229,088 8.6% 433 8.8% 
North-Western 142,689 5.4% 332 6.8% 
Southern 390,419 14.7% 746 15.2% 
South-Eastern 280,076 10.6% 604 12.3% 
Western 250,899 9.5% 484 9.8% 
Northern Ireland 1,090,990 100.0% 3516 100.0% 
Gender     
Males 539,644 49.5% 1,575 44.8% 
Females 551,346 50.5% 1,941 55.2% 
Age     
15-24 238,586 21.9% 547 15.6% 
25-34 242,221 22.2% 850 24.2% 
35-44 246,974 22.6% 821 23.4% 
45-54 200,890 18.4% 632 18.0% 
55-64 162,319 14.9% 666 18.9% 
Health Board     
EHSSB 430,909 39.5% 1,393 39.6% 
NHSSB 278,371 25.5% 877 24.9% 
SHSSB 199,438 18.3% 655 18.6% 
WHSSB 182,272 16.7% 591 16.8% 
*CSO Census 2002 data for the population aged between 15 and 64 
**NISRA Census 2001 data for the population aged between 16 and 74. 
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From this comparison it is clear that there are discrepancies between the profile of the sample and 
that of the population generally. In particular, it seems that the under-25 year olds are under-
represented in both jurisdictions, while male respondents and those in the Eastern Regional Health 
Authority (ERHA) appear to be under-represented in the Ireland survey.  Given that, as the 
EMCDDA point out, “no sample frame is perfect and perfect probability sampling does not exist”, it 
is perhaps inevitable that there would be some discrepancies.  The weighting procedures followed 
and outlined in a subsequent section of this report were aimed at alleviating the impact of any 
biases arising from the differences between sample and population.  The remainder of this section 
of the report looks at other areas, which might have given rise to bias in the results. 
 
 
4.9 Dublin Respondents 
 
One area of concern for the project team and the RAG was the high number of contacts per 
interview in the ERHA area.  This obviously reflected the difficulties faced by interviewers in 
successfully completing interviews in that area.  Since this area includes Ireland’s largest city, 
Dublin, and a number of localities, which have had particular difficulties with drug use, it was 
important to establish that the sample achieved for Dublin adequately represented its population.  
The table below compares the unweighted sample achieved in Dublin with CSO data for the city.  It 
also compares overall unweighted sample figures for Ireland with the corresponding data from the 
CSO. 
 
Ireland 
Population 
Survey 
Sample size 
CSO* 
000's 
Population 
Survey 
% 
CSO* 
% 
Working full-time (including 
self-employed) 2,495 1,450.5 50.8% 54.1% 
Working part-time  628 287.2 12.8% 10.7% 
Unemployed (Include 1st 
job seekers, seeking work) 137 84.8 2.8% 3.2% 
Not in Labour Force 1,648 860.6 33.4% 32.1% 
Not stated 10 - 0.2% - 
Total 4,918 2,683.0 100.0% 100.0% 
Dublin 
Population 
Survey 
Sample size 
CSO 
000's 
Population 
Survey 
% 
CSO 
% 
Working full-time (including 
self-employed) 723 449.4 55.1% 55.9% 
Working part-time  161 95.1 12.3% 11.8% 
Unemployed (Include 1st 
job seekers, seeking work) 41 24.1 3.1% 3.0% 
Not in Labour Force 385 234.8 29.4% 29.2% 
Not stated 1 - 0.1% - 
Total 1,311 803.3 100.0% 100.0% 
*CSO data based on Quarterly National Household Survey (December 2002 - February 2003) excluding under 15 and over 65s 
 
For the purposes of this comparison, employment data from the CSO’s Quarterly National 
Household Survey was used.  These include data on employment, unemployment and participation 
in the labour force.  As such, they served as a good proxy for the social make-up of the areas 
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looked at.  Bearing in mind that the population survey sample is unweighted, it is clear that the 
proportions of people in employment and unemployed were broadly in line with the CSO’s data on 
the labour force.  This was true both for the national figures and for the Dublin figures and 
suggests that concerns about any potential bias (especially for the latter) were unfounded. 
 
A similar analysis can be conducted for Northern Ireland, as follows: 
 
Northern Ireland 
Population 
Survey 
Sample size 
NISRA* 
000's 
Population 
Survey 
% 
NISRA* 
% 
Working full-time (including 
self-employed) 1,615 544.0 46.0% 45.8% 
Working part-time  425 118.0 12.1% 9.9% 
Unemployed (Include 1st 
job seekers, seeking work) 200 49.1 5.7% 4.1% 
Not in Labour Force 1,276 476.0 36.2% 40.1% 
Total 3,516 1,187.1 100.0% 100.0% 
*NISRA Census 2001 data for the population aged between 16 and 74. 
 
Once again, the profile of the respondents in the population study broadly matches the official 
population estimates.  The only discrepancy being a lower proportion of people outside the labour 
force (36.2%) compared to the official figure (40.1%).  In part this can be attributed to the fact 
that the NISRA data refers to the population between the ages of 16 and 74 years old.  
Consequently, the latter would include a higher proportion of pensioners than in the 15-64 age 
group. 
 
4.10 Contact Sheet Details 
 
In order to estimate the effects of non-response bias in the achieved sample, the contact sheet 
was used to ask interviewers to record, or estimate where necessary, the age, sex and ethnicity of 
the household of all those who refuse to take part.  Further, interviewers also coded the external 
features of households where contact had not been possible.  This information was compared with 
characteristics among the achieved sample to help assess its representativeness.  
 
AGE & GENDER 
 
The table below outlines the gender and age of those who refused to take part in the survey. 
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Area % of Sample % of Refusals 
Ireland 
Male 44 45 
Female 56 55 
15-24 years 18 6 
25-34 years 22 18 
35-44 years 25 26 
45-54 years 18 29 
55-64 years 16 21 
Northern Ireland 
Male 45 48 
Female 55 52 
15-24 years 16 6 
25-34 years 24 19 
35-44 years 23 31 
45-54 years 18 24 
55-64 years 19 19 
 
In terms of gender there appears to be little difference between the sample and the refusals, with 
males being the slightly larger group in both jurisdictions.  There was a higher proportion of people 
in the 45-54 age group among those who refused to take part.  This was apparent in both 
jurisdictions.  At the same time 15-24 year olds made up a smaller proportion of refusals compared 
to the sample (ie. 6% vs. 18% in Ireland and 6% Vs 16% in Northern Ireland.  In terms of the 
sample, however, these discrepancies are greatly reduced after weighting. 
 
TYPE OF HOUSE 
 
It was also of critical interest to compare the social makeup of those who refused with the actual 
sample.  By the definition, it was not possible to gather data on the social classification of those 
who refused to take part, which could be directly compared with the survey results.  As a rough 
measure of the social composition of the sample and of those who refused to take part, the contact 
sheets also included details on the external characteristics of the homes of all those, which they 
attempted to contact.  The following table compares the property types where completed 
interviews took place and those where potential respondents had refused to take part. 
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Type of Property % of Successful 
% of 
Refused 
Ireland 
House/bungalow - detached 52.2 38.8 
House/bungalow - semi-detached 23.7 29.5 
House/bungalow - mid terrace 14.5 17.5 
House/bungalow - end terrace 5.5 4.5 
Purpose built flat. etc, - building less than 6 floors 3.2 7.5 
Purpose built flat. etc, - building 6 or more floors 0.4 1.8 
Conversion flat/maisonette(s)/shared house 0.4 0.1 
Other 0.2 0.3 
TOTAL 100.0 100.0 
Northern Ireland 
House/bungalow - detached 33.6 32.4 
House/bungalow - semi-detached 24.8 27.6 
House/bungalow - mid terrace 26.5 26.2 
House/bungalow - end terrace 10.5 9.6 
Purpose built flat. etc, - building less than 6 floors 3.8 3.5 
Purpose built flat. etc, - building 6 or more floors * 0.3 
Conversion flat/maisonette(s)/shared house 0.6 0.3 
Hostel or Bed & Breakfast 0.2 * 
Other * 0.3 
Total 100.0 100.0 
*Negligible 
 
The property types associated with the sample for Northern Ireland are broadly similar to the 
properties of those who refused to take part, with no more than three percentage points between 
the figures.  In Ireland, those who refused to take part were less likely to live in a detached house 
than the sample, with over half the sample (52%) living in detached houses compared to 39% of 
those who refused to participate.  On the other hand those who refused were more likely to live in 
semi-detached houses, mid-terrace houses or purpose built flats with less than six floors. 
 
 
4.11 Frame Errors 
 
Refusals, of course, were not the only way that an interviewer may not achieve an interview at a 
selected address.  Frame errors, where contacts were ineligible for the defined universe (aged 15-
64), or where the property was ineligible, vacant, derelict, demolished, not found, or a business, 
were also explained how interviews were not conducted at all addresses.  As such it was important 
to check that frame errors were evenly distributed by region, as an uneven spread of frame errors 
may point to bias in the sample. The following table outlines the extent to which frame errors 
present in the health board regions in Ireland and Northern Ireland.  Besides frame errors, they 
also show breakdowns of the gross sample by:  
• Successful interview - persons belonging to the universe who were part of the sampling frame 
and completed the interview fully 
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• Non-response - households who refused to take part during the initial screening interview and 
respondent selection process, respondents who refused to take part once selected, and 
properties where wardens etc refused on the contact’s behalf, or where no contact could be 
made after multiple calls.  Reasons for non-response (refusals) are detailed in a subsequent 
table. 
 
Area Gross Sample Successful interviews Non-Response Frame Errors
Ireland 
TOTAL n 8474 4918 2119 1437
 % 100% 58% 25% 17%
Eastern  n 3175 1580 1097 498
 % 100% 50% 35% 16%
Midlands n 468 315 88 65
 % 100% 67% 19% 14%
Mid-West n 718 424 144 150
 % 100% 59% 20% 21%
North East n 701 433 129 139
 % 100% 62% 18% 20%
North West n 484 332 80 72
 % 100% 69% 17% 15%
South East n 938 604 172 162
 % 100% 64% 18% 17%
Southern n 1250 746 279 225
 % 100% 60% 22% 18%
Western n 740 484 130 126
 % 100% 65% 18% 17%
Northern Ireland 
Total n 8135 3516 2096 2523
 % 100% 43% 26% 31%
EHSSB n 3261 1393 810 1058
 % 100% 43% 25% 32%
NHSSB n 2078 877 558 643
 % 100% 42% 27% 31%
SHSSB n 1438 655 360 423
 % 100% 46% 25% 29%
WHSSB n 1358 591 368 399
 % 100% 44% 27% 29%
 
Frame errors accounted for 31% of the gross sample in Northern Ireland compared to 17% in 
Ireland.  There was little variation on these figures at health board level, with no more than a five 
percentage point gap between the proportion of frame errors in any given health board area and 
overall figure for the jurisdiction involved.  The difference between the proportions of frame errors 
on either side of border can be attributed to two factors: 
• The addresses for Ireland selected using GeoDirectory data are likely to be more up to date 
due to the quarterly updates conducted by that organisation. 
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• Northern Ireland had a slightly higher proportion of people aged 65 and over, 13.3% compared 
to 11.1% for Ireland. 
 
4.12 Response Rates for Population Survey 
 
Details of overall response rates for Ireland and Northern Ireland, along with rates for health 
boards, are shown below. 
 
  Health Board 
Region 
Gross 
Sample 
Valid 
Sample* Response 
% 
Response 
Ireland 
Total Ireland 8474 7037 4918 70 
Eastern 3175 2677 1580 59 
Southern 1250 1025 746 73 
South Eastern 938 776 604 78 
Western 740 614 484 79 
Mid Western 718 568                 424                  75 
North Eastern 701 562 433 77 
Midland 468 403 315 78 
North Western 484 412 332 81 
Northern Ireland 
Total Northern 
Ireland 8135 5612 3516 63 
EHSSB 3261 2203 1393 63 
NHSSB 2078 1435 877 61 
SHSSB 1438 1015 655 65 
WHSSB 1358 959 591 62 
*Valid Sample = Gross Sample – (frame errors + non-valid cases) 
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The following tables shows more detailed response and non-response distribution by health board.  
 
 
Response Rate by Health Board - 
Ireland
Final 
Outcome
Freq RR Freq RR Freq RR Freq RR Freq RR Freq RR Freq RR Freq RR Freq RR
Successful 
Interview Successful Interview 1580 59% 315 78% 424 75% 433 77% 332 81% 604 78% 746 73% 484 79% 4918 70%
Refused Refused before respondent selection 259 10% 21 5% 51 9% 61 11% 39 9% 47 6% 98 10% 57 9% 633 9%
Refused after respondent selection 147 5% 20 5% 18 3% 18 3% 18 4% 14 2% 21 2% 12 2% 268 4%
Entry to block/scheme refused by warden etc. 25 1% 0% 0% 1 0% 0% 3 0% 5 0% 0% 34 0%
No contact Occupied, no contact at address after 5+ calls 369 14% 32 8% 36 6% 23 4% 16 4% 46 6% 89 9% 34 6% 645 9%
No contact with selected resident, 4+ calls 125 5% 3 1% 16 3% 7 1% 1 0% 29 4% 24 2% 8 1% 213 3%
Occupier in but not answering door after 5+ calls 25 1% 3 1% 1 0% 3 1% 0% 5 1% 6 1% 2 0% 45 1%
Unsure if occupied, no contact after 5+ calls 61 2% 2 0% 7 1% 10 2% 3 1% 8 1% 18 2% 12 2% 121 2%
Property 
Ineligible Property vacant 74 9 37 15 11 44 71 31 292
Property derelict 3 2 6 5 1 6 3 26
Property demolished 4 2 1 2 9
Non-residential property 10 1 1 4 2 6 3 1 28
Property not found 55 10 24 26 9 22 42 7 195
Other Too ill to participate 18 1% 1 0% 7 1% 1 0% 0% 4 1% 2 0% 1 0% 34 0%
Away during fieldwork 15 1% 3 1% 0% 2 0% 1 0% 2 0% 3 0% 0% 26 0%
Household not eligible 351 52 71 89 50 88 101 84 886
Mother tongue required 3 0% 1 0% 0% 0% 0% 2 0% 1 0% 0% 7 0%
Other 54 2% 5 1% 4 1% 2 0% 2 0% 11 1% 13 1% 5 1% 96 1%
Total 3178 480 705 700 484 937 1251 741 8476
Total - Eligible households - excluded all property 2681 100% 406 100% 564 100% 561 100% 412 100% 775 100% 1026 100% 615 100% 7040 100%
ineligible and household ineligible
ERHA MHB MWHB NEHB TotalNWHB SEHB SHB WHB
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Repsonse Rate by 
Health Board _NI          
Final 
Outcome   NI - E NI - N NI - S NI - W NI - Total 
            
  Freq RR Freq RR Freq RR Freq RR Freq RR 
            
Successful 
Interview Successful Interview 1393 63% 877 61% 655 65% 591 62% 3516 63%
                 
Refused 
Refused before 
respondent selection 190 9% 109 8% 92 9% 79 8% 470 8%
 
Refused after 
respondent selection 123 6% 88 6% 54 5% 54 6% 319 6%
 
Entry to block/scheme 
refused by warden 
etc. 5 0%  0%     0% 5 0%
                 
No contact 
Occupied, no contact 
at address after 5+ 
calls 285 13% 216 15% 99 10% 60 6% 660 12%
 
No contact with 
selected resident, 4+ 
calls 101 5% 54 4% 51 5% 32 3% 238 4%
 
Occupier in but not 
answering door after 
5+ calls 24 1% 9 1% 17 2% 42 4% 92 2%
 
Unsure if occupied, 
no contact after 5+ 
calls 31 1% 28 2% 14 1% 39 4% 112 2%
                 
Property 
Ineligible Property vacant 143   152   75   88   458   
 Property derelict 19   13   26   24   82   
 Property demolished 62   4   5   6   77   
 
Non-residential 
property 78   42   21   66   207   
 Property not found 42   50   45   54   191   
                 
Other Too ill to participate 12 1% 6 0% 11 1% 2 0% 31 1%
 Away during fieldwork 7 0% 9 1%  0% 5 1% 21 0%
 Household not eligible 714   382   251 0 181   1508   
 
Mother tongue 
required 3 0% 4 0% 3 2% 1 0% 11 0%
 Other 29 1% 35 2% 19 2% 54 6% 137 2%
            
 Total 3261   2078   1438   1358   8135   
            
 
Total - Eligible 
households - 
excluded all property           
 
ineligible and 
household ineligible 2203 100% 1435 100% 1015 100% 959 100% 5612 100%
NACD/DAIRU – 2002/2003 Drug Prevalence Survey – Technical Report 
38 
5. Data Processing and Weighting 
 
 
5.1 Data Processing 
 
 
On receipt of the edited questionnaires, the responses questions relating to occupation and 
education in each questionnaire were coded for socio-economic group (A, B, C1, C2 etc.), as 
mentioned earlier.  At the same time the Northern Ireland questionnaires were coded for the 
Standard Occupational Classification (SOC2000).  The latter classification is a detailed 
grading system allocating codes to very specific job descriptions.  Each response was given a 
4 digit code corresponding to their specific occupation (ie. managers in construction would 
be coded 1122).   
 
Since the SOC2000 classification is designed as a series of increasing large groups, it would 
be possible to analyse response in a number of different occupational groups as appropriate.  
Taking the example of managers in construction they can be grouped with a broader group 
of Production Managers, who in turn are part of the larger group of Corporate Managers and 
so on (see box below) 
 
1 MANAGERS AND SENIOR OFFICIALS 
 
 11 CORPORATE MANAGERS 
 
  112 Production Managers 
 
   1122 Managers in construction 
 
 
In both jurisdictions responses to Q153 (other illegal drugs taken) were listed as coding was 
not necessary because there were too few responses.  The list for each jurisdiction is as 
follows: 
 
Ireland 
 
Name of Drugs Taken 
Elephant tranquilizer 
Hubly bubbly pipe 
Mandrox 
PF118’s 
PCP 
Purple Hearts 
G.H.B, D.M.T, M.D.A, M.D.M.A 
Mescalin 
G.H.B 
Not stated / refused 
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Northern Ireland 
 
Name of Drugs Taken 
G.H.V 
Blue Bombers 
Speed 
Poteen 
Ketamin 
Diazepam 
G.H.B 
Pot 
Ejjegen / body building 
Can’t remember 
Not stated / refused 
 
After coding, the questionnaires were data entered, in a format which would allow for the 
creation of an SPSS datafile.  Responses were recorded in text or numeric form as 
appropriate.  For numeric questions, “don’t know” responses were denoted by “-1”.  Where a 
respondent gave no answer to a question this was recorded as “-9”.  When questions were 
not relevant to a respondent’s particular circumstances (i.e. they were routed away from 
them) the cells in the SPSS data file were filled with a “.” which is the appropriate ‘system 
missing’ value for this data analysis software. 
 
During the data processing stage, 25% of questionnaires were double-punched to verify the 
accuracy of the data.  After data punching a variety of logic checks were also carried out on 
the datafile, including tests for consistency based on age, gender and drug use. An example 
section of this check program is shown in Appendix N. 
 
5.2 Weighting 
 
Surveys are carried out to obtain the values of variables in the target population identified 
for the particular population, in this instance 15-64 year olds resident in Ireland and 
Northern Ireland.  However, it is important to note that the results achieved are only 
estimators of population values.  To take account of sampling and response biases, a 
process of weighting was carried out to ensure that results more accurately represent the 
target population.  
 
Typically, when the sample of a survey is in some way not fully representative (because 
there are too many respondents from group A and not enough from group B), the results are 
reweighted.  In simple terms, in order to achieve the correct balance, responses are 
multiplied by a coefficient, which ensures that the answers of under-represented groups 
(group B) are emphasised and the answers from over-represented groups (group A) are de-
emphasised, for instance the answers of an under-represented group such as males aged 
15-24 living in the ERHA are emphasised, and the answers from an over-represented group 
such as females aged 35-44 living in the Southern Health Board area are de-emphasised.  In 
this way the raw data were adjusted to achieve data that more closely represents the overall 
population.  
 
Weights were prepared to ensure the sample was fully representative by gender, age and 
health board in Northern Ireland and in Ireland, according to latest census (Northern Ireland 
2001, Ireland 2002).  These weighting variables were agreed with the RAG as they were 
reliable, available and they could be used in both Northern Ireland and Ireland. They also 
facilitated All Ireland weighting of the data. Variables were combined, so within each health 
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board persons were classified by age group and gender.  The calculation of each individual 
weight was based on the aim to achieve complete correspondence of the distribution of 
these characteristics between response and population.   
 
5.3 Calculation of Weights 
 
The sample for the survey was subdivided into cells according to the respondent’s age 
group, gender and health board area (ie. 15-24 year old males in the ERHA region).  
Weights for each cell were then calculated by firstly establishing the proportion of the overall 
sample in each cell (the response ratio) and the proportion of the overall population 
represented by the cell (the population ratio).  The weights for each cell could then be 
calculated by dividing the population ratio by the response ratio. A list of the weights used 
for Ireland is found in the following table. 
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Weights Assigned to Respondents Living in Ireland  
   Design Effect = 1.076152 
 
Gender Area Age Response Response 
 Ratio (%) 
{S} 
Population Population  
Ratio (%) 
Weight 
{W} 
Squared 
Weights17 
{SWW} 
TOTAL TOTAL TOTAL 4918 100.00% 2653774 100.00%  1.076152 
Male Eastern 15-24 143 2.90769% 121,432  4.57582% 1.573699 0.072010 
Male Eastern 25-34 163 3.31436% 125,313  4.72207% 1.424732 0.067277 
Male Eastern 35-44 186 3.78203% 99,006  3.73076% 0.986446 0.036802 
Male Eastern 45-54 107 2.17568% 80,293  3.02562% 1.390652 0.042076 
Male Eastern 55-64 96 1.95201% 58,222  2.19393% 1.123933 0.024658 
Male Midland 15-24 31 0.63034% 18,220  0.68657% 1.089209 0.007478 
Male Midland 25-34 38 0.77267% 16,559  0.62398% 0.807561 0.005039 
Male Midland 35-44 25 0.50834% 16,579  0.62473% 1.228975 0.007678 
Male Midland 45-54 25 0.50834% 14,308  0.53916% 1.060629 0.005718 
Male Midland 55-64 19 0.38634% 10,054  0.37886% 0.980641 0.003715 
Male Mid-Western 15-24 36 0.73200% 28,742  1.08306% 1.479582 0.016025 
Male Mid-Western 25-34 33 0.67100% 25,286  0.95283% 1.420008 0.013530 
Male Mid-Western 35-44 41 0.83367% 24,276  0.91477% 1.097281 0.010038 
Male Mid-Western 45-54 39 0.79301% 21,996  0.82886% 1.045210 0.008663 
Male Mid-Western 55-64 35 0.71167% 15,967  0.60167% 0.845434 0.005087 
Male North-East 15-24 43 0.87434% 27,985  1.05454% 1.206095 0.012719 
Male North-East 25-34 29 0.58967% 26,506  0.99880% 1.693834 0.016918 
Male North-East 35-44 44 0.89467% 25,687  0.96794% 1.081895 0.010472 
Male North-East 45-54 35 0.71167% 21,777  0.82060% 1.153067 0.009462 
Male North-East 55-64 30 0.61000% 15,273  0.57552% 0.943469 0.005430 
Male North-Western 15-24 29 0.58967% 17,244  0.64979% 1.101957 0.007160 
Male North-Western 25-34 35 0.71167% 14,498  0.54632% 0.767652 0.004194 
Male North-Western 35-44 36 0.73200% 15,020  0.56599% 0.773200 0.004376 
Male North-Western 45-54 30 0.61000% 14,318  0.53953% 0.884475 0.004772 
Male North-Western 55-64 22 0.44734% 11,191  0.42170% 0.942694 0.003975 
Male Southern 15-24 62 1.26068% 46,937  1.76869% 1.402969 0.024814 
Male Southern 25-34 75 1.52501% 43,380  1.63465% 1.071897 0.017522 
Male Southern 35-44 79 1.60634% 42,069  1.58525% 0.986869 0.015644 
Male Southern 45-54 64 1.30134% 37,003  1.39435% 1.071474 0.014940 
Male Southern 55-64 55 1.11834% 27,719  1.04451% 0.933984 0.009756 
Male South-Eastern 15-24 47 0.95567% 33,869  1.27626% 1.335455 0.017044 
Male South-Eastern 25-34 45 0.91501% 30,506  1.14953% 1.256312 0.014442 
Male South-Eastern 35-44 66 1.34201% 30,635  1.15439% 0.860198 0.009930 
Male South-Eastern 45-54 64 1.30134% 26,982  1.01674% 0.781302 0.007944 
Male South-Eastern 55-64 36 0.73200% 20,442  0.77030% 1.052314 0.008106 
Male Western 15-24 33 0.67100% 31,276  1.17855% 1.756394 0.020700 
Male Western 25-34 50 1.01667% 26,429  0.99590% 0.97957 0.009756 
Male Western 35-44 37 0.75234% 26,559  1.00080% 1.330254 0.013313 
Male Western 45-54 48 0.97601% 24,889  0.93787% 0.960928 0.009012 
Male Western 55-64 36 0.73200% 18,518  0.69780% 0.953271 0.006652 
Female Eastern 15-24 163 3.31436% 122,520  4.61682% 1.392977 0.064311 
Female Eastern 25-34 211 4.29036% 128,579  4.84514% 1.129307 0.054716 
                                                           
17 “Squared Weights” – these are equal to the Response Ratio multiplied by the weight squared (ie. Response 
Ratio x Weight2 ) 
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Weights Assigned to Respondents Living in Ireland  
   Design Effect = 1.076152 
 
Gender Area Age Response Response 
 Ratio (%) 
{S} 
Population Population  
Ratio (%) 
Weight 
{W} 
Squared 
Weights17 
{SWW} 
TOTAL TOTAL TOTAL 4918 100.00% 2653774 100.00%  1.076152 
Female Eastern 35-44 236 4.79870% 103,728  3.90870% 0.814533 0.031838 
Female Eastern 45-54 151 3.07035% 84,974  3.20201% 1.042878 0.033393 
Female Eastern 55-64 124 2.52135% 61,118  2.30306% 0.913423 0.021037 
Female Midland 15-24 35 0.71167% 16,632  0.62673% 0.880645 0.005519 
Female Midland 25-34 37 0.75234% 15,968  0.60171% 0.799785 0.004812 
Female Midland 35-44 41 0.83367% 15,940  0.60065% 0.720492 0.004328 
Female Midland 45-54 34 0.69134% 13,505  0.50890% 0.736106 0.003746 
Female Midland 55-64 30 0.61000% 9,523  0.35885% 0.588271 0.002111 
Female Mid-Western 15-24 40 0.81334% 27,242  1.02654% 1.262129 0.012956 
Female Mid-Western 25-34 48 0.97601% 24,467  0.92197% 0.944635 0.008709 
Female Mid-Western 35-44 62 1.26068% 23,641  0.89084% 0.706641 0.006295 
Female Mid-Western 45-54 34 0.69134% 20,981  0.79061% 1.143594 0.009041 
Female Mid-Western 55-64 56 1.13867% 15,532  0.58528% 0.514001 0.003008 
Female North-East 15-24 48 0.97601% 25,983  0.97910% 1.046782 0.010695 
Female North-East 25-34 59 1.19967% 26,041  0.98128% 0.817957 0.008026 
Female North-East 35-44 81 1.64701% 25,031  0.94322% 0.572688 0.005402 
Female North-East 45-54 34 0.69134% 20,471  0.77139% 1.115796 0.008607 
Female North-East 55-64 32 0.65067% 14,334  0.54014% 0.830122 0.004484 
Female North-Western 15-24 25 0.50834% 16,321  0.61501% 1.209849 0.007441 
Female North-Western 25-34 37 0.75234% 14,636  0.55152% 0.73307 0.004043 
Female North-Western 35-44 43 0.87434% 15,423  0.58117% 0.664699 0.003863 
Female North-Western 45-54 41 0.83367% 13,809  0.52035% 0.62417 0.003248 
Female North-Western 55-64 34 0.69134% 10,229  0.38545% 0.557544 0.002149 
Female Southern 15-24 66 1.34201% 45,607  1.71857% 1.280596 0.022008 
Female Southern 25-34 96 1.95201% 42,838  1.61423% 0.826956 0.013349 
Female Southern 35-44 110 2.23668% 41,819  1.57583% 0.70454 0.011102 
Female Southern 45-54 70 1.42334% 35,966  1.35528% 0.952179 0.012905 
Female Southern 55-64 69 1.40301% 27,081  1.02047% 0.727345 0.007422 
Female South-Eastern 15-24 47 0.95567% 31,445  1.18492% 1.239876 0.014691 
Female South-Eastern 25-34 76 1.54534% 30,066  1.13295% 0.73314 0.008306 
Female South-Eastern 35-44 96 1.95201% 30,915  1.16494% 0.596791 0.006952 
Female South-Eastern 45-54 70 1.423343% 25,637  0.96606% 0.678725 0.006557 
Female South-Eastern 55-64 57 1.159008% 19,579  0.73778% 0.636561 0.004696 
Female Western 15-24 47 0.955673% 30,067  1.13299% 1.185542 0.013432 
Female Western 25-34 70 1.423343% 26,297  0.99093% 0.696198 0.006899 
Female Western 35-44 65 1.321675% 26,562  1.00091% 0.757307 0.007580 
Female Western 45-54 54 1.098007% 23,538  0.88696% 0.807794 0.007165 
Female Western 55-64 44 0.894673% 16,764  0.63170% 0.706073 0.004460 
 
A similar list of weights for Northern Ireland is displayed overleaf. 
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Weights Assigned to Respondents Living in Northern Ireland   
   Design Effect  = 1.059080
     
Gender Area Age  Response  Response 
 Ratio (%)
{S} 
Population
000 
 
Population 
Ratio (%) 
Weight 
{W} 
Square 
Weights 
{SWW} 
TOTAL TOTAL TOTAL 3516 100% 1,090.990 100%  1.059080 
Male EHSSB 15-24 80 2.27531% 47.1600  4.32268% 1.899818 0.082123 
Male EHSSB 25-34 142 4.03868% 45.2500  4.14761% 1.026971 0.042595 
Male EHSSB 35-44 130 3.69738% 46.7360  4.28382% 1.158607 0.049633 
Male EHSSB 45-54 114 3.24232% 38.8450  3.56053% 1.098142 0.039100 
Male EHSSB 55-64 139 3.95336% 31.5660  2.89334% 0.731868 0.021175 
Male NHSSB 15-24 65 1.84869% 28.9400  2.65264% 1.434872 0.038062 
Male NHSSB 25-34 97 2.75882% 30.7620  2.81964% 1.022047 0.028818 
Male NHSSB 35-44 91 2.58817% 31.2200  2.86162% 1.105655 0.031640 
Male NHSSB 45-54 64 1.82025% 26.2610  2.40708% 1.322389 0.031831 
Male NHSSB 55-64 84 2.38908% 20.9950  1.92440% 0.805498 0.015501 
Male SHSSB 15-24 52 1.47895% 22.2650  2.04081% 1.379899 0.028161 
Male SHSSB 25-34 67 1.90557% 22.4690  2.05951% 1.080779 0.022259 
Male SHSSB 35-44 90 2.55973% 22.9110  2.10002% 0.820408 0.017229 
Male SHSSB 45-54 54 1.53584% 18.3480  1.68178% 1.095023 0.018416 
Male SHSSB 55-64 43 1.22298% 14.2130  1.30276% 1.065235 0.013877 
Male WHSSB 15-24 46 1.30830% 22.1460  2.02990% 1.551549 0.031495 
Male WHSSB 25-34 64 1.82025% 20.6340  1.89131% 1.039038 0.019651 
Male WHSSB 35-44 64 1.82025% 19.9950  1.83274% 1.006861 0.018453 
Male WHSSB 45-54 47 1.33675% 16.7160  1.53219% 1.146206 0.017562 
Male WHSSB 55-64 42 1.19454% 12.2120  1.11935% 0.937056 0.010489 
Female EHSSB 15-24 112 3.18544% 47.6360  4.36631% 1.370709 0.059849 
Female EHSSB 25-34 207 5.88737% 48.4630  4.44211% 0.754515 0.033516 
Female EHSSB 35-44 182 5.17634% 51.1230  4.68593% 0.905259 0.042420 
Female EHSSB 45-54 132 3.75427% 40.1250  3.67785% 0.979646 0.036030 
Female EHSSB 55-64 155 4.40842% 34.0050  3.11689% 0.707032 0.022037 
Female NHSSB 15-24 72 2.04778% 28.5870  2.62028% 1.279570 0.033528 
Female NHSSB 25-34 97 2.75882% 31.3070  2.86960% 1.040154 0.029848 
Female NHSSB 35-44 115 3.27076% 31.9770  2.93101% 0.896124 0.026265 
Female NHSSB 45-54 93 2.64505% 26.1000  2.39232% 0.904452 0.021637 
Female NHSSB 55-64 99 2.81570% 22.2220  2.03687% 0.723396 0.014735 
Female SHSSB 15-24 55 1.56428% 21.2810  1.95061% 1.246974 0.024324 
Female SHSSB 25-34 93 2.64505% 22.4080  2.05391% 0.776512 0.015949 
Female SHSSB 35-44 85 2.41752% 22.6700  2.07793% 0.859529 0.017860 
Female SHSSB 45-54 57 1.62116% 18.1310  1.66189% 1.025121 0.017036 
Female SHSSB 55-64 59 1.67804% 14.7420  1.35125% 0.805253 0.010881 
Female WHSSB 15-24 65 1.84869% 20.5710  1.88554% 1.019929 0.019231 
Female WHSSB 25-34 83 2.36064% 20.9280  1.91826% 0.812602 0.015588 
Female WHSSB 35-44 64 1.82025% 20.3420  1.86455% 1.024334 0.019099 
Female WHSSB 45-54 71 2.01934% 16.3640 1.49992% 0.742778 0.011141 
Female WHSSB 55-64 45 1.27986% 12.3640 1.13328% 0.885471 0.010035 
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6. Statistical Reliability 
 
 
The respondents to the survey are only a sample of the total “population”, so it is not 
possible to be certain that the figures obtained are exactly those that would have been 
obtained if everybody had been interviewed (the “true” values).  However, the variation 
between the sample results and the “true” values can be predicted from knowledge of the 
size of the samples on which the results are based and on the number of times that a 
particular answer is given.  The confidence with which this prediction can be made is usually 
chosen to be 95% - that is, the chances are 95 in 100 that the “true” value will fall within a 
specified range. 
 
In addition, the data for this survey are weighted (as outlined above).  However, it should be 
noted that a sample which is weighted is less accurate (i.e. has a larger standard error) than 
an unweighted sample of the same size.  The effect of this weighting, therefore, needs to be 
taken into account when considering statistical reliability.  The formula for calculating the 
size of the equivalent unweighted sample is pw², where p is the proportion of the sample 
(unweighted) in the various sectors with weighting factors applied, and w is the weight 
applied to those sectors.  The weighting applied to the example data set shown above gives 
a design factor of 1.059080 in Northern Ireland and 1.076152 in Ireland thereby reducing 
the actual sample size from 4,918 to an effective sample size of 4,570 in Ireland and from 
3,516 to an effective sample size of 3,320 in Northern Ireland.  The same rule applies to 
sub-groups of the total sample, as the table below demonstrates. 
 
 
 
Health Board Region Design Effect 
Ireland 1.076152 
Eastern 0.448118 
Midland 0.050145 
Mid-Western 0.093353 
North East 0.092215 
North Western 0.045222 
Southern 0.149462 
South Eastern 0.098668 
Western 0.098969 
Northern Ireland 1.059080 
EHSSB 0.428478 
NHSSB 0.271866 
SHSSB 0.185992 
WHSSB 0.172744 
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The table below illustrates the predicted ranges for different sample sizes and percentage 
results at the “95 confidence interval”, assuming no design effect. 
 
  Sampling tolerances applicable to 
results at or near these percentages 
(based on 95% confidence level) 
Health Board 
Region 
Sample 
Size 10/90% 30/70% 50% 
Republic of Ireland 
  +% +% +% 
Total 4,918 0.84 1.28 1.40 
Eastern 1,580 1.48 2.26 2.47 
Southern 746 2.15 3.29 3.59 
South Eastern 604 2.39 3.65 3.99 
Western 484 2.67 4.08 4.45 
Mid Western 424 2.86 4.36 4.76 
North Eastern 433 2.83 4.32 4.71 
Midland 315 3.31 5.06 5.52 
North Western 332 3.23 4.93 5.38 
Northern Ireland 
  +% +% +% 
Total Northern 
Ireland 3,516 0.99 1.51 1.65 
EHSSB 1,393 1.58 2.41 2.63 
NHSSB 877 1.99 3.03 3.31 
SHSSB 655 2.30 3.51 3.83 
WHSSB 591 2.42 3.69 4.03 
 
For example, with a total sample size of 4,918 completed interviews, where 50% give a 
particular answer, the chances are 19 in 20 that the “true” value (which would have been 
obtained if the whole population had been interviewed) will fall within the range of + 1.40 
percentage points from the sample result; in fact the actual result is proportionately more 
likely to be closer to the centre (50%) than the extremes of the range (51.40 % or 48.60 %). 
 
When the results are compared between separate sub-groups within a sample, different 
results may be obtained.  The difference may be “real,” or it may occur by chance (because 
not everyone in the population has been interviewed).  To test if the difference is a real one 
- i.e. if it is “statistically significant” - it is again necessary to know the total population, the 
size of the samples, the percentage giving a certain answer, and the degree of confidence 
chosen.   Assuming a “95% confidence interval”, the differences between the two sub-
sample results must be greater than the values given in the table below: 
 
 Sampling tolerances applicable to results at or near 
these percentages (based on 95% confidence level)
10/90% 20/80% 30/70% 40/60% 50/50%Sample size 
+/- +/- +/- +/- +/- 
8,434 (Island of Ireland) 0.64 0.85 0.98 1.05 1.07 
4,918 (Ireland) 0.84 1.12 1.28 1.37 1.40 
3,516 (Northern Ireland) 0.99 1.32 1.51 1.62 1.65 
4,100 (Ireland) vs. 3,500 
(Northern Ireland) 1.33 1.76 2.00 2.13 2.17 
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6.1 Calculation of Denominators for Drug Prevalence. 
 
Example – Cannabis (see endnote 1) 
 
          Total Number of respondents in Survey = N 
 Questions labels A,B,C etc for clarity. D not used as variable label to ensure not confused with symbol for denominator.  
 dA = Denominator for question A ; dB = Denominator for question B etc 
 Appropriate denominator also needs to be used when calculating averages (for example, with age variables) 
 
Q 
No. 
Question Label Responses Reponses 
Label 
Denominator Comment 
Q24 Have you ever heard of cannabis? A Yes 
No 
Not Stated 
AY 
AN 
ANS 
 
dA = N – ANS Those who did not respond to this 
question (ANS) are excluded from the 
denominator.  As this group is routed out 
of any further questions, they are also 
excluded from the denominators for 
subsequent questions.  
 
Q25 Know people who take cannabis? B Yes 
No 
Not Stated 
BY 
BN 
BNS 
 
dB = dA – BNS For logic see Q26 but also see endnote 2. 
Q26 Have you ever taken cannabis? C Yes 
No 
Not Stated 
CY 
CN 
CNS 
 
dC = dA – CNS The denominator should include those 
who have said they have never heard of 
cannabis (ie answered “no” to Q24). The 
logic behind this is that those who have 
never heard of a drug will have never 
(knowingly) taken it. Therefore they 
should appear in the denominator but not 
the numerator. See endnote 2. 
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Q 
No. 
Question Label Responses Reponses 
Label 
Denominator Comment 
Q27 Age first taken cannabis? 
Notes – the following assumptions  have 
been made: 
• If age = -1, it is assumed that age 
was not stated 
• If age = 0, it is assumed that age is 
incorrect 
 
There will also need to be logical 
checks on age (if these have not 
already been carried out). If age 
calculated to be inappropriate value 
(eg greater than current age), these 
cases will also have to be omitted 
from any calculation.  
E (Age) 
-1 
0 
E(Age) 
Eminus1 
Ezero 
 
 
 
dE = CY – 
(Ezero + 
Eminus1) 
This variable could be reported on in a 
number of ways. Probably the most logical is 
the age profile (including average age) of 
those who have taken the drug hence the 
“starting point” is those who have answered 
“yes” to Q26 (ie CY). People whose age is 
missing or is logically incorrect also have to be 
excluded from any calculation.  
Q28 Taken cannabis in last 12 months? F Yes 
No 
Not Stated 
FY 
FN 
FNS 
 
dF = dC – FNS For last month prevalence it is assumed that 
people who have never heard of cannabis (ie 
those who answered “no” to Q24) and those 
who have never taken cannabis (ie those who 
have answered “no” to Q26) will not have 
taken cannabis in the last month. Therefore, 
they appear in the denominator as the formula 
shows (see endnote 3). 
Q29 Taken cannabis in last 30 days? G Yes 
No 
Not Stated 
GY 
GN 
GNS 
 
dG = dF – GNS Logic as per Q28 – those who have answered 
“no” to having taken in the last year will not 
have taken in the last 30 days.  
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Q 
No. 
Question Label Responses Reponses 
Label 
Denominator Comment 
Q30 How many days taken cannabis? 
(notes 
assume if days = -1, days not stated 
assume if days = 0, days incorrect) 
 
H (No of days) 
-1 
0 
H(No of 
Days) 
Hminus1 
Hzero 
 
 
 
dH = GY – 
(Hzero + 
Hminus) 
This information is most logically reported on 
those who have taken in the last month and so 
those who have answered “yes” to Q29 are the 
denominator, again with the proviso that those 
for whom the number of days is missing or 
logically incorrect are excluded 
Q31 Type of cannabis taken? J (Type) 
Don’t Know 
Not stated 
J(Type) 
JDK 
JNS 
 
dJ = GY – (JDK 
+ JNS) 
Ditto comments Q31. 
Q32 Method for taking cannabis? K (Method) 
Don’t Know 
Not stated 
K(Method) 
KDK 
KNS 
 
dK = GY – (KDK 
+ KNS) 
Ditto comments Q31. 
 
Endnote: 
 
1 This model can be used for all drugs except alcohol and tobacco. It is assumed that everyone will have heard of these two substances and therefore the 
“knowledge” question was not asked. The lifetime prevalence denominator (using the same symbols as in the cannabis example above) for alcohol and 
tobacco therefore becomes dC = N – CNS. All other calculations remain unaltered.  
 
2 There are strong reasons for including those who have never heard of a drug in the denominator. The logical reason is given in the comment - ie, if you 
have never heard of the drug, you have never knowingly taken it (and it is worth noting that all prevalence estimates are based on those who “knowingly” 
take a drug).  
It is also worth considering what the prevalence estimates are trying to ascertain. They are trying to estimate what the prevalence of drug taking is in the 
general population. Therefore, it is entirely legitimate to exclude from the calculation those who have refused to answer the question. They may have a 
number of reasons for refusing to answer, and we cannot just assume that they have not taken the drug. However, if you exclude those who have never 
heard of a drug from the denominator, then you risk getting some very strange results.  
 
3 Again, when looking at last year and last month prevalence rates we are interested in the rate in the general population. There are circumstances where we 
are interested in how many people who have ever taken a drug have used in the last year, last month etc this is known as the “continuation rate”, and tables 
will be specified separately), but when looking at the overall population (ie what proportion of the Irish population have used cannabis in the last year) it is 
clear that those who have never taken cannabis must be retained in the denominator.  
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7. Monitoring the Study        
 
 
 
The RAG continued to meet (as mentioned in chapter one) throughout 2003, 2004 and 2005 
to monitor the study, agreed the accuracy of the data and to finalise each of the Bulletins 
emerging from the study.  The meetings enabled discussion and clarification of issues which 
arose in the controls and cross checks carried out by the RAG as set out below.  Meetings 
were held in alternate locations, agendas were agreed in advance and notes taken which 
noted the actions or steps to be taken.  Fourteen meetings took place between 2004 and 
2005 and there was also continuous correspondence by email for the duration of the study.  
 
DATA PROCESSING 
 
When the “pen and paper” method of data collection is used, the stage of data processing 
where errors are most likely to occur is when transferring the data from the paper 
questionnaires into electronic format. It is therefore necessary to “clean” the data file to 
ensure everything recorded on the paper questionnaires matches the numbers in the data 
file. 
  
DATA VALIDATION AND DATA CLEANING 
 
Data validation and data cleaning are the procedures that check the data are valid and 
sensible/reasonable before they are processed in the appropriate software (SPSS in this 
case). Given the importance of the data in this study and the prevalence figures it 
generated, quality control of the highest standards had to be used.  
 
CONTRACTOR DATA CHECKING 
 
At the outset the following data validation measures were agreed with MORI MRC:  
 
• 25% of questionnaires would be double punched and compared directly for 
inconsistencies.  
• A variety of logic checks were to be carried out on the resulting data file including 
tests for consistency based on age, gender and drug use. The checks were designed 
and deployed in-house by MORI MRC. 
 
The RAG was assured these checks were performed as part of the cleaning of the original 
data file. 
 
DATA ERRORS 
 
On receipt of the original data final, both the NACD and DAIRU performed some additional 
checks, initially based on frequency analyses, to determine the quality of the data. 
Unfortunately, some inconsistencies were uncovered and it emerged that the tests 
performed by the contractor were insufficient to ensure the data was of the highest quality. 
The issues with data integrity appeared to have occurred as a result of human error during 
data entry. 
 
ENHANCED DATA VALIDATION AND DATA CLEANING PROCEDURES 
  
Because errors were uncovered, a new strategy had to be developed to comprehensively 
clean and validate all the data. 
 
The enhanced process for validating the data occurred in the following stages: 
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• All the data (100%) was re-punched, twice. 
 
• The two data files that emerged from the double punching exercise were 
compared for any differences. Any differences that did emerge were corrected by 
referring back to the original paper questionnaires. 
 
• The new data file was compared with the first data file to re-assess the errors in 
the original data file. 
 
• A program was developed to assess the internal consistency of the final SPSS 
data file and to perform a wide range of data checks including, but not limited to: 
 
o Range checks – These ensure that the data lie within a specified range of 
values (e.g. if a person has taken a drug within the last 30 days, the number 
of days on which this person has taken the drug must be between 1 and 30). 
 
o Presence checks – These ensure that important data are actually present 
and have not been missed out (e.g. questions on regular use were asked of 
recent users) 
 
o Consistency checks – These assess the internal consistency of the data file 
to ensure the data adheres to the routing structure of the questionnaire (e.g. 
if a respondent has taken a drug, but not in the last 12 months, they are 
routed away from the remaining questions on current use and the relevant 
cells in the data file are filled with the appropriate ‘system missing’ value). 
 
o Logic checks – In this study, this type of check involved determining 
whether answers to various related questions logically make sense in 
accordance with practical and mathematical reasoning (e.g. the age a person 
started regularly taking a drug must be greater than or equal to the age when 
they first took the drug).  
 
 
SIGNING OFF THE DATA FILE 
 
Upon receipt of the final data file from MORI MRC the automated program performed 
hundreds of individual checks on all variables containing prevalence data and further checks 
on other variables that contained data on drug use, but did not directly measure prevalence. 
Further checks based on gender and age were also performed. All checks were passed and 
although the file did have some missing data, this data had been clearly and appropriately 
accounted for. An example section of the check program (which examined all variables 
relating to cannabis use) can be found in Appendix N. 
 
REVISED PUBLICATIONS 
 
The identification of the above mentioned errors, although small, required us to recalculate 
the prevalence information and as a consequence required us to publish minor revisions to 
those figures previously published. 
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A.  Letter to Ms. Jo Daykin 
 
28th March 2002 
 
Jo Daykin 
NI Drug and Alcohol Strategy Coordinator 
Room C.4.13 
Castle Buildings 
Upper Newtownards Road 
Belfast  
BT4 3SJ 
 
 
Dear Jo 
 
Following a meeting with Mr Kieron Moore and Mr Damien Buchanan, we have reached an agreement to 
collaborate on an All Ireland Population Survey on Illegal Drug Use.   
 
This survey will be carried out according to the Guidelines provided by the EMCDDA and will therefore 
include questions on tobacco, alcohol and prescribed drug use as well as illegal drug use.  The sampling 
frame has yet to be decided but we aim to survey three population strands: 18 – 64 year olds, 12 to 17 year 
olds (this group may change) and the out of school youth population. 
 
We have committed funds up to €350,000 in our budget to this project and have the commitment of the 
Health Promotion Unit in the Republic of up to €63,000 from their budget next year.  We estimate the total 
cost of the project to be in the region of €738,000 which will cover interviews with up to 9,000 people 
(sample size must be decided jointly) at  €65 per interview with the balance providing for detailed and 
extensive analysis, report writing and publication, administration of the project.  We expect the fieldwork 
to take place in 2002 and the analysis to be completed in early 2003. 
 
In order to embark on this project immediately and commission the survey as soon as possible we will need 
funds to the value of €325,000 to be transferred to us for this purpose.  A cheque or bank draft will need to 
be made out to the Department of Tourism, Sport and Recreation for the amount stated. 
 
We look forward to this exciting collaboration and the information it will yield.  The survey will meet the 
European standards for cross country/region comparison and will be an excellent All Ireland baseline 
indicator that will guide future studies. 
 
Yours sincerely 
 
____________ 
Mairéad Lyons 
Director 
 
 
 
 
 
 
cc: Kieron Moore, Drug and Alcohol Information and Research Unit  
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B. Press Release 
 
DRUG USE SURVEY TO BE CARRIED OUT ON AN ALL 
ISLAND BASIS 
 
 
-Eoin Ryan 
 
Mr. Eoin Ryan Minister for Local Development with special responsibility for the National Drugs Strategy 
today (14th May 2002) warmly welcomed the decision by the National Advisory Committee on Drugs 
(NACD) and the Drug and Alcohol Information and Research Unit (DAIRU) in Northern Ireland to jointly 
undertake a population survey on drug-use on an all island basis.  
 
Minister Ryan said “I established the National Advisory Committee on Drugs in 2000 to provide the 
Government with reliable and relevant information on the drug problem in Ireland.  This research will, for 
the first time, provide robust statistical information on drug use on an all island basis, and for both 
jurisdictions.  This will enable both the NACD and DAIRU to make comparisons across regions and health 
boards on the prevalence of drug use in the general population.  The sample population to be surveyed will 
be the 15 – 64 age group. Information on lifetime use, last year use and last month use will be examined”.   
 
The population survey will be conducted using the EMCDDA recommended questionnaire and method of 
face-to-face interviews and participants will be interviewed on the use of all drug types including alcohol, 
tobacco, prescribed drugs and illegal drugs.  The contract notice is going out to tender this month and the 
field work for the survey will be carried out in the latter months of this year the results of which will be 
available in mid 2003.   
 
It is particularly important that the research clearly identifies the extent and nature of drug use amongst the 
general population, specifically identifying trends amongst different segments of the population.  Analysis 
of the findings will show differences (where they exist) for each drug by age, gender and region for 
example. 
 
The measurement of the extent and pattern of drug use in the general population in Ireland is one of the key 
priorities set out by the NACD.  “It is imperative that reliable and comparable data is obtained and 
consequently, I am delighted that the NACD and the DAIRU are jointly commissioning this work which 
will provide very valuable information for the future”  Minister Ryan concluded.  
 
ENDS. 
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C. OJEC Notice Re Expression of Interest 
 
EUROPEAN UNION 
Publication of Supplement to the Official Journal of the European Communities 
2, rue Mercier,  L-2985 Luxembourg 
Telefax: (+352) 29 29 44 619, (+352) 29 29 44 623, (+352) 29 29 42 670 
E-mail: mp-ojs@opoce.cec.eu.int On-line notification: http://simap.eu.int 
 
CONTRACT NOTICE 
 
Works    
Supplies   
Services x  
Reserved for the Publication Office 
 
Date of receipt of the notice __________________ 
Identifier _________________________________ 
 
Is this contract covered by the Government Procurement Agreement (GPA)?     NO     YES   x 
 
SECTION I: CONTRACTING AUTHORITY 
 
I.1) OFFICIAL NAME AND ADDRESS OF THE CONTRACTING AUTHORITY 
 
Organisation  
 
National Advisory Committee on Drugs (NACD) 
 
For the attention of 
 
Pat O’Grady 
Address  
 
3rd Floor Shelbourne House, Shelbourne Road 
 
Postal code  
 
4 
Town  
 
Dublin  
 
Country  
 
Ireland 
Telephone 
 
00 353 1 667 0760 
Fax 
00 353 1 667 0828 
Electronic mail (e-mail) 
 
pat@nacd.ie 
Internet address (URL) 
 
www.nacd.ie 
 
I.2) ADDRESS FROM WHICH FURTHER INFORMATION CAN BE OBTAINED:   
As in I.1  x      If different, see Annex A 
I.3) ADDRESS FROM WHICH DOCUMENTATION MAY BE OBTAINED:   
As in I.1  x      If different, see Annex A 
I.4) ADDRESS TO WHICH TENDERS/REQUESTS TO PARTICIPATE MUST BE SENT:   
As in I.1  x        If different, see Annex A 
I.5) TYPE OF CONTRACTING AUTHORITY* 
Central level x EU Institution   Other   
Regional/local level   Body governed by public law     
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SECTION II: OBJECT OF THE CONTRACT  
II.1) DESCRIPTION 
II.1.1) Type of works contract ( in case of works contract )  
Execution   Design and execution   Execution, by whatever means of a work,   
    corresponding to the requirements 
     specified by the contracting authority 
II.1.2) Type of supplies contract  ( in case of supplies contract )  
Purchase   Rent   Lease   Hire-purchase   A combination of these   
II.1.3) Type of service contract  ( in case of service contract )  
 Service category   1A 
II.1.4) Is it a framework agreement ? * NO   YES x 
 
II.1.5) Title attributed to the contract by the contracting authority * 
Population Survey 
II.1.6) Description/object of the contract (use continuation sheet if necessary) 
The Brief: 
 
As part of efforts set out in the EU Action Plan on Drugs to establish the prevalence of drug use in the general 
population, the NACD and DAIRU have decided to jointly undertake a population survey to be completed by end 
May 2003 so that for the first time we will have robust statistical information on drug use on an all island basis, and 
for both jurisdictions.  This will enable us to make comparisons across regions and to meet commitments to provide 
the European Monitoring Centre for Drugs EMCDDA) and Drug Addiction with the relevant information.  The 
proposed survey will be carried out using a pre-prepared questionnaire and face to face interviews (preferred method 
under EMCDDA guidelines) among the 15 – 64 age group.  Information on lifetime use, last year and last month use 
will be just of the issues explored. 
 
We are developing our survey based on the guidelines produced by the EMCDDA which state as 
the main aims: 
 
• To report prevalence and continuation rates of the most common illicit drugs in the general population by 
gender and age groups; 
• To allow cross country assessment of relationships between general patterns of use of illicit an licit drugs; 
• To allow the assessment of relationships between particular population attributes and the use of illicit drugs. 
_____________________________________________________________________________________ 
 
II.1.7) Site or location of works, place of delivery or performance 
_____________________________________________________________________________________ 
NUTS code * _______________ 
 
II.1.8) Nomenclature 
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II.1.8.1) Common Procurement Vocabulary (CPV) * 
 Main vocabulary Supplementary vocabulary (when applicable) 
Main object   .  .  .  -      -       -       -  
Additional 
objects 
  .  .  .  -  
  .  .  .  -  
  .  .  .  -  
  .  .  .  -  
    -       -       -  
    -       -       -  
    -       -       -  
    -       -       -  
 
II.1.8.2) Other relevant nomenclature (CPA / NACE / CPC) ______________________________________ 
 
II.1.9) Division into lots  (for details about lots use Annex B as many times as needed) 
NO   YES   
Tenders may be submitted for: one lot   several lots   all lots   
 
II.1.10) Will variants be accepted (where applicable) 
NO   YES   
II.2) QUANTITY OR SCOPE OF THE CONTRACT 
II.2.1) Total quantity or scope (including all lots and options, if applicable)  
_____________________________________________________________________________________ 
_____________________________________________________________________________________ 
_____________________________________________________________________________________ 
II.2.2) Options  (if applicable). Description and time when they may be exercised (if possible) 
 
_____________________________________________________________________________________ 
_____________________________________________________________________________________ 
 
 
II.3) DURATION OF THE CONTRACT OR TIME LIMIT FOR COMPLETION 
Either: Period in month/s      and/or  days      (from the award of the contract) 
Or: Starting   /09/2002 and/or ending 30/05/2003  (dd/mm/yyyy) 
 
 
SECTION III: LEGAL, ECONOMIC, FINANCIAL AND TECHNICAL INFORMATION 
 
III.1) CONDITIONS RELATING TO THE CONTRACT  
 
III.1.1) Deposits and guarantees required (if applicable)  
_____________________________________________________________________________________ 
 
III.1.2) Main terms of financing and payment and/or reference to the relevant provisions (if  applicable)  
_____________________________________________________________________________________ 
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III.1.3) Legal form to be taken by the grouping of suppliers, contractors or service providers to whom 
the contract is awarded  (if applicable) 
_____________________________________________________________________________________ 
_____________________________________________________________________________________ 
 
III.2) CONDITIONS FOR  PARTICIPATION   
Prospective tenderers must submit an expression of interest detailing the following: 
• Qualifications to carry out and analyse such a survey and the proposed methodology to be employed; 
• Technical ability and financial standing to carry out and analyse the survey in Ireland and Northern Ireland; 
• Track record of project management team and any consultants to be used; 
• The capacity, including fieldwork, to carry out the survey within the proposed timescale in both 
jurisdictions; 
 
As this is an all island survey, the successful tenderer must demonstrate the capacity to conduct 
interviews in Ireland and Northern Ireland with an appropriate skilled workforce.  However, the 
NACD/DAIRU would welcome consultants forming partnerships with other consultants to bring 
particular expertise to the project and/or to ensure adequate coverage of both Ireland and 
Northern Ireland.  However, partnerships will be required to nominate a project manager who 
will oversee and be responsible for all aspects of the project. 
 
Once the data have been collected a comprehensive analysis must be carried out.  The substantive report 
will include an analysis by drug, by age, by gender and by region.  It would be expected that comparisons 
be made between groups together with a commentary on the results.  The main findings should be 
summarised.  A separate complete financial report for the project will also be required.  Copyright will 
rest with the NACD and DAIRU. 
 
An invitation to tender for the survey will be issued to between 5 and 10 companies based on the 
information received to this notice.  Contract documents will issue with a more detailed tender notice at 
the next stage.  Selection criteria for evaluating tenders will be set out in the full tender notice. 
 
 
III.2.1.1) Legal position – means of proof required 
Statement of legal position ________________________________________________________________ 
_____________________________________________________________________________________ 
_____________________________________________________________________________________ 
_____________________________________________________________________________________ 
 
III.2.1.2) Economic and financial capacity – means of proof required 
Annual report or financial statement or recent accounts to be available for inspection if requested.  Tax 
clearance certificate from the Revenue Commissioners or appropriate tax clearance for EU applicants_____ 
_____________________________________________________________________________________ 
_____________________________________________________________________________________ 
 
III.2.1.3) Technical capacity – means of proof required  
Description of experience, expertise, and publications __________________________________________ 
_____________________________________________________________________________________ 
 
III.3) CONDITIONS SPECIFIC TO SERVICES CONTRACTS  
III.3.1) Is provision of the service reserved to a specific profession? 
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NO   YES   
       If yes, reference of the relevant law, regulation or administrative provision   
_____________________________________________________________________________________ 
_____________________________________________________________________________________ 
III.3.2) Will legal entities be required to state the names and professional qualifications of the personnel 
responsible for execution of the contract? 
NO   YES x 
SECTION IV: PROCEDURE 
IV.1) TYPE OF PROCEDURE  
 
Open   Accelerated restricted     
Restricted x Accelerated negotiated    
Negotiated      
 
IV.1.1) Have candidates already been selected? (for negotiated procedure only and if applicable) 
NO x YES   If yes, provide details under Other information (section VI)  
 
IV.1.2) Justification for the choice of accelerated procedure (if applicable) 
_____________________________________________________________________________________ 
_____________________________________________________________________________________ 
 
IV.1.3) Previous publication concerning the same contract  (if applicable)  
IV.1.3.1) Prior information notice concerning the same contract  (if applicable) 
Notice number in 
OJ content list      /S    -          of   /  /     (dd/mm/yyyy) 
IV.1.3.2) Other previous publications 
Notice number in 
OJ content list      /S    -          of   /  /     (dd/mm/yyyy) 
 
IV.1.4) Envisaged number of suppliers which will be  invited to tender  (when applicable) 
Number      or: Minimum   05  /   Maximum  10 
IV.2) AWARD CRITERIA  
 
 A) Lowest price      
 or 
 B) The most economically advantageous tender in terms of: x 
B1) criteria as stated below (in descending order of priority where possible)   
  1 _______________________  4 ________________________ 7 ______________________ 
  2 _______________________ 5 ________________________ 8 ______________________ 
  3 _______________________ 6 ________________________ 9 ______________________ 
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In descending order of priority : NO     YES     
or: 
B2) criteria as stated in contract documents    x 
 
IV.3) ADMINISTRATIVE INFORMATION 
 
IV.3.1) Reference number attributed to the file by the contracting authority *   RFT/popSurvey _________ 
_____________________________________________________________________________________ 
 
 
IV.3.2) Conditions for obtaining contract document and additional documents 
Obtainable until   /  /      (dd/mm/yyyy) 
Price (where applicable) _____________________Currency ___________________________________ 
Terms and method of payment ____________________________________________________________ 
_____________________________________________________________________________________ 
_____________________________________________________________________________________ 
 
IV.3.3) Time-limit for receipt of tenders or requests to participate (depending whether it is an open, 
restricted or negotiated procedure) 
  /  /     (dd/mm/yyyy)     or       37 days from dispatch of notice  
Time (when applicable): _________________ 
  
IV.3.4) Dispatch of invitations to tender to selected candidates (In restricted and negotiated procedure) 
 
Estimated date : 28/06/2002  (dd/mm/yyyy) 
 
IV.3.5) Language or languages in which tenders or requests to participate can be drawn up 
 
ES DA DE EL EN FR IT NL PT FI SV Other (s) – third country 
    x       ___________________ 
 
IV.3.6) Minimum time frame during which the tenderer must maintain its tender (in case of an open 
procedure) 
Until     /  /      (dd/mm/yyyy)     or    months and/or     days from 
the deadline stated for receipt of tenders 
IV.3.7) Conditions for opening tenders 
IV 3.7.1) Persons authorised to be present at the opening of tenders (where applicable) 
_____________________________________________________________________________________ 
_____________________________________________________________________________________ 
IV.3.7.2) Date, time and place 
Date     /  /      (dd/mm/yyyy) Time: _____________________________ 
Place ________________________________________________________________________________ 
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SECTION VI: OTHER INFORMATION 
 
VI.1) IS THIS NOTICE A NON-MANDATORY ONE? 
NO x YES   
 
VI.2) IF APPLICABLE, INDICATE WHETHER THIS PROCUREMENT IS A RECURRENT ONE AND THE ESTIMATED 
TIMING FOR FURTHER NOTICES TO BE PUBLISHED 
_____________________________________________________________________________________ 
_____________________________________________________________________________________ 
 
 
VI.3) DOES THE CONTRACT RELATE TO A PROJECT / PROGRAMME FINANCED BY EU-FUNDS?* 
NO x YES   
 If yes, indicate the project/programme and any useful reference __________________________________ 
_____________________________________________________________________________________ 
_____________________________________________________________________________________ 
 
VI.4) ADDITIONAL INFORMATION (if applicable) 
Background: 
 
The National Advisory Committee on Drugs (NACD) was established in July 2000 to advise the Irish 
Government in relation to the prevalence, prevention, treatment/rehabilitation and consequences of 
problem drug use in Ireland, based on analysis of research findings and information.  The Committee is 
overseeing the delivery of a three-year work programme on the extent, nature, causes and effects of drug 
use in Ireland.  The Committee comprises representatives nominated from relevant agencies and sectors 
both statutory and non-statutory.  The Committee operates under the aegis of the Department of Tourism, 
Sport and Recreation and report to the Minister of State responsible for the National Drugs Strategy.  
Further information can be obtained from the Committee’s website: www.nacd.ie 
 
The Drug and Alcohol Information and Research Unit (DAIRU) was established in May 2001 to develop and 
manage a programme of information  and research work in support of the joint implementation of the Northern 
Ireland Executive’s Drug and Alcohol Strategies, building on previous work to support the Drugs Strategy alone.  
DAIRU is located within the Department of Health, Social Services and Public Safety.  Further information can be 
obtained from the DHSSPS website: www.dhsspsni.gov.uk/iau 
_____________________________________________________________________________________ 
_____________________________________________________________________________________ 
 
VI.5) DATE OF DISPATCH OF THIS NOTICE:    15/05/2002  (dd/mm/yyyy) 
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ANNEX A 
 
 
1.2) ADDRESS FROM WHICH FURTHER INFORMATION CAN BE OBTAINED 
 
Organisation  
 
 
For the attention of 
Address  
 
 
Postal code  
Town   
 
 
Country  
 
Telephone 
 
Fax 
Electronic mail (e-mail) Internet address (URL) 
 
 
 
1.3) ADDRESS FROM WHICH DOCUMENTATION MAY BE OBTAINED 
 
 
Organisation  
 
 
For the attention of 
Address  
 
 
Postal code  
Town  
 
 
Country  
 
Telephone 
 
Fax 
Electronic mail (e-mail) Internet address (URL) 
 
 
 
1.4) ADDRESS TO WHICH TENDERS/REQUESTS TO PARTICIPATE MUST BE SENT 
 
Organisation  
 
 
For the attention of 
Address  
 
 
Postal code  
Town  
 
 
Country  
 
Telephone 
 
Fax 
Electronic mail (e-mail) Internet address (URL) 
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ANNEX B – INFORMATION ABOUT LOTS 
 
LOT n°    ........................................................................................................................................................ 
1) Nomenclature 
1.1) Common Procurement Vocabulary (CPV) * 
 Main vocabulary Supplementary vocabulary (when applicable) 
Main object   .  .  .  -      -       -       -  
Additional 
objects 
  .  .  .  -  
  .  .  .  -  
  .  .  .  -  
  .  .  .  -  
    -       -       -  
    -       -       -  
    -       -       -  
    -       -       -  
1.2) Other relevant nomenclature (CPA/NACE/CPC) ____________________________________________ 
_____________________________________________________________________________________ 
 
2) Short description ________________________________________________________________________ 
_____________________________________________________________________________________ 
_____________________________________________________________________________________ 
 
3) Scope or quantity ________________________________________________________________________ 
_____________________________________________________________________________________ 
 
4) Indication about different starting/delivery date (if applicable) 
Starting   /  /     (dd/mm/yyyy) / delivery   /  /     (dd/mm/yyyy) 
 
LOT n°    ........................................................................................................................................................ 
1) Nomenclature 
1.1) Common Procurement Vocabulary (CPV) * 
 Main vocabulary Supplementary vocabulary (when applicable) 
Main object   .  .  .  -      -       -       -  
Additional 
objects 
  .  .  .  -  
  .  .  .  -  
  .  .  .  -  
  .  .  .  -  
    -       -       -  
    -       -       -  
    -       -       -  
    -       -       -  
1.2) Other relevant nomenclature (CPA/NACE/CPC) ____________________________________________ 
_____________________________________________________________________________________ 
 
2) Short description ________________________________________________________________________ 
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_____________________________________________________________________________________ 
_____________________________________________________________________________________ 
 
3) Scope or quantity ________________________________________________________________________ 
_____________________________________________________________________________________ 
 
4) Indication about different starting/delivery date (if applicable) 
Starting   /  /     (dd/mm/yyyy) / delivery   /  /     (dd/mm/yyyy) 
 
..................................................  (Use present annex as many times as necessary) ..................................................
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D. Tender Brief for Population Survey 
 
TENDER BRIEF FOR POPULATION SURVEY 
Background 
The National Advisory Committee on Drugs (NACD) was established in July 2000 to advise the Irish Government in 
relation to the prevalence, prevention, treatment / rehabilitation and consequences of problem drug use in Ireland, 
based on the analysis of research findings and information. The Committee is overseeing the delivery of a three-year 
work programme on the extent, nature, causes and effects of drug use in Ireland. The Committee comprises 
representatives nominated from relevant agencies and sectors, both statutory and non-statutory. The Committee 
reports to the Minister of State responsible for the National Drugs Strategy. Further information can be obtained 
from the National Advisory Committee on Drug’s website www.nacd.ie. 
 
The Drug and Alcohol Information and Research Unit (DAIRU) was established in May 2001 to develop and 
manage a programme of information and research work in support of the joint implementation of the Northern 
Ireland Executive’s Drug and Alcohol Strategies, building on previous work to support the Drug Strategy alone.  
DAIRU is located within the Department of Health, Social Services and Public Safety.  Further information can be 
obtained from the DHSSPS website www.dhsspsni.gov.uk/iau. 
 
In Ireland, the measurement of the extent and pattern of drug use in the general population is one of the priorities set 
out by the NACD in deciding its 3-year work programme.   As the extent and pattern of drug use in the general 
population is one of the key five indicators produced by the EMCDDA18 (www.emcdda.org) and adopted by EU 
Member States, it is imperative that reliable and comparable data is obtained in this regard.   
 
In Ireland, the Government has agreed the NACD’s three-year work programme.  As part of this programme, the 
NACD has commissioned several research projects to assist in establishing an estimate of problem drug use in 
Ireland.  At present, a Capture/Recapture Study and a Network Analysis Study on Opiate Use are being carried out. 
 
In Northern Ireland, the primary focus of DAIRU is the development of a joint programme of drug and alcohol 
information and research work in support of the Drug Strategy for Northern Ireland and the Strategy for Reducing 
Alcohol Related Harm.  Both strategies highlight the need for detailed information on drug use and drinking patterns 
and behaviours in order to effectively target policy and practice. DAIRU is also involved in the evaluation of projects 
and initiatives funded through the Drug Strategy, management and development of the Northern Ireland Drug 
Misuse Database and dissemination of available information. 
 
The brief 
As part of efforts set out in the EU Action Plan on Drugs 2000 - 2004 to establish the prevalence of drug use in the 
general population, the NACD and DAIRU have decided to jointly undertake a population survey to be completed 
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by the end of May 2003 so that for the first time we will have robust statistical information on drug use on an all 
island basis, and for both jurisdictions.  This will enable us to make comparisons across regions and to meet 
commitments to provide the EMCDDA with the relevant information.  The proposed survey will be carried out using 
a pre-prepared questionnaire and face to face interviews (preferred method under EMCDDA guidelines) among the 
15 – 64 age group.  Information on lifetime use, last year and last month use will be just some of the issues explored. 
 
We are developing our survey based on the guidelines produced by the EMCDDA which state as the main aims: 
 
(1) To report prevalence and continuation rates of the most common illicit drugs in the general population 
by gender and age groups; 
 
(2) To allow cross country assessment of relationships between general patterns of use of illicit and licit 
drugs; 
 
(3) To allow the assessment of relationships between particular population attributes and the use of illicit 
drugs. 
 
Potential bidders should refer to the EMCDDA guidelines on conducting population surveys in relation to drug use, a 
copy of which is enclosed for your information. 
 
(i) Data Collection 
Survey mode 
The EMCDDA have produced a questionnaire instrument for this purpose, which we have amended and made more 
relevant to the all island context (preliminary draft enclosed).  It is expected that the successful bidder will, in 
conjunction with the RAG, explore the inclusion of further questions on, for example, cessation of drug use and how 
drugs are usually obtained.  The inclusion of such additional questions cannot jeopardise the integrity of prevalence 
estimates being derived from this survey.  Tenderers  are invited to explore these issues in their submission.  The 
population survey will be conducted by face-to-face interview and participants will be interviewed on use of all drug 
types to include alcohol, tobacco, prescribed medicines and illicit drugs. 
 
Sampling frame 
The sample population to be surveyed will be the 15 - 64 age group.  Information on lifetime use, last year use and 
last month use is required.  Non-contacts and refusals must be dealt with as per EMCDDA guidelines.  Tenderers are 
invited to suggest to us the sampling design appropriate to this survey and what mechanisms you would use to 
interview difficult to reach age groups. 
 
RAG 
The RAGcomprising representatives from the NACD, DAIRU, the Drug Misuse Research Division of the Health 
Research Board, and other interested parties will be appointed to oversee the project and the tenderers should show 
how and when progress in the research is to be reported to this Group.  Close collaboration with the RAGis expected 
during the lifetime of this research project to enable any design or other research difficulties be identified early and 
resolved quickly.   The RAGwill expect to have some involvement when fieldworkers are briefed on their tasks and 
targets and during the pilot-testing phase.  The fieldwork company will control the data entry and the company 
                                                                                                                                                                                            
18 EMCDDA the European Monitoring Centre for Drugs and Drug Addiction 
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should be able to demonstrate compliance with industry standards and quality assurance protocols consistent with 
maintaining a code of ethics in carrying out this work.  
 
Exact proceedings will be specified in a technical report as outlined in the EMCDDA Guidelines to be delivered on 
completion of the fieldwork and before analysis can begin.  Records must be maintained on the same database 
structure as the EMCDDA for easy transfer of information.  All data collected and information from analysis 
whether in hard copy and/or electronic form will be the property of the NACD and DAIRU and must be returned to 
the NACD on completion. 
 
Analysis of data collected 
Once the data has been collected a comprehensive analysis must be carried out.  The substantive report will include 
an analysis by drug, by age, by gender and by region (all island, Northern Ireland, Ireland and health boards in both 
jurisdictions).  We expect comparisons to be made between groups together with a commentary on the results.  The 
main findings should be summarised.  A separate complete financial report for the project will also be required.  
Copyright will rest with the NACD and DAIRU. 
Reports 
Reports should come to the RAGin stages; an interim report outlining the agreed sampling design and pilot test, and 
a second interim report outlining the completed fieldwork with the technical details and financial expenditure.  A 
third and final report should detail the analysis. 
Timescale 
A final report is expected no later than May 2003.  The budget available is in the region of €650,000 
Requirements 
Tenderers must submit a written proposal detailing the following:  the research methodology to be employed; data 
collection methods (e.g. CAPI; self completion questionnaire; interviewer completed questionnaire etc) and 
justification of outputs; project management from conception to completion with clear milestones; personnel 
involved, their credentials, use of consultants and track record of these consultants. 
 
Tenderers should provide a full and detailed breakdown of fees and costs resulting from the study (excluding VAT).  
There should be a breakdown (in terms of numbers of days) of the time which individual consultants in the team are 
expected to spend on the project along with a breakdown of the expected fees to be paid for each individual 
consultant’s time.  Costings for survey work should also be detailed.  Estimates of expenses which will be expected 
to arise during the course of the project (eg travel), should also be included. 
 
As this is an all island survey, the successful bidder must demonstrate the capacity to conduct interviews in both 
jurisdictions with an appropriately skilled workforce.  However, the RAGwould welcome consultants forming 
partnerships with other consultants to bring particular expertise to the project and/or to ensure adequate coverage on 
an all island basis.  However, partnerships will be required to nominate a project manager who will oversee and be 
responsible for all aspects of the project. 
 
Evaluation of the submissions be will based on the following criteria: 
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Research methodology: 
 
Understanding of the issues involved; 
Understanding of the work involved; 
Feasibility of the approach(es) suggested; 
 Methods to ensure confidentiality; 
 
Project management 
 
Ability to deliver key outputs on time; 
Clarity in description of milestones; 
Credibility of personnel and consultants involved; 
Track record; 
 
Value for Money 
 
Please send 7 copies of tenders no later than 12noon Friday 9th August 2002. 
 
Tenderers may be shortlisted to make a presentation to the RAG.  Tenderers should also be available by telephone on 
Friday 16th August 2002 should any clarification relating to the submission be sought by the assessing group. 
 
Tenders should be returned to: 
 
The Secretariat 
NACD 
3rd Floor 
Shelbourne House 
Shelbourne Road 
Ballsbridge 
Dublin 4 
Tel No: +353 1 667 0760/765;  Fax No: +353 1 667 0828; 
Email: info@nacd.ie  Web: www.nacd.ie 
All tenders should be marked REF/Ten/Popsurvey.
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E. About MORI MRC 
 
 
MORI MRC is a professional all-Ireland research agency, and a fully integrated part of MORI 
(Market & Opinion Research International) – the largest independent research agency in the 
UK.   
 
MORI MRC has considerable experience of undertaking rigorous, high quality, qualitative and 
quantitative research studies.  MORI conducts more social and public sector research than 
any other agency in the UK, and MORI MRC works with numerous government departments, 
health boards, and other public sector organisations in Ireland.   
 
For further details, please see www.morimrc.ie or www.mori.com.   
 
FIELDWORK 
 
OUR COMMITMENT TO QUALITY 
 
MORI MRC is fully committed to providing services of the highest quality to our clients. 
Outstanding and improving quality has always been one of our guiding principles.  All our 
research operations are governed by the Market Research Society’s Code of Conduct.  In 
addition, all MORI MRC’s fieldwork has been carried out to (Interviewer Quality Control 
Scheme (IQCS) standards since its inception. MORI MRC has been accredited to ISO 9001 
since 1995, making MORI MRC the only market research agency working across Ireland to 
work to these standards. 
 
In 1996, MORI became one of only two full service agencies to achieve accreditation under 
MRQSA (Market Research Quality Standards Association), and MORI MRC operates to the 
same high standards.  This sets out standards for each stage of a market research study and 
is designed to enable accredited companies to provide a superior service to their clients.  It 
is the only assurance that clients can have that key aspects of the study are being 
undertaken to externally imposed and audited standards. 
 
We regard these various standards as minimum requirements and not as goals in their own 
right.  
 
ISO 9001 
MORI MRC has been fully accredited to ISO 9001 since 1995, and has an established set of 
procedural checks which apply to all our research studies and are constantly under review as 
new opportunities for quality improvement arise.  Mandatory checks are made of 
questionnaires, reports and other materials to ensure the high quality of all documents, 
crucial aspects of study specifications are agreed in writing to alleviate confusion and study 
management forms enable increased control. Regular external audits of the system by 
Hallmark Quality Assurance are conducted and improvements, where suitable, are made. We 
are in the process of working towards achieving the new standard ISO 9004.  
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The MORI MRC Fieldforce and IQCS 
 
All interviewing was carried out by members of the MORI MRC Interviewer Panel who have 
been trained and work to the standards of the Interviewer Quality Control Scheme (IQCS). 
 
IQCS is the only industry scheme, which independently audits the fieldwork standards of its 
member companies, and it was devised to professionalise the market research supply 
industry.  It is fully endorsed by the Market Research Society. 
 
From its inception in 1987, MORI MRC recognised that any research company is only as 
good as its people in the field and we decided therefore to work to IQCS standards from the 
beginning and seek membership immediately.  We went to enormous lengths to select the 
right people to become interviewers, to give them the right training and we continually 
monitor and assess the quality of their work. 
 
We became members of IQCS after our first inspection and have followed the same policy 
ever since. Our membership of IQCS is renewed annually, following independent audits. We 
are currently the only company operating throughout Ireland who are members of IQCS.  
 
Fieldforce Training and Appraisals 
 
All applicants to the MORI MRC Fieldforce have a personal interview with a supervisor.  They 
carry out some Trial Interviewing designed to assess the standard of those who claim 
interviewing experience and to provide practical insight into the difficulties of the job for 
those who have never interviewed before.  Those who wish to continue and are deemed 
suitable, receive an initial three days' training, two in-house and one in the field.  The ratio 
of instructor to recruit is high; a typical training session is one instructor to no more than six 
trainees in-house, and one to three in the field. 
 
Only after these three full days of training, which cover an explanation of: 
 
1. Different types of market research; 
2. Sampling methods; 
3. Respondents/interviewer interface; 
4. Social classification; 
5. Administration and completion of questionnaire; 
6. Code of conduct, respondents' rights etc.; 
7. Assurance of confidentiality and respondent anonymity; 
8. Quality control 
 
is an Interviewer Identity Card issued and a trainee allowed to work on a 'live' job. 
 
All MORI MRC Interviewers and Recruiters carry Identity Cards issued by the Market 
Research Society (MRS). MRS Identity Cards, which bear the photograph and signature of 
the interviewer, are issued only after the signing of a declaration which states that the 
interviewer has read and agrees to abide by the MRS Code of Conduct.  This Identity Card is 
shown to each respondent before an interview takes place, to reassure them that the study 
is genuine. Furthermore, respondents are given a leaflet, which stresses the confidentiality of 
the process, and provides the telephone number of MORI MRC’s Field department to call if 
they have any further queries. 
 
A new interviewer is accompanied by his/her regional supervisor on each new type of job 
worked on and thereafter at least once in a six-month period.  Regular assessment and 
further training on an ongoing basis means a MORI MRC interviewer gains experience in 
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quota sampling, random selection, and other forms of market research fieldwork.  This 
enables us to offer a comprehensive service to clients. Fieldwork is carried out by a panel of 
around 300 fully trained interviewers across Ireland. These interviewers are controlled by ten 
strategically placed regional supervisors who, in turn, answer directly to the Field Director. 
We firmly believe that this service is unrivalled anywhere in terms of quality and 
commitment. 
 
The responsibility for all recruitment and training remains with our Field Director who has 
many years' fieldwork experience and this ensures absolute uniformity in the application of 
our fieldwork standards. 
 
Fieldwork Quality Control 
 
The success of the survey is entirely dependent on the quality of the data collected by the 
interviewers.  MORI MRC takes pride in our quality control procedures and we believe that 
they are second to none. 
 
MORI MRC maintains ten regional supervisors who have been personally trained by our Field 
Director in all aspects of quality control.  MORI MRC believes that regular accompaniment of 
interviewers, both highly experienced and newly recruited is vital to the continuation of its 
high standard of interviewing so each interviewer is accompanied at least once in a six-
month period by his/her regional supervisor.  An accompaniment lasts a minimum of three 
hours and the interviewer is assessed on the initial approach made, administration of the 
questionnaire, accuracy of recording the responses, attitude to the work etc. Feedback and 
guidance are given as appropriate and documented.  Other appraisals take the form of a 
discussion between interviewer and field staff where information gathered from validation 
checks, editing and coding together with feedback from accompaniments and field/staff 
executives is presented.  Again supporting documentation is retained. The contact with the 
Field Department through the local supervisor gives the interviewer a realisation that his/her 
work is valued and therefore valuable which, in turn, creates a more professional approach 
to the job of interviewing. 
 
MORI MRC is the only company in Ireland, which appraises interviewers in an ongoing and 
carefully controlled fashion. 
A minimum of 10% of completed interviews are backchecked on all quantitative surveys 
carried out by MORI MRC using a combination of telephone recall, personal recall or postal 
check card. This is applied to ensure that the interviewers have conducted the interviews 
professionally and in line with survey specifications. In general, respondents are asked to 
comment on among other things, the duration of the interview, their recollection of the 
being asked specific questions, being shown interviewer identification and their reaction to 
both the interview and the interviewer.  On surveys covering considerable time, such as this 
survey, backchecking is a continuous process throughout the fieldwork period, although each 
individual backcheck is carried out within two weeks of the interview.  Because of this MORI 
MRC identifies and corrects particular problems.  All interviewers on MORI MRC's Panel have 
their work backchecked and are advised of the results. 
 
For the Population Survey, we needed to reassure the respondent that responses would 
remain confidential, therefore, respondent contact details, which are necessary for this 
backchecking process, were recorded on a separate document to the completed 
questionnaire. Additionally, our backchecking questions confirmed completion of the survey 
and whether questions about certain topics were asked.  
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The final checking process involved supervisors editing all (100%) completed questionnaires. 
The supervisors quickly identified any problems which arose and ensured that they were 
corrected promptly. 
 
These procedures enabled us to provide detailed information on problems encountered 
during fieldwork, and our methods for correcting these problems, thus ensuring that 
potential survey bias can be adequately evaluated. It also ensured that any difficulties were 
identified in good time and swiftly resolved. 
 
 
MRS Code of Conduct 
 
MORI MRC directors and executive/field staff are members of the Market Research Society, 
and all MORI MRC directors, executives and interviewers are subject to the requirements of 
the Market Research Society (MRS) Code of Conduct. This assures all respondents that the 
information gathered during the course of an interview is confidential and that their opinions 
and views will remain anonymous. 
 
 
Customer Service Monitor 
 
In addition to the regular quality surveillance visits carried out by external bodies in 
connection with IQCS, and ISO 9001, MORI MRC has its own auditing and quality team, 
including our own Customer Service Monitor which provides feedback from our clients on the 
standard and quality of service we provide.  
 
The MORI MRC Promise 
 
At this juncture in the interview we informed the respondent of the ‘The MORI MRC Promise’ 
and showed them a card.  The MORI MRC Promise is a reassurance we include on many 
MORI MRC studies, which stresses our independence and objectivity.  The promise also 
reassures respondents that MORI MRC is bound by the Market Research Society’s Code of 
Conduct whereby we are bound not to identify respondent’s personal details to anyone 
outside this research study.   
 
Our promise also states that all details collected are purely for the purpose of market 
research and that information will be represented in statistical format. The MORI MRC 
Promise, we find, lets respondents feel confident about their anonymity with studies of a 
sensitive nature and helps to enhance response rates. The images overleaf indicate how ‘The 
MORI MRC Promise’ was shown to potential respondents on a double-sided card.   
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Promise
Contact Telephone Numbers:
ROI 1890 631133
NI  028 9050 0810
The
"We are an independent research
company.  All information you give
will be treated confidentially. All
details collected are purely for the
purpose of market research and the
information is used purely
for statistical purposes.
We abide by the
Market Research Code
of Conduct"
Promise
The
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F. Contact Sheet 
 
 
 
An example of the contact sheets used for Ireland is displayed on the pages, which follow.  
The contact sheet used for Northern Ireland was identical except for the substitution of the 
Department of Community, Rural and Gaeltacht Affairs with the Department of Health, Social 
Services and Public Safety. 
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CONTACT SHEET –225347 (Ireland) 
 
 
 
Interviewer 
  
Interviewer 
Number 
 
 
 
 
Q.C1 
WEEKDAY 
(1-7) 
TIME  
(1-3) 
DATE  
(1-31) 
MONTH (1-
12) COMMENTS - record outcome of each call 
1     
2     
3     
4     
5
     
6     
7     
8     
     
  
TOTAL NUMBER OF CALLS (WRITE IN BOX) 
   
You must record at least 5 attempts in total to make appointment/complete interview before abandoning 
address. 
 At least one call must be an evening and one at a weekend plus one further evening or weekend call. 
WEEKDAY  MON = 1 $ TUES = 2 $  WED = 3 $ THURS = 4 $ FRI = 5 $ SAT = 6 $ SUN = 7 
C
O
N
TA
C
T 
R
EC
O
R
D
 
CONTACT CODES: 
TIME  UP TO 12 NOON = 1  $   12 NOON TO 3PM = 2   $   3-6PM = 3  $    AFTER 6PM = 4 
 
 
* INTRODUCTION * 
Good morning/afternoon/evening.  My name is .... from MORI MRC, an independent research 
company.  We are conducting a study today about lifestyles such as alcohol, tobacco and drugs, 
and I’d like to ask you some questions.  The interview will last approximately 15 minutes. 
 
IF ASKED STATE ….. This study is being conducted on behalf of the Department of Community, 
Rural and Gaeltacht Affairs. 
 
IF UNSURE/CONCERNED ABOUT CONFIDENTIALITY STATE: 
We would like to stress that all information you give in the questionnaire will be treated 
confidentially.  No information about you as an individual, including your name and address, will be 
passed on to anyone outside this research study.  All the details collected are purely for the purpose 
of market research and the information is used purely for statistical purposes. 
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*  RESPONDENT SELECTION * 
 
 
Q.C2 I’d like to interview one of the people aged 15 - 64 who live in this household, 
and in order to choose fairly, I’d like to ask a few questions.  Can you tell me 
how many people (aged between 15 and 64) currently live here as part of this 
household? 
  One only 01 COMPLETE INTERVIEW 
  Two or more 02 COMPLETE DETAILS BELOW 
  None 03 GO TO Q.C5 
 
 
 
Q.C3 We have a special way of selecting which person to interview and in order to choose 
fairly, can you please tell me the first name or initial of each member of the household 
(aged between 15 & 64), and the date and month they have their birthday. 
LIST NAMES/INITIALS BELOW  
PERSON 
NO. 
NAME OR 
INITIAL 
DATE &MONTH 
OF BIRTH 
AGE 
NOW* INCLUDE: 
1    People normally living here away for up 
to 6 months 
2    People away at work for whom this is 
main address 
3    Boarders and lodgers 
4     
5    EXCLUDE 
6    People 18+ living elsewhere for 
study/work 
7    Spouses separated and no longer 
resident 
8    People away for 6 months or more 
9     
10     
 
INTERVIEWER:  CIRCLE PERSON NUMBER WHO HAD BIRTHDAY LAST – YOU MUST ATTEMPT TO 
INTERVIEW THIS PERSON.  NO SUBSTITUTIONS ARE ALLOWED ONCE SELECTED.  MAKE 
APPOINTMENT IF NECESSARY. 
 
* ONLY ASK AGE OF SELECTED RESPONDENT- IF 15 OBTAIN PARENTAL PERMISSION 
 
 
 
Q.C4 RECORD RESPONDENT’S FULL NAME & TELEPHONE NUMBER, (INCLUDING 
STD). 
 
TITLE:  FULL NAME:  
TELEPHONE (INC STD CODE):   
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*  DWELLING INFORMATION  * 
 
Q.C5 Code property type of printed address: 
 
House/bungalow – detached 01 
House/bungalow – semi-detached 02 
House/bungalow – mid terrace 03 
House/bungalow – end terrace 04 
Purpose built flat/maisonette(s)/ apartment(s) - building less than six floors 05 
Purpose built flat/maisonette(s)/ apartment(s)  - building six or more floors 06 
Conversion flat/maisonette(s)/Shared House 07 
Hostel or bed and breakfast 08 
Other (WRITE IN) 09 
  
 
 
 
Q.C6 
FINAL OUTCOME  
Successful interview 01 
Refused before respondent selection  02 
Refused after respondent selection 03 
R
EF
U
SE
D
 
Entry to block/scheme refused by warden etc 04 
Occupied, no contact at address after  5+ calls 05 
No contact with selected resident, 4+ calls 06 
Occupier in but not answering door after 5+ calls 07 N
O
 
C
O
N
TA
C
T 
Unsure if occupied, no contact after 5+ calls 08 
Property vacant 09 
Property derelict 10 
Property demolished 11 
Non-residential property 12 PR
O
PE
R
TY
 
IN
EL
IG
IB
LE
 
Property not found 13 
Too ill to participate 
WRITE IN DESCRIPTION 14 
Away during fieldwork  
WRITE IN DATE BACK 15 
Household Not Eligible 
WRITE IN REASON 16 
Mother tongue required  
WRITE IN LANGUAGE 17 
Other  
WRITE IN 18 
O
TH
ER
 
Withdrawn by Head Office 19 
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Q.C7 
REFUSAL INFORMATION 
Never does surveys 01 
Interview takes too long 02 
Taken part in too many surveys  03 
Interview is too intrusive 04 
Too busy at this time 05 
Always too busy 06 
Worried about misuse of information  07 
Worried about confidentiality 08 
Worried about safety/security 09 
Survey is a waste of money 10 
Not interested in helping government 11 
Not interested in subject matter 12 
“Nothing in it for me” 13 
Other (WRITE IN) 14 
R
EA
SO
N
 F
O
R
 R
EF
U
SA
L 
 (M
U
LT
IC
O
D
E 
O
K
) 
 
 
 
R
E
-
C
O
N
TA
C
T 
DO NOT RECONTACT 
respondent likely to take offence or be potentially dangerous if further efforts made 
to persuade them to take part 
15 
Estimated Age  
WRITE IN 
 
Male 01 Sex of person refusing: 
Female 02 
White 01 
ES
TI
M
A
TE
D
 C
O
N
TA
C
T 
D
ET
A
IL
S 
Ethnic Origin: 
Other 02 
 
 
Remember to return all contact sheets to the office (productives and failures) 
as soon as possible. 
 
Check all relevant sections have been code. 
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G. Questionnaire - Ireland 
 
 
 
The questionnaire for Ireland is displayed on the pages, which follow: 
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Unique 
Address Code 
    Sample Point 
Number 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REPUBLIC OF IRELAND 
 
POPULATION STUDY 
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POPULATION STUDY 
 
INTRODUCTION 
 
Good morning/afternoon/evening. my name is .... from MORI MRC, an independent research 
company.  We are conducting a study today about lifestyles such as alcohol, tobacco and 
drugs, and I’d like to ask you some questions. The interview will last approximately 15 
minutes. 
 
IF ASKED : This study is being conducted on behalf of the Department of Community, Rural 
& Gaeltacht Affairs in the Republic of Ireland. 
 
IF UNSURE/CONCERNED ABOUT CONFIDENTIALITY STATE: 
We would like to stress that all information you give in the questionnaire will be treated 
confidentially.  No information about you as an individual, including your name and address, 
will be passed on to anyone outside this research study.  All the details collected are purely 
for the purpose of research and the information is used purely for statistical purposes. 
Tobacco 
 
First of all I’m going to ask a few questions about tobacco. 
Q1 Yes 1 GO TO Q.3 
 
Do you smoke tobacco products, such as cigarettes, 
cigars or a pipe? No 2 CONTINUE 
 
 
Q2 Yes 1 CONTINUE 
 
Have you ever smoked tobacco products in 
the past? No 2 
  Don’t know 3 
GO TO Q8 
 
 
Q3  # INSERT 
AGE 
 
At what age did you smoke tobacco products 
for the first time? 
Don’t know -1  
 
 
Q4 Yes 1 CONTINUE 
 
During the last 12 months have you smoked tobacco 
products? No 2 GO TO Q8 
 
 
Q5 Yes 1 CONTINUE 
 
During the last 30 days have you smoked tobacco? 
No 2 GO TO Q8 
 
 
Q6  # INSERT 
FIGURE 
 
During the last 30 days on how many days 
have you smoked? 
Don’t know -1  
 
 
Q7 Branded cigarettes 1  
 Hand rolled cigarettes 2 
 Cigars 3 
 Pipe 4 
 
What type of tobacco product do 
you most commonly use?  READ 
OUT – MULTI CODE 
Don’t know 5 
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Alcohol 
 
Now I’m going to ask a few questions about alcohol. 
Q8 Yes 1 GO TO Q.10 
 
Do you drink alcohol? 
No 2 CONTINUE 
 
 
Q9 Yes 1 CONTINUE 
 
Have you ever drunk alcohol? 
No 2 GO TO Q15 
 
 
Q10  # INSERT 
AGE 
 
At what age did you first drink alcohol? 
Don’t know -1  
 
Q11 Yes 1 CONTINUE 
 
During the last 12 months, have you drunk any 
alcohol? No 2 GO TO Q15 
 
Q12 Yes 1 CONTINUE 
 
During the last 30 days have you drunk any alcohol? 
No 2 GO TO Q15 
 
Q13  # INSERT 
FIGURE 
 
During the last 30 days, on how many days 
have you drunk alcohol? 
Don’t know -1  
 
Q14 Daily or almost daily 1  
 2/3 times a week 2  
 Every week 3 
 2/3 times a month 4 
 Every month 5 
 
 Less often than every month 6  
 
How often do you drink six or 
more alcoholic drinks on the 
same occasion?  READ OUT 
Never 7  
Now I’m going to ask a few questions about drugs that are sometimes used as 
medicines. 
 
SHOW CARD 15 
Q15 Yes 1 CONTINUE 
 No 2 GO TO Q24 
 
Have you ever heard of any of these …………..? 
SHOW CARD, IF YES TO ANY LISTED ON CARD 
CODE YES AND CONTINUE    
 
Q16 Yes 1  
 
Do you personally know people who take sedatives, 
tranquillisers or anti-depressants? No 2  
 
Q17 Yes 1 CONTINUE 
 
Have you ever taken sedatives tranquillisers, or anti-
depressants? No 2 GO TO Q24 
 
Q18  # INSERT 
AGE 
 
 
At what age did you first take sedatives, 
tranquillisers or anti-depressants? 
Don’t know -1  
Q19 Yes 1 CONTINUE 
 
During the last 12 months have you taken sedatives, 
tranquillisers or anti-depressants? No 2 GO TO Q24 
Q20 Yes 1 CONTINUE 
 
During the last 30 days have you taken sedatives, 
tranquillisers or anti-depressants? No 2 GO TO Q24 
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Q21  # INSERT 
FIGURE 
 
During the last 30 days, on how many days 
have you taken sedatives, tranquillisers or 
anti-depressants? Don’t know -1  
 
SHOW CARD 22 
Q22 Tablets 1  
 Injection with a needle 2 
 Other (specify) 
___________________ 
3  
 
What method do you commonly 
use to take sedatives, 
tranquillisers or anti-depressants? 
Just call me out the numbers 
from the card – MULTI CODE Don’t know 4  
 
SHOW CARD 23 
Q23 I got them on a prescription 1  
 I got them from someone else I know 2 
 I bought them without a prescription 
in a chemist 
3  
 None of the above 4  
 
The last occasion 
you took sedatives, 
tranquillisers or 
anti-depressants 
how had you 
obtained them? 
JUST CALL ME OUT 
THE NUMBER FROM 
THE CARD 
   
 
 
Now I’m going to ask a few questions about other drugs 
 
SHOW CARD 24 
Q24 Yes 1 CONTINUE 
 No 2 GO TO Q33 
 
Have you ever heard of any of these …………..? 
SHOW CARD, IF YES TO ANY LISTED ON CARD 
CODE YES AND CONTINUE    
 
 
Q25 Yes 1  
 
Do you personally know people who take cannabis? 
No 2  
 
 
Q26 Yes 1 CONTINUE 
 
Have you ever taken cannabis? 
No 2 GO TO Q33 
 
 
Q27  # INSERT 
AGE 
 
At what age did you first take cannabis? 
Don’t know -1  
 
 
Q28 Yes 1 CONTINUE 
 
During the last 12 months have you taken cannabis? 
No 2 GO TO Q33 
 
 
Q29 Yes 1 CONTINUE 
 
During the last 30 days have you taken cannabis? 
No 2 GO TO Q33 
 
 
Q30  # INSERT 
FIGURE 
 
During the last 30 days, on how many days 
have you taken cannabis? 
Don’t know -1  
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SHOW CARD 31 
Q31 What type of cannabis do you most commonly use? 
Just call me out the numbers from the card – MULTI CODE 
Grass 1 Resin 7 
Weed 2 
Skunk 3 
Hash Oil 4 
Other (specify) 
__________________________ 
 
8 
Herb 5 Don’t know 9 
Hash 6   
 
SHOW CARD 32 
Q32 Joint 1  
 Pipe 2  
 Bong 3  
 Eat 4  
 Other (specify) 
__________________ 
5  
 
What method do you most 
commonly use to take cannabis? 
 
Just call me out the numbers 
from the card – MULTI CODE 
Don’t know 6  
 
SHOW CARD 33 
Q33 Yes 1 CONTINUE 
 No 2 GO TO Q40 
 
Have you ever heard of any of these …………..? 
SHOW CARD, IF YES TO ANY LISTED ON CARD 
CODE YES AND CONTINUE    
 
Q34 Yes 1  
 
Do you personally know people who take ecstasy? 
No 2  
 
Q35 Yes 1 CONTINUE 
 
Have you ever taken ecstasy? 
No 2 GO TO Q40 
 
Q36  # INSERT 
AGE 
 
At what age did you first take ecstasy? 
Don’t know -1  
 
Q37 Yes 1 CONTINUE 
 
During the last 12 months have you taken ecstasy? 
No 2 GO TO Q40 
 
Q38 Yes 1 CONTINUE 
 
During the last 30 days have you taken ecstasy? 
No 2 GO TO Q40 
 
Q39  # INSERT 
FIGURE 
 
During the last 30 days, on how many days 
have you taken ecstasy? 
Don’t know -1  
SHOW CARD 40 
Q40 Yes 1 CONTINUE 
 No 2 GO TO Q47 
 
Have you ever heard of any of these …………..? 
SHOW CARD, IF YES TO ANY LISTED ON CARD 
CODE YES AND CONTINUE    
Q41 Yes 1  
 
Do you personally know people who take 
amphetamines? No 2  
 
Q42 Yes 1 CONTINUE 
 
Have you ever taken amphetamines? 
No 2 GO TO Q47 
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Q43  # INSERT 
AGE 
 
At what age did you first take amphetamines? 
Don’t know -1  
 
Q44 Yes 1 CONTINUE 
 
During the last 12 months have you taken 
amphetamines? No 2 GO TO Q47 
 
Q45 Yes 1 CONTINUE 
 
During the last 30 days have you taken 
amphetamines? No 2 GO TO Q47 
 
Q46  # INSERT 
FIGURE 
 
During the last 30 days, on how many days 
have you taken amphetamines? 
Don’t know -1  
SHOW CARD 47 
Q47 Yes 1 CONTINUE 
 No 2 GO TO Q54 
 
Have you ever heard of any of these …………..? 
SHOW CARD, IF YES TO ANY LISTED ON CARD 
CODE YES AND CONTINUE    
 
Q48 Yes 1  
 
Do you personally know people who take crack? 
No 2  
 
Q49 Yes 1 CONTINUE 
 
Have you ever taken crack? 
No 2 GO TO Q54 
 
Q50  # INSERT 
AGE 
 
At what age did you first take crack? 
Don’t know -1  
Q51 Yes 1 CONTINUE 
 
During the last 12 months have you taken crack? 
No 2 GO TO Q54 
Q52 Yes 1 CONTINUE 
 
During the last 30 days have you taken crack? 
No 2 GO TO Q54 
Q53  # INSERT 
FIGURE 
 
During the last 30 days, on how many days 
have you taken crack? 
Don’t know -1  
SHOW CARD 54 
Q54 Yes 1 CONTINUE 
 No 2 GO TO Q62 
 
Have you ever heard of any of these …………..? 
SHOW CARD, IF YES TO ANY LISTED ON CARD 
CODE YES AND CONTINUE    
 
Q55 Yes 1  
 
Do you personally know people who take cocaine? 
No 2  
 
Q56 Yes 1 CONTINUE 
 
Have you ever taken cocaine? 
No 2 GO TO Q62 
 
Q57  # INSERT 
AGE 
 
At what age did you first take cocaine? 
Don’t know -1  
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Q58 Yes 1 CONTINUE 
 
During the last 12 months have you taken cocaine? 
No 2 GO TO Q62 
 
Q59 Yes 1 CONTINUE 
 
During the last 30 days have you taken cocaine? 
No 2 GO TO Q62 
 
Q60  # INSERT 
FIGURE 
 
During the last 30 days, on how many days 
have you taken cocaine? 
Don’t know -1  
SHOW CARD 61 
Q61 Doing a line/Snort 1  
 Injection with a needle 2  
 Other (specify) 
_____________________ 
3  
 
What method do you commonly 
use to take cocaine? 
Just call me out the number 
from the card – MULTI CODE 
 Don’t know 4  
SHOW CARD 62 
Q62 Yes 1 CONTINUE 
 No 2 GO TO Q70 
 
Have you ever heard of any of these …………..? 
SHOW CARD, IF YES TO ANY LISTED ON CARD 
CODE YES AND CONTINUE    
 
Q63 Yes 1  
 
Do you personally know people who take heroin? 
No 2  
 
Q64 Yes 1 CONTINUE 
 
Have you ever taken heroin? 
No 2 GO TO Q70 
 
Q65  # INSERT 
AGE 
 
At what age did you first take heroin? 
Don’t know -1  
 
Q66 Yes 1 CONTINUE 
 
During the last 12 months have you taken heroin? 
No 2 GO TO Q70 
 
Q67 Yes 1 CONTINUE 
 
During the last 30 days have you taken heroin? 
No 2 GO TO Q70 
 
Q68  # INSERT 
FIGURE 
 
During the last 30 days, on how many days 
have you taken heroin? 
Don’t know -1  
SHOW CARD 69 
Q69 Smoke 1  
 Injection with a needle 2  
 ‘Chasing the dragon’ 3  
 Other (specify) 
_____________________ 
4  
 
What method do you commonly 
use to take heroin? Just call 
me out the number from the 
card – MULTI CODE 
Don’t know 5  
SHOW CARD 70 
Q70 Yes 1 CONTINUE 
 No 2 GO TO Q77 
 
Have you ever heard of any of these …………..? 
SHOW CARD, IF YES TO ANY LISTED ON CARD 
CODE YES AND CONTINUE    
Q71 Yes 1  
 
Do you personally know people who take LSD? 
No 2  
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Q72 Yes 1 CONTINUE 
 
Have you ever taken LSD? 
No 2 GO TO Q77 
 
Q73  # INSERT 
AGE 
 
At what age did you first take LSD? 
Don’t know -1  
 
Q74 Yes 1 CONTINUE 
 
During the last 12 months have you taken LSD? 
No 2 GO TO Q77 
 
Q75 Yes 1 CONTINUE 
 
During the last 30 days have you taken LSD? 
No 2 GO TO Q77 
 
Q76  # INSERT 
FIGURE 
 
During the last 30 days, on how many days 
have you taken LSD? 
Don’t know -1  
SHOW CARD 77 
Q77 Yes 1 CONTINUE 
 No 2 GO TO Q84 
 
Have you ever heard of any of these …………..? 
SHOW CARD, IF YES TO ANY LISTED ON CARD 
CODE YES AND CONTINUE    
 
Q78 Yes 1  
 
Do you personally know people who take solvents? 
No 2  
 
Q79 Yes 1 CONTINUE 
 
Have you ever taken solvents? 
No 2 GO TO Q84 
 
Q80  # INSERT 
AGE 
 
At what age did you first take solvents? 
Don’t know -1  
 
Q81 Yes 1 CONTINUE 
 
During the last 12 months have you taken solvents? 
No 2 GO TO Q84 
 
Q82 Yes 1 CONTINUE 
 
During the last 30 days have you taken solvents? 
No 2 GO TO Q84 
 
Q83  # INSERT 
FIGURE 
 
During the last 30 days, on how many days 
have you taken solvents? 
Don’t know -1  
SHOW CARD 84 
Q84 Yes 1 CONTINUE 
 No 2 GO TO Q91 
 
Have you ever heard of any of these …………..? 
SHOW CARD, IF YES TO ANY LISTED ON CARD 
CODE YES AND CONTINUE    
 
Q85 Yes 1  
 
Do you personally know people who take poppers? 
No 2  
 
Q86 Yes 1 CONTINUE 
 
Have you ever taken poppers? 
No 2 GO TO Q91 
Q87  # INSERT 
AGE 
 
At what age did you first take poppers? 
Don’t know -1  
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Q88 Yes 1 CONTINUE 
 
During the last 12 months have you taken poppers? 
No 2 GO TO Q91 
 
Q89 Yes 1 CONTINUE 
 
During the last 30 days have you taken poppers? 
No 2 GO TO Q91 
 
Q90  # INSERT 
FIGURE 
 
During the last 30 days, on how many days 
have you taken poppers? 
Don’t know -1  
SHOW CARD 91 
Q91 Yes 1 CONTINUE 
 No 2 GO TO Q98 
 
Have you ever heard of any of these …………..? 
SHOW CARD, IF YES TO ANY LISTED ON CARD 
CODE YES AND CONTINUE    
 
Q92 Yes 1  
 
Do you personally know people who take magic 
mushrooms? No 2  
 
Q93 Yes 1 CONTINUE 
 
Have you ever taken take magic mushrooms? 
No 2 GO TO Q98 
 
Q94  # INSERT 
AGE 
 
At what age did you first take magic 
mushrooms? 
Don’t know -1  
 
Q95 Yes 1 CONTINUE 
 
During the last 12 months have you taken magic 
mushrooms? No 2 GO TO Q98 
 
Q96 Yes 1 CONTINUE 
 
During the last 30 days have you taken magic 
mushrooms? No 2 GO TO Q98 
 
Q97  # INSERT 
FIGURE 
 
During the last 30 days, on how many days 
have you taken take magic mushrooms? 
Don’t know -1  
SHOW CARD 98 
Q98 Yes 1 CONTINUE 
 No 2 GO TO Q112 
 
Have you ever heard of any of these …………..? 
SHOW CARD, IF YES TO ANY LISTED ON CARD 
CODE YES AND CONTINUE    
Q99 Yes 1  
 
Do you personally know people who take 
methadone? No 2  
 
Q100 Yes 1 CONTINUE 
 
Have you ever taken methadone? 
No 2 GO TO Q112 
 
Q101  # INSERT 
AGE 
 
At what age did you first take methadone? 
Don’t know -1  
 
Q102 Yes 1 CONTINUE 
 
During the last 12 months have you taken 
methadone? No 2 GO TO Q112 
 
Q103 Yes 1 CONTINUE 
 
During the last 30 days have you taken methadone? 
No 2 GO TO Q112 
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Q104a  # INSERT 
FIGURE 
 
During the last 30 days, on how many days 
have you taken methadone? 
Don’t know -1  
SHOW CARD 104b 
Q104b I got it on a prescription 1  
 I got it from someone else I know 2 
 I bought it without a prescription in a 
chemist 
3  
 None of the above 4  
 
The last occasion 
you took 
methadone how 
had you obtained 
it? 
JUST CALL ME OUT 
THE NUMBER FROM 
THE CARD 
   
 
NOTE TO INTERVIEWER: Q105-Q111 NOT APPLICABLE TO ROI 
QUESTIONNAIRE 
 
SHOW CARD 112 
Q112 Yes 1 CONTINUE 
 No 2 GO TO Q126 
 
Have you ever heard of any of these …………..? 
SHOW CARD, IF YES TO ANY LISTED ON CARD 
CODE YES AND CONTINUE    
 
Q113 Yes 1  
 
Do you personally know people who take other 
opiates? No 2  
 
Q114 Yes 1 CONTINUE 
 
Have you ever taken other opiates? 
No 2 GO TO Q126 
 
Q115  # INSERT 
AGE 
 
At what age did you first take other opiates? 
Don’t know -1  
 
Q116 Yes 1 CONTINUE 
 
During the last 12 months have you taken other 
opiates? No 2 GO TO Q126 
 
Q117 Yes 1 CONTINUE 
 
During the last 30 days have you taken other 
opiates? No 2 GO TO Q126 
 
Q118a  # INSERT 
FIGURE 
 
During the last 30 days, on how many days 
have you taken other opiates? 
Don’t know -1  
SHOW CARD 118b 
Q118b I got them on a prescription 1  
 I got them from someone else I know 2 
 I bought them without a prescription 
in a chemist 
3  
 None of the above 4  
 
The last occasion 
you took other 
opiates how had you 
obtained them? JUST 
CALL ME OUT THE 
NUMBER FROM THE 
CARD 
   
 
 
NOTE TO INTERVIEWER: Q119-Q125 NOT APPLICABLE TO ROI 
QUESTIONNAIRE  
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Now, I’d like to get your opinions. 
SHOW CARD 126 
Q126 More as a criminal 1  
 More as a patient 2  
 Neither a criminal nor a patient 3  
 Both a criminal and a patient 4  
 
Do you perceive a drug 
addict more as a criminal 
or more as a patient? 
Don’t know, cannot decide 5  
SHOW CARD 127 
Q127 TO WHAT EXTENT DO YOU AGREE WITH THE FOLLOWING STATEMENTS …. 
READ OUT IN TURN 
% 
Fully 
agree 
Largely 
agree 
Neither Largely 
disagree 
Fully 
disagree 
Don’t 
know 
“People should be permitted to take 
cannabis for medical reasons” 1 2 3 4 5 6 
“People should be permitted to take 
cannabis for recreational reasons” 1 2 3 4 5 6 
”People should be permitted to take 
heroin” 1 2 3 4 5 6 
 
SHOW CARD 128 
Q128 Individuals differ in whether or not they disapprove of people doing certain things. I 
will mention a few things, which some people might do.  Can you tell me if you 
would not disapprove, disapprove or strongly disapprove when people do any of 
these things? 
READ OUT IN TURN 
% 
Do not 
disapprove 
Disapprove Strongly 
disapprove 
Don’t 
know 
Trying ecstasy once or twice 1 2 3 4 
Trying heroin once or twice 1 2 3 4 
Smoking 10 cigarettes a day 1 2 3 4 
Having one or two drinks several times a week 1 2 3 4 
Smoking cannabis occasionally 1 2 3 4 
 
SHOW CARD 129 
Q129 Now I would like to know how much do you think that people risk harming 
themselves, physically or in other ways, if they do certain things. I will again mention 
a few things some people might do. Please tell me if you consider it to be no risk, a 
slight risk, a moderate risk or a great risk, if people do such things. 
READ OUT IN TURN 
% 
No 
risk 
Slight 
risk 
Moderate 
risk 
Great 
risk 
Don’t 
know 
Smoke one or more packs of cigarettes a day 1 2 3 4 5 
Have five or more drinks at the weekend 1 2 3 4 5 
Smoke cannabis regularly 1 2 3 4 5 
Try ecstasy once or twice 1 2 3 4 5 
Try cocaine or crack once or twice 1 2 3 4 5 
 
Q130 Yes 1  
 
Here in Ireland have you ever been offered illegal 
drugs? No 2  
ASK ALL WHO DRINK ALCOHOL AT Q8 OR HAVE EVER DRUNK ALCOHOL AT Q9 
Q131 Yes 1 CONTINUE 
 
Earlier in the study you stated that you have drunk 
alcohol, have you ever drunk alcohol regularly? No 2 GO TO Q133 
 
Q132  # INSERT 
AGE 
 
Earlier in the study you stated the age when 
you first drank alcohol, can you tell us at what 
age you first drank alcohol regularly? Don’t know -1  
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ASK ALL WHO EVER TAKE CANNABIS AT Q26 
 
Q133 Yes 1 CONTINUE 
 
Earlier in the study you stated that you have taken 
cannabis, have you ever taken cannabis regularly? No 2 GO TO Q137 
 
Q134  # INSERT 
AGE 
 
Earlier in the study you stated the age when 
you first took cannabis, can you tell us at what 
age did you first take cannabis regularly? Don’t know -1  
SHOW CARD 135 
Q135 Yes – tried to and stopped 1 CONTINUE 
 Yes -  tried to but not stopped 2 
 
Have you ever tried to stop 
taking cannabis?  
No 3 
GO TO Q137 
SHOW CARD 136 
Q136 What was the reason (s) for stopping taking cannabis? 
Just call me out the numbers from the card – MULTI CODE 
Cost 1 Put on rehabilitation programme 8 
Persuaded by friends/family 2 Did not want to take anymore 9 
Impact on job/friends/family 3 Did not enjoy after effects 10 
No longer part of social life 4 The pros of taking did not outweigh the cons 11 
Concern about health/health reasons 5 Could no longer afford it 12 
Pregnancy 6 Other (specify) _________________ 13 
Less available supply 7 Don’t know 14 
 
ASK ALL WHO EVER TAKE ECSTASY AT Q35 
 
Q137 Yes 1 CONTINUE 
 
Earlier in the study you stated that you have taken 
ecstasy, have you ever taken ecstasy regularly? No 2 GO TO Q141 
 
Q138  # INSERT 
AGE 
 
Earlier in the study you stated the age when 
you first took ecstasy, can you tell us at what 
age did you first take ecstasy regularly? Don’t know 2  
SHOW CARD 139 
Q139 Yes – tried to and stopped 1 CONTINUE 
 Yes -  tried to but not stopped 2 
 
Have you ever tried to stop 
taking ecstasy?  
No 3 
GO TO Q141 
SHOW CARD 140 
Q0 Wht was the reason (s) for stopping taking ecstasy?   
Just call me out the numbers from the card – MULTI CODE 
Cost 1 Put on rehabilitation programme 8 
Persuaded by friends/family 2 Did not want to take anymore 9 
Impact on job/friends/family 3 Did not enjoy after effects 10 
No longer part of social life 4 The pros of taking did not outweigh the cons 11 
Concern about health/health reasons 5 Could no longer afford it 12 
Pregnancy 6 Other (specify) _________________ 13 
Less available supply 7 Don’t know 14 
ASK ALL WHO EVER TAKE COCAINE AT Q56 
Q141 Yes 1 CONTINUE 
 
Earlier in the study you stated that you have taken 
cocaine, have you ever taken cocaine regularly? No 2 GO TO Q145 
Q142  # INSERT 
AGE 
 
Earlier in the study you stated the age when 
you first took cocaine, can you tell us at what 
age did you first take cocaine regularly? Don’t know -1  
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SHOW CARD 143 
Q143 Yes – tried to and stopped 1 CONTINUE 
 Yes -  tried to but not stopped 2 
 
Have you ever tried to stop 
taking cocaine?  
No  
GO TO Q145 
SHOW CARD 144 
Q4 h was the reason (s) for stopping taking cocaine?  
Just call me out the numbers from the card – MULTI CODE 
Cost 1 Put on rehabilitation programme 8 
Persuaded by friends/family 2 Did not want to take anymore 9 
Impact on job/friends/family 3 Did not enjoy after effects 10 
No longer part of social life 4 The pros of taking did not outweigh the cons 11 
Concern about health/health reasons 5 Could no longer afford it 12 
Pregnancy 6 Other (specify) _________________ 13 
Less available supply 7 Don’t know 14 
 
ASK ALL WHO EVER TAKE HEROIN AT Q64 
 
Q145 Yes 1 CONTINUE 
 
Earlier in the study you stated that you have taken 
heroin, have you ever taken heroin regularly? No 2 GO TO Q149 
 
Q146  # INSERT 
AGE 
 
Earlier in the study you stated the age when 
you first took heroin, can you tell us at what 
age did you first take heroin regularly? Don’t know -1  
SHOW CARD 147 
Q147 Yes – tried to and stopped 1 CONTINUE 
 Yes -  tried to but not stopped 2 
 
Have you ever tried to stop 
taking heroin? 
No  
GO TO Q149 
SHOW CARD 148 
Q18 What was the reason (s) for stopping taking heroin?  
Just call me out the numbers from the card – MULTI CODE 
Cost 1 Put on rehabilitation programme 8 
Persuaded by friends/family 2 Did not want to take anymore 9 
Impact on job/friends/family 3 Did not enjoy after effects 10 
No longer part of social life 4 The pros of taking did not outweigh the cons 11 
Concern about health/health reasons 5 Could no longer afford it 12 
Pregnancy 6 Other (specify) _________________ 13 
Less available supply 7 Don’t know 14 
 
ASK ALL WHO HAVE EITHER USED CANNABIS (Yes at Q28), ECSTASY (Yes at 
Q37), COCAINE (Yes at Q58) OR HEROIN (Yes at Q66) IN LAST 12 MONTHS 
 
SHOW CARD 149 
Q149 Given by family/friend 1  
 Given by a contact I did not know 
personally 
2  
 Given by a stranger 3  
 Shared amongst group of friends 4  
 Bought from a friend 5  
 
How did you get the 
drugs on the last 
occasion you used 
them? 
Just call me out the 
number from the 
card Bought from a contact I did not 
know personally 
6  
  Bought from a stranger 7  
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ASK ALL WHO HAVE EITHER USED CANNABIS (Yes at Q28), ECSTASY (Yes at 
Q37), COCAINE (Yes at Q58) OR HEROIN (Yes at Q66) IN LAST 12 MONTHS 
 
SHOW CARD 150 
Q150 Street/park 1  
 Disco/bar/club 2  
 Office/workplace 3  
 School/college 4  
 House of a dealer 5  
 House of a friend 6  
 Ordered by phone for 
collection/delivery  
7  
 Other (specify) 
_____________________ 
8  
 
In which of the following 
places did you obtain drugs on 
the last occasion you used 
them? 
 
 
Just call me out the 
number from the card 
Don’t know 9  
 
ASK ALL WHO HAVE USED CANNABIS (Yes at Q28) IN LAST 12 MONTHS 
 
SHOW CARD 151 
Q151a Very easy 1  
 Fairly easy 2  
 Neither easy nor difficult 3  
 Fairly difficult 4  
 Very difficult 5  
 
How easy or difficult is it to 
obtain cannabis in a 24 hour 
period? 
Just call me out the number 
from the card 
Don’t know 6  
 
ASK ALL WHO HAVE USED ECSTASY (Yes at Q37), IN LAST 12 MONTHS 
 
SHOW CARD 151 
Q151b Very easy 1  
 Fairly easy 2  
 Neither easy nor difficult 3  
 Fairly difficult 4  
 Very difficult 5  
 
How easy or difficult is it to 
obtain ecstasy in a 24 hour 
period? 
Just call me out the number 
from the card 
Don’t know 6  
 
ASK ALL WHO HAVE USED COCAINE (Yes at Q58) IN LAST 12 MONTHS 
 
SHOW CARD 151 
Q151c Very easy 1  
 Fairly easy 2  
 Neither easy nor difficult 3  
 Fairly difficult 4  
 Very difficult 5  
 
How easy or difficult is it to 
obtain cocaine in a 24 hour 
period? 
Just call me out the number 
from the card 
Don’t know 6  
 
ASK ALL WHO HAVE USED HEROIN (Yes at Q66) IN LAST 12 MONTHS 
SHOW CARD 151 
Q151d Very easy 1  
 Fairly easy 2  
 Neither easy nor difficult 3  
 Fairly difficult 4  
 Very difficult 5  
 
How easy or difficult is it to 
obtain heroin in a 24 hour 
period? 
Just call me out the number 
from the card 
Don’t know 6  
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ASK ALL 
Q152 Yes 1 CONTINUE 
 
Have you taken any other illegal or illicit drug(s) not 
already mentioned in this study? No 2 GO TO Q154 
 
IF YES ASK: 
Q153 What is the name the drug(s) that you took? 
  
  
  
  
ASK ALL 
Q154 Yes 1  
 
In the last month, have you taken a pill or smoked 
something and did not know what it was? No 2  
 
 
THANK RESPONDENT 
 
 
WHEN COLLECTING DEMOGRAPHICS AND TAKING CONTACT DETAILS STATE: 
 
Your name, address and telephone number are taken for quality control purposes 
ONLY, i.e. you may get a phone call or a letter from MORI MRC to check that the 
interviewer has carried out your interview according to instructions” 
 
REPEAT CONFIDENTIALITY REASSURANCE IF CONCERNED ABOUT 
CONFIDENTIALITY 
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O.U.O  Job No: 225347 
CLASSIFICATION 
MORI MRC 
24 Windsor Place, Lower Pembroke St, Dublin 2 
92-96 Lisburn Road, Belfast BT9 6AG 
C.1 What was your age last birthday? 
STATE EXACT AGE 
AND CODE: 
  
15– 16 1 31 - 34 5 
17 - 19 2 35 - 40 6 
20 - 24 3 41 – 54 7 
25 - 30 4 55 - 64 8 
SHOW CARD C2 
C.2 Which of these describes you? 
Single (never married) 1 Separated 4 
Married  2 Divorced 5 
Co-habiting 3 Widowed 6 
    
C.3 Please circle one Male 1 
 of the following: Female 2 
 
 
C.4 Is your home owned or rented?  PROBE 
Owned outright 1 
Owned with a mortgage 2 
Rented from a private landlord 3 
Rented from a local authority 4 
Rented from a housing association 5 
Part owned/Part rented 6 
Other (Specify) ____________ 7 
Don’t know 8 
  
SHOW CARD C5 
C.5 Which of these best describes you? 
 
Self-employed 1 
Working full-time 30 hrs +/week 2 
Working part time 3 
Seeking work for the first time 4 
Unemployed (having lost/given up job) 5 
Home (domestic) duties 6 
Unable to work due to permanent 
illness/disability
7 
Not working (seeking work) 8 
Not working (not seeking work) 9 
On Gov. training/education scheme 10 
On Government employment scheme 
(CE, job options etc)
11 
Retired 12 
Student 13 
Other (Specify) ____________________ 14 
 
 
 
 
 
 
 
 
 
C.6 Which member of your household would you 
say is the CHIEF INCOME EARNER, that is 
the person with the largest income, whether 
from employment, pensions, state benefits, 
investments or any other sources?  (If 
equal income is claimed for two people, 
classify the elder as the C.I.E.) 
Self A Go to Q8 
Other (WRITE IN) 
 B Go to Q.7 
 
C.7 Is ............ related to you? 
Yes A Go to Q.8 
No B Go to Q.8 (Respondent is C.I.E) 
 
ASK ALL 
C.8 Employment Status of C.I.E: 
 Does the C.I.E. have a paid job full-time or 
part-time? 
Yes A Go to Q.10 
No B Go to Q.9 
 
SHOW CARD C9 
C.9 Looking at this card, please tell me the 
statement that best describes the C.I.E.  Just 
read out the letter of one that best applies. 
 
A-Retired, gets pension from previous job A   Ask occ. 
B-Unemployed, less than 2 months  B   details of 
C-Sick, still receiving pay or statutory pay       previous 
    from job    C   job-Q.10 
 
D-Widow, receiving pension from       Ask occ. 
 husband’s previous job   D  details of 
E-Divorced/separated, receiving mainten-     husband’s 
   ance from ex-husband   E  prev. Job 
 
F-Full-time student   F - Code SG 
        C1 at Q.11 
 
G-Not working, private means  G - Assess 
        SG at Q.11 
 
H-Unemployed longer than 2 mths  H  Code SG  
I-Sick - only receiving Income Support 
   or Invalidity Benefit   I    E at Q.11 
J-Receiving State Pension only  J 
 
C.10 Employment Status of C.I.E.: 
• What type of firm/organisation does/did (C.I.E.) 
work for? 
      WRITE IN: _________________________ 
• What job does ......... do? 
      WRITE IN: _________________________ 
• Does ....... have any position/rank/grade in the 
organisation (ie., responsible for the work of 
other people)? 
Yes A No B 
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PROMPT AS APPROPRIATE (Foreman, 
Sergeant, Office Manager, Executive, Officer 
etc.) 
IF YES,WRITE IN: _____________________ 
AND ASK: How many people is ...... responsible for? 
 
 
• Does ..... have any qualifications? 
Yes A No B 
 
PROMPT AS APPROPRIATE: Apprenticeship, 
professional qualifications, University degree) 
WRITE IN: __________________________ 
 
• IF FARMER ASK:  How many acres do you 
farm? 
 
 
C.11 Assess Social Grade: 
A 1 C2 4 
B 2 D 5 
C1 3 E 6 
 
SHOW CARD C12 AND READ OUT 
C.12 A person has a disability if he/she has a 
physical or mental impairment which has a 
substantial and long-term adverse effect on 
his/her ability to carry out normal day to day 
activities.  On the basis of this definition, do you 
regard yourself as being disabled? 
Yes 1 No 2 Don’t know 3 
 
SHOW CARD C13 
C.13 What is the highest level of education 
that you have completed, was it ...?   
No formal education 1 
Primary education 2 
Second level 3 
LOWER SECONDARY 
(Junior/Intermediate/Group Certificate, ‘O’ 
levels/GCSEs, NCVA Foundation Certificate, basic Skills 
Training Certificate or equivalent) 
4 
UPPER SECONDARY 
Leaving certificate, (including Applied and Vocational 
Programmes), ‘A’ Levels NCVA       Level 1Certificate 
or equivalent) 
5 
THIRD LEVEL 
Non degree qualification 
(National Certificate, Diploma NCEA/Institute of 
Technology or equivalent) 
 
6 
Primary degree (Third level bachelor degree) 7 
Professional qualification (of degree status at least) 8 
Both a degree and a professional qualification 9 
Postgraduate certificate or diplomas 10 
Postgraduate degree or masters 11 
Doctorate (PhD) 12 
 
 
C.15 Have you ceased your full time 
education? 
Yes 1 
No 2 
If Yes – At what age?  
 
C.15 INTERVIEWER TO COMPLETE 
Carlow 1 Clare 18 
Dublin City 2 Kerry 19 
Dublin Belgard 3 Limerick City 20 
Dublin Fingal 4 Limerick County 21 
Dun laoghaire 5 Tipperary NR 22 
Kildare 6 Tipperary SR 23 
Kilkenny 7 Waterford City 24 
Laois 8 Waterford County 25 
Longford 9 Galway City 26 
Louth 10 Galway County 27 
Meath 11 Leitrim 28 
Offaly 12 Mayo 29 
Westmeath 13 Roscommon 30 
Wexford 14 Sligo 31 
Wicklow 15 Cavan 32 
Cork City 16 Donegal 33 
Cork county 17 Monaghan 34 
 
 
C.16 Interviewer to code  
ROI 1 
NI 2 
 
 
 
 
 
I certify that this interview has been 
carried out strictly in accordance with 
your instructions and within the Code of 
Conduct of the MRS. 
Intv. Sign:  
Intv. No:    
Date of 
Interview 
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IF AGED 15 SAY TO PARENT/RESPONSIBLE 
ADULT: 
 
Under the rules of the Market Research Society 
we are not allowed to ask children any 
questions without an adult’s permission.  May 
I have your permission to interview your child 
about lifestyles, such as alcohol, tobacco and 
drugs?  I will explain that he/she does not 
have to answer any question that he/she 
doesn’t want to. 
 
IF NECESSARY:  We need to interview 15 year 
olds because it is important to understand 
changes to lifestyles over time 
 
REASSURE AS NECESSARY WITH REGARDS TO 
CONFIDENTIALITY, FOR RESEARCH PURPOSES 
ONLY ETC. 
 
HAND STANDARD LETTER TO PARENT OR 
RESPONSIBLE ADULT. 
 
PERMISSION & SIGNATURE MUST BE 
OBTAINED FROM A RESPONSIBLE ADULT 
BEFORE INTERVIEWING ANYONE AGED 15 
 
NAME AND SIGNATURE OF ADULT GIVING 
AUTHORITY FOR INTERVIEW: 
 
PRINT NAME:  
SIGNATURE:  
RELATIONSHIP TO CHILD:  
 
 
 
Interviewer record: 
Parent present during interview 1 
Parent not present during interview 2 
 
 
 
 
 
OFFICE USE ONLY 
Intervr. 
Checked 
Supervisor 
Checked 
Supervisor 
Accomp. 
Back- 
checked 
   Tel 1 
   Visit 2 
   Post 3 
   Date: 
 
Initials: 
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H. Questionnaire - Northern Ireland 
 
 
 
The questionnaire for Northern Ireland is displayed on the pages, which follow: 
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Unique 
Address Code 
    Sample Point 
Number 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NORTHERN IRELAND 
 
POPULATION STUDY 
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POPULATION STUDY 
 
INTRODUCTION 
 
Good morning/afternoon/evening.  My name is .... from MORI MRC, an independent research 
company.  We are conducting a study today about lifestyles such as alcohol, tobacco and drugs, 
and I’d like to ask you some questions.  The interview will last approximately 15 minutes. 
 
IF ASKED STATE ….. This study is being conducted on behalf of the Department of 
Health, Social Services and Public Safety in Northern Ireland 
 
IF UNSURE/CONCERNED ABOUT CONFIDENTIALITY STATE: 
We would like to stress that all information you give in the questionnaire will be treated 
confidentially.  No information about you as an individual, including your name and address, will be 
passed on to anyone outside this research study.  All the details collected are purely for the 
purpose of market research and the information is used purely for statistical purposes. 
 
 
Tobacco 
 
First of all I’m going to ask a few questions about tobacco. 
Q1 Yes 1 GO TO Q.3 
 
Do you smoke tobacco products, such as cigarettes, 
cigars or a pipe? No 2 CONTINUE 
 
Q2 Yes 1 CONTINUE 
 
Have you ever smoked tobacco products in 
the past? No 2 
  Don’t know 3 
GO TO Q8 
 
Q3  # INSERT 
AGE 
 
At what age did you smoke tobacco products 
for the first time? 
Don’t know -1  
 
Q4 Yes 1 CONTINUE 
 
During the last 12 months have you smoked tobacco 
products? No 2 GO TO Q8 
 
Q5 Yes 1 CONTINUE 
 
During the last 30 days have you smoked tobacco 
products? No 2 GO TO Q8 
 
Q6  # INSERT 
FIGURE 
 
During the last 30 days on how many days 
have you smoked? 
Don’t know -1  
 
Q7 Branded cigarettes 1  
 Hand rolled cigarettes 2 
 Cigars 3 
 
What type of tobacco product do 
you most commonly use? 
READ OUT – MULTI CODE 
Pipe 4 
  Don’t know 5 
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Alcohol 
 
Now I’m going to ask a few questions about alcohol. 
Q8 Yes 1 GO TO Q.10 
 
Do you drink alcohol? 
No 2 CONTINUE 
 
Q9 Yes 1 CONTINUE 
 
Have you ever drunk alcohol? 
No 2 GO TO Q15 
 
Q10  # INSERT 
AGE 
 
At what age did you first drink alcohol? 
Don’t know -1  
 
Q11 Yes 1 CONTINUE 
 
During the last 12 months, have you drunk any 
alcohol? No 2 GO TO Q15 
 
Q12 Yes 1 CONTINUE 
 
During the last 30 days have you drunk any alcohol? 
No 2 GO TO Q15 
 
Q13  # INSERT 
FIGURE 
 
During the last 30 days, on how many days 
have you drunk alcohol? 
Don’t know -1  
 
Q14 Daily or almost daily 1  
 2/3 times a week 2  
 Every week 3 
 2/3 times a month 4 
 Every month 5 
 
 Less often than every month 6  
 
How often do you drink six or 
more alcoholic drinks on the 
same occasion?  READ OUT 
Never 7  
 
Now I’m going to ask a few questions about drugs that are sometimes used as 
medicines. 
 
SHOW CARD 15 
Q15 Yes 1 CONTINUE 
 No 2 GO TO Q24 
 
Have you ever heard of any of these …………..? 
SHOW CARD, IF YES TO ANY LISTED ON CARD 
CODE YES AND CONTINUE    
 
Q16 Yes 1  
 
Do you personally know people who take sedatives, 
tranquillisers or anti-depressants? No 2  
 
Q17 Yes 1 CONTINUE 
 
Have you ever taken sedatives, tranquillisers or anti-
depressants? No 2 GO TO Q24 
 
Q18  # INSERT 
AGE 
 
At what age did you first take sedatives or 
tranquillisers or anti-depressants? 
Don’t know -1  
 
Q19 Yes 1 CONTINUE 
 
During the last 12 months have you taken sedatives, 
tranquillisers or anti-depressants? No 2 GO TO Q24 
 
Q20 Yes 1 CONTINUE 
 
During the last 30 days have you taken sedatives, 
tranquillisers or anti-depressants? No 2 GO TO Q24 
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Q21  # INSERT 
FIGURE 
 
During the last 30 days, on how many days 
have you taken sedatives, tranquillisers or 
anti-depressants? Don’t know -1  
 
SHOW CARD 22 
Q22 Tablets 1  
 Injection with a needle 2 
 Other (specify) 
___________________ 
3  
 
What method do you commonly 
use to take sedatives, 
tranquillisers or anti-depressants? 
Just call me out the number 
from the card – MULTI CODE Don’t know 4  
 
SHOW CARD 23 
Q23 I got them on a prescription 1  
 I got them from someone else I know 2 
 I bought them without a prescription 
in a chemist 
3  
 None of the above 4  
 
The last occasion 
you took sedatives, 
tranquillisers or 
anti-depressants 
how had you 
obtained them? 
JUST CALL ME OUT 
THE NUMBER FROM 
THE CARD 
   
 
Now I’m going to ask a few questions about other drugs. 
 
SHOW CARD 24 
Q24 Yes 1 CONTINUE 
 No 2 GO TO Q33 
 
Have you ever heard of any of these …………..? 
SHOW CARD, IF YES TO ANY LISTED ON CARD 
CODE YES AND CONTINUE    
 
Q25 Yes 1  
 
Do you personally know people who take cannabis? 
No 2  
 
 
Q26 Yes 1 CONTINUE 
 
Have you ever taken cannabis? 
No 2 GO TO Q33 
 
 
Q27  # INSERT 
AGE 
 
At what age did you first take cannabis? 
Don’t know -1  
 
 
Q28 Yes 1 CONTINUE 
 
During the last 12 months have you taken cannabis? 
No 2 GO TO Q33 
 
 
Q29 Yes 1 CONTINUE 
 
During the last 30 days have you taken cannabis? 
No 2 GO TO Q33 
 
 
Q30  # INSERT 
FIGURE 
 
During the last 30 days, on how many days 
have you taken cannabis? 
Don’t know -1  
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SHOW CARD 31 
Q31 What type of cannabis do you most commonly use? 
Just call me out the numbers from the card – MULTI CODE 
Grass 1 Resin 7 
Weed 2 
Skunk 3 
Hash Oil 4 
Other (specify) 
__________________________ 
8 
Herb 5 Don’t know 9 
Hash 6   
 
SHOW CARD 32 
Q32 Joint 1  
 Pipe 2  
 Bong 3  
 Eat 4  
 Other (specify) 
__________________ 
5  
 
What method do you most 
commonly use to take cannabis? 
 
Just call me out the numbers 
from the card – MULTI CODE 
Don’t know 6  
 
SHOW CARD 33 
Q33 Yes 1 CONTINUE 
 No 2 GO TO Q40 
 
Have you ever heard of any of these …………..? 
SHOW CARD, IF YES TO ANY LISTED ON CARD 
CODE YES AND CONTINUE    
 
Q34 Yes 1  
 
Do you personally know people who take ecstasy? 
No 2  
 
Q35 Yes 1 CONTINUE 
 
Have you ever taken ecstasy? 
No 2 GO TO Q40 
 
Q36  # INSERT 
AGE 
 
At what age did you first take ecstasy? 
Don’t know -1  
 
Q37 Yes 1 CONTINUE 
 
During the last 12 months have you taken ecstasy? 
No 2 GO TO Q40 
 
Q38 Yes 1 CONTINUE 
 
During the last 30 days have you taken ecstasy? 
No 2 GO TO Q40 
 
Q39  # INSERT 
FIGURE 
 
During the last 30 days, on how many days 
have you taken ecstasy? 
Don’t know -1  
SHOW CARD 40 
Q40 Yes 1 CONTINUE 
 No 2 GO TO Q47 
 
Have you ever heard of any of these …………..? 
SHOW CARD, IF YES TO ANY LISTED ON CARD 
CODE YES AND CONTINUE    
 
Q41 Yes 1  
 
Do you personally know people who take 
amphetamines? No 2  
 
Q42 Yes 1 CONTINUE 
 
Have you ever taken amphetamines? 
No 2 GO TO Q47 
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Q43  # INSERT 
AGE 
 
At what age did you first take amphetamines? 
Don’t know -1  
 
Q44 Yes 1 CONTINUE 
 
During the last 12 months have you taken 
amphetamines? No 2 GO TO Q47 
 
Q45 Yes 1 CONTINUE 
 
During the last 30 days have you taken 
amphetamines? No 2 GO TO Q47 
 
Q46a  # INSERT 
FIGURE 
 
During the last 30 days, on how many days 
have you taken amphetamines? 
Don’t know -1  
SHOW CARD 46b 
Q46b I got them on a prescription 1  
 I got them from someone else I know 2 
 I bought them without a prescription 
in a chemist 
3  
 None of the above 4  
 
The last occasion 
you took 
amphetamines how 
had you obtained 
them? 
JUST CALL ME OUT 
THE NUMBER FROM 
THE CARD 
   
SHOW CARD 47 
Q47 Yes 1 CONTINUE 
 No 2 GO TO Q54 
 
Have you ever heard of any of these …………..? 
SHOW CARD, IF YES TO ANY LISTED ON CARD 
CODE YES AND CONTINUE    
 
Q48 Yes 1  
 
Do you personally know people who take crack? 
No 2  
 
Q49 Yes 1 CONTINUE 
 
Have you ever taken crack? 
No 2 GO TO Q54 
 
Q50  # INSERT 
AGE 
 
At what age did you first take crack? 
Don’t know -1  
 
Q51 Yes 1 CONTINUE 
 
During the last 12 months have you taken crack? 
No 2 GO TO Q54 
 
Q52 Yes 1 CONTINUE 
 
During the last 30 days have you taken crack? 
No 2 GO TO Q54 
 
Q53  # INSERT 
FIGURE 
 
During the last 30 days, on how many days 
have you taken crack? 
Don’t know -1  
SHOW CARD 54 
Q54 Yes 1 CONTINUE 
 No 2 GO TO Q62 
 
Have you ever heard of any of these …………..? 
SHOW CARD, IF YES TO ANY LISTED ON CARD 
CODE YES AND CONTINUE    
Q55 Yes 1  
 
Do you personally know people who take cocaine? 
No 2  
 
Q56 Have you ever taken cocaine? Yes 1 CONTINUE 
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  No 2 GO TO Q62 
 
Q57  # INSERT 
AGE 
 
At what age did you first take cocaine? 
Don’t know -1  
 
Q58 Yes 1 CONTINUE 
 
During the last 12 months have you taken cocaine? 
No 2 GO TO Q62 
 
Q59 Yes 1 CONTINUE 
 
During the last 30 days have you taken cocaine? 
No 2 GO TO Q62 
 
Q60  # INSERT 
FIGURE 
 
During the last 30 days, on how many days 
have you taken cocaine? 
Don’t know -1  
SHOW CARD 61 
Q61 Doing a line/Snort 1  
 Injection with a needle 2  
 Other (specify) 
_____________________ 
3  
 
What method do you commonly 
use to take cocaine? Just call 
me out the number from the 
card – MULTI CODE 
Don’t know 4  
SHOW CARD 62 
Q62 Yes 1 CONTINUE 
 No 2 GO TO Q70 
 
Have you ever heard of any of these …………..? 
SHOW CARD, IF YES TO ANY LISTED ON CARD 
CODE YES AND CONTINUE     
 
Q63 Yes 1  
 
Do you personally know people who take heroin? 
No 2  
 
Q64 Yes 1 CONTINUE 
 
Have you ever taken heroin? 
No 2 GO TO Q70 
 
Q65  # INSERT 
AGE 
 
At what age did you first take heroin? 
Don’t know -1  
 
Q66 Yes 1 CONTINUE 
 
During the last 12 months have you taken heroin? 
No 2 GO TO Q70 
 
Q67 Yes 1 CONTINUE 
 
During the last 30 days have you taken heroin? 
No 2 GO TO Q70 
 
Q68  # INSERT 
FIGURE 
 
During the last 30 days, on how many days 
have you taken heroin? 
Don’t know 2  
SHOW CARD 69 
Q69 Smoke 1  
 Injection with a needle 2  
 ‘Chasing the dragon’ 3  
 Other (specify) 
_____________________ 
4  
 
What method do you commonly 
use to take heroin? Just call 
me out the number from the 
card – MULTICODE 
Don’t know 5  
 
SHOW CARD 70 
NACD/DAIRU – 2002/2003 Drug Prevalence Survey – Technical Report 
Appendix H 
105 
Q70 Yes 1 CONTINUE 
 No 2 GO TO Q77 
 
Have you ever heard of any of these …………..? 
SHOW CARD, IF YES TO ANY LISTED ON CARD 
CODE YES AND CONTINUE    
 
Q71 Yes 1  
 
Do you personally know people who take LSD? 
No 2  
 
Q72 Yes 1 CONTINUE 
 
Have you ever taken LSD? 
No 2 GO TO Q77 
 
Q73  # INSERT 
AGE 
 
At what age did you first take LSD? 
Don’t know -1  
 
Q74 Yes 1 CONTINUE 
 
During the last 12 months have you taken LSD? 
No 2 GO TO Q77 
 
Q75 Yes 1 CONTINUE 
 
During the last 30 days have you taken LSD? 
No 2 GO TO Q77 
 
Q76  # INSERT 
FIGURE 
 
During the last 30 days, on how many days 
have you taken LSD? 
Don’t know -1  
SHOW CARD 77 
Q77 Yes 1 CONTINUE 
 No 2 GO TO Q84 
 
Have you ever heard of any of these …………..? 
SHOW CARD, IF YES TO ANY LISTED ON CARD 
CODE YES AND CONTINUE    
 
Q78 Yes 1  
 
Do you personally know people who take solvents? 
No 2  
 
Q79 Yes 1 CONTINUE 
 
Have you ever taken solvents? 
No 2 GO TO Q84 
 
Q80  # INSERT 
AGE 
 
At what age did you first take solvents? 
Don’t know -1  
 
Q81 Yes 1 CONTINUE 
 
During the last 12 months have you taken solvents? 
No 2 GO TO Q84 
 
Q82 Yes 1 CONTINUE 
 
During the last 30 days have you taken solvents? 
No 2 GO TO Q84 
 
Q83  # INSERT 
FIGURE 
 
During the last 30 days, on how many days 
have you taken solvents? 
Don’t know -1  
SHOW CARD 84 
Q84 Yes 1 CONTINUE 
 No 2 GO TO Q91 
 
Have you ever heard of any of these …………..? 
SHOW CARD, IF YES TO ANY LISTED ON CARD 
CODE YES AND CONTINUE    
 
Q85 Yes 1  
 
Do you personally know people who take poppers? 
No 2  
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Q86 Yes 1 CONTINUE 
 
Have you ever taken poppers? 
No 2 GO TO Q91 
 
Q87  # INSERT 
AGE 
 
At what age did you first take poppers? 
Don’t know -1  
 
Q88 Yes 1 CONTINUE 
 
During the last 12 months have you taken poppers? 
No 2 GO TO Q91 
 
Q89 Yes 1 CONTINUE 
 
During the last 30 days have you taken poppers? 
No 2 GO TO Q91 
 
Q90  # INSERT 
FIGURE 
 
During the last 30 days, on how many days 
have you taken poppers? 
Don’t know -1  
SHOW CARD 91 
Q91 Yes 1 CONTINUE 
 No 2 GO TO Q98 
 
Have you ever heard of any of these …………..? 
SHOW CARD, IF YES TO ANY LISTED ON CARD 
CODE YES AND CONTINUE    
 
Q92 Yes 1  
 
Do you personally know people who take magic 
mushrooms? No 2  
 
Q93 Yes 1 CONTINUE 
 
Have you ever taken magic mushrooms? 
No 2 GO TO Q98 
 
Q94  # INSERT 
AGE 
 
At what age did you first take magic 
mushrooms? 
Don’t know -1  
 
Q95 Yes 1 CONTINUE 
 
During the last 12 months have you taken magic 
mushrooms? No 2 GO TO Q98 
 
Q96 Yes 1 CONTINUE 
 
During the last 30 days have you taken magic 
mushrooms? No 2 GO TO Q98 
 
Q97  # INSERT 
FIGURE 
 
During the last 30 days, on how many days 
have you taken magic mushrooms? 
Don’t know -1  
SHOW CARD 98 
Q98 Yes 1 CONTINUE 
 No 2 GO TO Q105 
 
Have you ever heard of any of these …………..? 
SHOW CARD, IF YES TO ANY LISTED ON CARD 
CODE YES AND CONTINUE    
 
Q99 Yes 1  
 
Do you personally know people who take 
methadone? No 2  
 
Q100 Yes 1 CONTINUE 
 
Have you ever taken methadone? 
No 2 GO TO Q105 
 
Q101  # INSERT 
AGE 
 
At what age did you first take methadone? 
Don’t know -1  
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Q102 Yes 1 CONTINUE 
 
During the last 12 months have you taken 
methadone? No 2 GO TO Q105 
 
Q103 Yes 1 CONTINUE 
 
During the last 30 days have you taken methadone? 
No 2 GO TO Q105 
 
Q104a  # INSERT 
FIGURE 
 
During the last 30 days, on how many days 
have you taken methadone? 
Don’t know -1  
SHOW CARD 104b 
Q104b I got it on a prescription 1  
 I got it from someone else I know 2 
 I bought it without a prescription in a 
chemist 
3  
 None of the above 4  
 
The last occasion 
you took 
methadone how 
had you obtained 
it? JUST CALL ME 
OUT THE NUMBER 
FROM THE CARD 
   
 
SHOW CARD 105    
Q105 Yes 1 CONTINUE 
 
Have you ever heard of this? SHOW CARD, IF 
YES CODE YES AND CONTINUE No 2 GO TO Q112 
 
Q106 Yes 1  
 
Do you personally know people who take nubain? 
No 2  
 
Q107 Yes 1 CONTINUE 
 
Have you ever taken nubain? 
No 2 GO TO Q112 
 
Q108  # INSERT 
AGE 
 
At what age did you first take nubain? 
Don’t know -1  
 
Q109 Yes 1 CONTINUE 
 
During the last 12 months have you taken nubain? 
No 2 GO TO Q112 
 
Q110 Yes 1 CONTINUE 
 
During the last 30 days have you taken nubain? 
No 2 GO TO Q112 
 
Q111  # INSERT 
FIGURE 
 
During the last 30 days, on how many days 
have you taken nubain? 
Don’t know -1  
SHOW CARD 112 
Q112 Yes 1 CONTINUE 
 No 2 GO TO Q119 
 
Have you ever heard of any of these …………..? 
SHOW CARD, IF YES TO ANY LISTED ON CARD 
CODE YES AND CONTINUE    
 
Q113 Yes 1  
 
Do you personally know people who take other 
opiates? No 2  
Q114 Yes 1 CONTINUE 
 
Have you ever taken other opiates? 
No 2 GO TO Q119 
 
Q115  # INSERT 
AGE 
 
At what age did you first take other opiates? 
Don’t know -1  
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Q116 Yes 1 CONTINUE 
 
During the last 12 months have you taken other 
opiates? No 2 GO TO Q119 
 
Q117 Yes 1 CONTINUE 
 
During the last 30 days have you taken other 
opiates? No 2 GO TO Q119 
 
Q118a  # INSERT 
FIGURE 
 
During the last 30 days, on how many days 
have you taken other opiates? 
Don’t know -1  
SHOW CARD 118b 
Q118b I got them on a prescription 1  
 I got them from someone else I know 2 
 I bought them without a prescription 
in a chemist 
3  
 None of the above 4  
 
The last occasion 
you took other 
opiates how had you 
obtained them? JUST 
CALL ME OUT THE 
NUMBER FROM THE 
CARD 
   
 
SHOW CARD 119 
Q119 Yes 1 CONTINUE 
 No 2 GO TO Q126 
 
Have you ever heard of any of these …………..? 
SHOW CARD, IF YES TO ANY LISTED ON CARD 
CODE YES AND CONTINUE    
 
Q120 Yes 1  
 
Do you personally know people who take anabolic 
steroids? No 2  
 
Q121 Yes 1 CONTINUE 
 
Have you ever taken anabolic steroids? 
No 2 GO TO Q126 
 
Q122  # INSERT 
AGE 
 
At what age did you first take anabolic 
steroids? 
Don’t know -1  
 
Q123 Yes 1 CONTINUE 
 
During the last 12 months have you taken anabolic 
steroids? No 2 GO TO Q126 
 
Q124 Yes 1 CONTINUE 
 
During the last 30 days have you taken anabolic 
steroids? No 2 GO TO Q126 
 
Q125a  # INSERT 
FIGURE 
 
During the last 30 days, on how many days 
have you taken anabolic steroids? 
Don’t know -1  
SHOW CARD 125b 
Q125b I got them on a prescription 1  
 I got them from someone else I know 2 
 I bought them without a prescription 
in a chemist 
3  
 None of the above 4  
 
The last occasion 
you took anabolic 
steroids how had 
you obtained them?  
JUST CALL ME OUT 
THE NUMBER FROM 
THE CARD 
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Now, I’d like to get your opinions. 
 
SHOW CARD 126 
Q126 More as a criminal 1  
 More as a patient 2  
 Neither a criminal nor a patient 3  
 Both a criminal and a patient 4  
 
Do you perceive a drug 
addict more as a criminal 
or more as a patient? 
Don’t know, cannot decide 5  
SHOW CARD 127 
Q127 TO WHAT EXTENT DO YOU AGREE WITH THE FOLLOWING STATEMENTS …. 
READ OUT IN TURN 
% 
Fully 
agree 
Largely 
agree 
Neither Largely 
disagree 
Fully 
disagree 
Don’t 
know 
“People should be permitted to take 
cannabis for medical reasons” 1 2 3 4 5 6 
“People should be permitted to take 
cannabis for recreational reasons” 1 2 3 4 5 6 
”People should be permitted to take 
heroin” 1 2 3 4 5 6 
 
SHOW CARD 128 
Q128 Individuals differ in whether or not they disapprove of people doing certain things. I will 
mention a few things, which some people might do.  Can you tell me if you would not 
disapprove, disapprove or strongly disapprove when people do any of these things? 
READ OUT IN TURN 
% 
Do not 
disapprove 
Disapprove Strongly 
disapprove 
Don’t 
know 
Trying ecstasy once or twice 1 2 3 4 
Trying heroin once or twice 1 2 3 4 
Smoking 10 cigarettes a day 1 2 3 4 
Having one or two drinks several times a week 1 2 3 4 
Smoking cannabis occasionally 1 2 3 4 
 
SHOW CARD 129 
Q129 Now I would like to know how much do you think that people risk harming themselves, 
physically or in other ways, if they do certain things. I will again mention a few things some 
people might do. Please tell me if you consider it to be no risk, a slight risk, a moderate risk 
or a great risk, if people do such things. 
READ OUT IN TURN 
% 
No 
risk 
Slight 
risk 
Moderate 
risk 
Great 
risk 
Don’t 
know 
Smoke one or more packs of cigarettes a day 1 2 3 4 5 
Have five or more drinks at the weekend 1 2 3 4 5 
Smoke cannabis regularly 1 2 3 4 5 
Try ecstasy once or twice 1 2 3 4 5 
Try cocaine or crack once or twice 1 2 3 4 5 
 
Q130 Yes 1  
 
Here in Northern Ireland and the Republic of Ireland 
have you ever been offered illegal drugs? No 2  
 
ASK ALL WHO DRINK ALCOHOL AT Q8 OR HAVE EVER DRUNK ALCOHOL AT Q9 
 
Q131 Yes 1 CONTINUE 
 
Earlier in the study you stated that you have drunk 
alcohol, have you ever drunk alcohol regularly? No 2 GO TO Q133 
 
Q132  # INSERT 
AGE 
 
Earlier in the study you stated the age when 
you first drank alcohol, can you tell us at what 
age you first drank alcohol regularly? Don’t know -1  
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ASK ALL WHO EVER TAKE CANNABIS AT Q26 
 
Q133 Yes 1 CONTINUE 
 
Earlier in the study you stated that you have taken 
cannabis, have you ever taken cannabis regularly? No 2 GO TO Q137 
 
Q134  # INSERT 
AGE 
 
Earlier in the study you stated the age when 
you first took cannabis, can you tell us at what 
age did you first take cannabis regularly? Don’t know -1  
SHOW CARD 135 
Q135 Yes – tried to and stopped 1 CONTINUE 
 Yes -  tried to but not stopped 2 
 
Have you ever tried to stop 
taking cannabis?  
No 3 
GO TO Q137 
SHOW CARD 136 
Q136 What was the reason (s) for stopping taking cannabis? 
Just call me out the numbers from the card – MULTI CODE 
Cost 1 Put on rehabilitation programme 8 
Persuaded by friends/family 2 Did not want to take anymore 9 
Impact on job/friends/family 3 Did not enjoy after effects 10 
No longer part of social life 4 The pros of taking did not outweigh the cons 11 
Concern about health/health reasons 5 Could no longer afford it 12 
Pregnancy 6 Other (specify) _________________ 13 
Less available supply 7 Don’t know 14 
 
ASK ALL WHO EVER TAKE ECSTASY AT Q35 
 
Q137 Yes 1 CONTINUE 
 
Earlier in the study you stated that you have taken 
ecstasy, have you ever taken ecstasy regularly? No 2 GO TO Q141 
 
Q138  # INSERT 
AGE 
 
Earlier in the study you stated the age when 
you first took ecstasy, can you tell us at what 
age did you first take ecstasy regularly? Don’t know -1  
SHOW CARD 139 
Q139 Yes – tried to and stopped 1 CONTINUE 
 Yes -  tried to but not stopped 2 
 
Have you ever tried to stop 
taking ecstasy?  
No 3 
GO TO Q141 
SHOW CARD 140 
Q140 What was the reason (s) for stopping taking ecstasy?   
Just call me out the numbers from the card – MULTI CODE 
Cost 1 Put on rehabilitation programme 8 
Persuaded by friends/family 2 Did not want to take anymore 9 
Impact on job/friends/family 3 Did not enjoy after effects 10 
No longer part of social life 4 The pros of taking did not outweigh the cons 11 
Concern about health/health reasons 5 Could no longer afford it 12 
Pregnancy 6 Other (specify) _________________ 13 
Less available supply 7 Don’t know 14 
 
ASK ALL WHO EVER TAKE COCAINE AT Q56 
 
Q141 Yes 1 CONTINUE 
 
Earlier in the study you stated that you have taken 
cocaine, have you ever taken cocaine regularly? No 2 GO TO Q145 
 
 
Q142 Earlier in the study you stated the age when 
you first took cocaine, can you tell us at what 
 # INSERT 
AGE 
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 age did you first take cocaine regularly? Don’t know -1  
SHOW CARD 143 
Q143 Yes – tried to and stopped 1 CONTINUE 
 Yes -  tried to but not stopped 2 
 
Have you ever tried to stop 
taking cocaine?  
No  
GO TO Q145 
SHOW CARD 144 
Q144 What was the reason (s) for stopping taking cocaine?  
Just call me out the numbers from the card – MULTI CODE 
Cost 1 Put on rehabilitation programme 8 
Persuaded by friends/family 2 Did not want to take anymore 9 
Impact on job/friends/family 3 Did not enjoy after effects 10 
No longer part of social life 4 The pros of taking did not outweigh the cons 11 
Concern about health/health reasons 5 Could no longer afford it 12 
Pregnancy 6 Other (specify) _________________ 13 
Less available supply 7 Don’t know 14 
 
ASK ALL WHO EVER TAKE HEROIN AT Q64 
 
Q145 Yes 1 CONTINUE 
 
Earlier in the study you stated that you have taken 
heroin, have you ever taken heroin regularly? No 2 GO TO Q149 
 
Q146  # INSERT 
AGE 
 
Earlier in the study you stated the age when 
you first took heroin, can you tell us at what 
age did you first take heroin regularly? Don’t know -1  
SHOW CARD 147 
Q147 Yes – tried to and stopped 1 CONTINUE 
 Yes -  tried to but not stopped 2 
 
Have you ever tried to stop 
taking heroin? 
No  
GO TO Q149 
SHOW CARD 148 
Q148 What was the reason (s) for stopping taking heroin?  
Just call me out the numbers from the card – MULTI CODE 
Cost 1 Put on rehabilitation programme 8 
Persuaded by friends/family 2 Did not want to take anymore 9 
Impact on job/friends/family 3 Did not enjoy after effects 10 
No longer part of social life 4 The pros of taking did not outweigh the cons 11 
Concern about health/health reasons 5 Could no longer afford it 12 
Pregnancy 6 Other (specify) _________________ 13 
Less available supply 7 Don’t know 14 
 
ASK ALL WHO HAVE EITHER USED CANNABIS (Yes at Q28), ECSTASY (Yes at Q37), 
COCAINE (Yes at Q58) OR HEROIN (Yes at Q66) IN LAST 12 MONTHS 
 
SHOW CARD 149 Given by family/friend 1  
Q149 Given by a contact I did not know 
personally 
2  
 Given by a stranger 3  
 Shared amongst group of friends 4  
 Bought from a friend 5  
 Bought from a contact I did not 
know personally 
6  
 
How did you get the 
drugs on the last 
occasion you used 
them? 
Just call me out the 
number from the 
card 
Bought from a stranger 7  
 
ASK ALL WHO HAVE EITHER USED CANNABIS (Yes at Q28), ECSTASY (Yes at Q37), 
COCAINE (Yes at Q58) OR HEROIN (Yes at Q66) IN LAST 12 MONTHS 
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SHOW CARD 150 Street/park 1  
Q150 Disco/bar/club 2  
 Office/workplace 3  
 School/college 4  
 House of a dealer 5  
 House of a friend 6  
 Ordered by phone for 
collection/delivery 
7  
 Other (specify)__________________ 8  
 
In which of the 
following places did 
you obtain the drugs 
on the last occasion 
you used them? 
Just call me out the 
number from the 
card 
Don’t know 9  
 
ASK ALL WHO HAVE USED CANNABIS (Yes at Q28) IN LAST 12 MONTHS 
 
SHOW CARD 151 
Q151a Very easy 1  
 Fairly easy 2  
 Neither easy nor difficult 3  
 Fairly difficult 4  
 Very difficult 5  
 
How easy or difficult is it to 
obtain cannabis in a 24 hour 
period? 
Just call me out the number 
from the card 
Don’t know 6  
 
ASK ALL WHO HAVE USED ECSTASY (Yes at Q37), IN LAST 12 MONTHS 
 
SHOW CARD 151 
Q151b Very easy 1  
 Fairly easy 2  
 Neither easy nor difficult 3  
 Fairly difficult 4  
 Very difficult 5  
 
How easy or difficult is it to 
obtain ecstasy in a 24-hour 
period? 
Just call me out the number 
from the card 
Don’t know 6  
 
ASK ALL WHO HAVE USED COCAINE (Yes at Q58) IN LAST 12 MONTHS 
 
SHOW CARD 151 
Q151c Very easy 1  
 Fairly easy 2  
 Neither easy nor difficult 3  
 Fairly difficult 4  
 Very difficult 5  
 
How easy or difficult is it to 
obtain cocaine in a 24 hour 
period? 
Just call me out the number 
from the card 
Don’t know 6  
 
ASK ALL WHO HAVE USED HEROIN (Yes at Q66) IN LAST 12 MONTHS 
 
SHOW CARD 151 
Q151d Very easy 1  
 Fairly easy 2  
 Neither easy nor difficult 3  
 Fairly difficult 4  
 Very difficult 5  
 
How easy or difficult is it to 
obtain heroin in a 24 hour 
period? 
Just call me out the number 
from the card 
Don’t know 6  
ASK ALL 
Q152 Yes 1 CONTINUE 
 
Have you taken any other illegal or illicit drug(s) not 
already mentioned in this study? No 2 GOT TO Q154 
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IYES ASK: 
Q153 What is the name of the drug(s) that you took? 
  
  
  
  
 
ASK ALL 
Q154 Yes 1  
 
In the last month, have you taken a pill or smoked 
something and did not know what it was? No 2  
 
 
THANK RESPONDENT 
 
WHEN COLLECTING DEMOGRAPHICS AND TAKING CONTACT DETAILS STATE: 
 
Your name, address and telephone number are taken for quality control purposes ONLY, 
i.e. you may get a phone call or a letter from MORI MRC to check that the interviewer 
has carried out your interview according to instructions” 
 
REPEAT CONFIDENTIALITY REASSURANCE IF CONCERNED ABOUT CONFIDENTIALITY 
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O.U.O  Job No: 220543 
 
CLASSIFICATION 
MORI MRC 
92-96 Lisburn Road, Belfast BT9 6AG 
24 Windsor Place, Lower Pembroke St, Dublin 2 
 
C.1 What was your age last birthday? 
STATE EXACT 
AND CODE: 
  
15– 16 1 31 - 34 5 
17 - 19 2 35 - 40 6 
20 - 24 3 41 – 54 7 
25 - 30 4 55 - 64 8 
SHOW CARD C2 
C.2 Which of these describes you? 
Single (never married) 1 Separated 4 
Married  2 Divorced 5 
Co-habiting 3 Widowed 6 
    
C.3 Please circle one Male 1 
 of the following: Female 2 
 
C.4 Is your home owned or rented?  PROBE 
Owned outright 1 
Owned with a mortgage/loan 2 
Part mortgage/Part rented (shared ownership) 3 
Rented from a private landlord 4 
Rented from N. Ireland Housing Executive 5 
Rented from a housing association 6 
Lives here rent free 7 
Other (Specify) _______________________ 8 
Don’t know 9 
 
C.5A How many children , including children 
aged 16-18 in full time education,  are 
dependent on you? 
0 1 2 3 4 5 6 7 8 9+ 
 
C.5B What is the age of your youngest  
 dependent child? 
 STATE EXACT AGE 
  
 
C.6 In this household, do you care for an  
 adult who requires substantial 
assistance with the activities of daily life? 
Yes 1 No 2 
 
 
 
SHOW CARD C7 
C.7 Which of these best describes you? 
Self-employed 1 
Working full-time 30 hrs+/week 2 
In 
Paid 
Job Working part time 3 
Unemployed and seeking work 4 
Home (domestic) duties 5 
Unable to work due to permanent 
illness/disability
6 
Not working (seeking work) 7 
Not working (not seeking work) 8 
On Gov. training/education scheme 
(Jobskills, Training for Work, New Deal)
9 
On Gov. employment scheme (New 
Deal, Workteach)
10 
Full time education 11 
Part time education 12 
Retired 13 
No 
Paid 
Job 
Other (Specify) ____________________ 14 
 
C.8 IF NOT IN PAID JOB:  Have you ever 
had a paid job? 
Yes 1 No 2 
 
C.9a If at work – self-employed, employee:  
What is your main occupation? 
WRITE IN: 
 
 
 
 
 
 
 
SOC 
2000 
CODE
  
 
 
C.9b If unemployed/retired/engaged in home 
duties or on government training scheme and 
previously employed 
• What was the main occupation you previously 
held?  WRITE IN: ________________________ 
 
C.10 Are you currently in receipt of any of 
the following benefits/allowances? 
Jobseekers Allowance 1 
Incapacity Benefit 2 
Working Families Tax Credit 3 
Disabled Persons Tax Credit 4 
Income Support 5 
None of these 6 
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C.11 Which member of your household would you 
say is the CHIEF INCOME EARNER, that is 
the person with the largest income, whether 
from employment, pensions, state benefits, 
investments or any other sources?  (If 
equal income is claimed for two people, 
classify the elder as the C.I.E.) 
Self A GO TO Q13 
Other (WRITE IN) 
 B Go to Q.12 
 
C.12 Is ............ related to you? 
Yes A Go to Q.13 
No B Go to Q.13 (Respondent is C.I.E) 
 
ASK ALL 
C.13 Employment Status of C.I.E: 
 Does the C.I.E. have a paid job full-time or 
part-time? 
Yes A Go to Q.15 
No B Go to Q.14 
 
SHOW CARD C14 
C.14 Looking at this card, please tell me the 
statement that best describes the C.I.E.  Just 
read out the letter of one that best applies. 
 
A-Retired, gets pension from previous job A   Ask occ. 
B-Unemployed, less than 2 months  B   details of 
C-Sick, still receiving pay or statutory pay       previous 
    from job    C   job-Q.15 
 
D-Widow, receiving pension from       Ask occ. 
 husband’s previous job   D  details of 
E-Divorced/separated, receiving mainten-     husband’s 
   ance from ex-husband   E  prev. Job 
 
F-Full-time student   F - Code SG 
        C1 at Q.16 
 
G-Not working, private means  G - Assess 
        SG at Q.16 
 
H-Unemployed longer than 2 mths  H  Code SG  
I-Sick - only receiving Income Support 
   or Invalidity Benefit   I    E at Q.16 
J-Receiving State Pension only  J 
 
C.15 Employment Status of C.I.E.: 
• What type of firm/organisation does/did (C.I.E.) 
work for? 
      WRITE IN: _________________________ 
• What job does ......... do? 
      WRITE IN: _________________________ 
• Does ....... have any position/rank/grade in the 
organisation (ie., responsible for the work of 
other people)? 
Yes A No B 
 
PROMPT AS APPROPRIATE (Foreman, 
Sergeant, Office Manager, Executive, Officer 
etc.) 
IF YES,WRITE IN: _____________________ 
AND ASK: How many people is ...... responsible for? 
 
 
• Does ..... have any qualifications? 
Yes A No B 
 
PROMPT AS APPROPRIATE: Apprenticeship, 
professional qualifications, University degree) 
WRITE IN: __________________________ 
 
• IF FARMER ASK:  How many acres do you 
farm? 
 
 
C.16 Assess Social Grade: 
A 1 C2 4 
B 2 D 5 
C1 3 E 6 
SHOW CARD C17 AND READ OUT 
C.17 A person has a disability if he/she has a 
physical or mental impairment, which has a 
substantial and long-term adverse effect on 
his/her ability to carry out normal day to day 
activities.  On the basis of this definition, do you 
regard yourself as being disabled? 
Yes 1 No 2 DK 3 
 
SHOW CARD C18 
C.18 Which of these best describes your 
ethnic origin? 
White 1 Bangladeshi 6 
Chinese 2 Black African 7 
Irish Traveller 3 Black Caribbean 8 
Indian 4 Black Other 9 
Pakistani 5 Mixed ethnic group 10 
 
SHOW CARD C19 
C.19 What is the highest level of education 
that you have completed, was it ...?   
GCSE (grades G-D), CSE (grades 2-5), NVQ 
Level 1, GNVQ Foundation 
1 
1-4 CSEs (grade 1), 1-4 GCSEs (grades A-C), 1-
4 ‘O’ Level Passes 
2 
5+ CSEs (grade 1), 5+ GCSEs (grades A-C), 5+ 
‘O’ Level passes, Senior Certificate, NVQ Level 
2, GNVQ Intermediate 
3 
1 ‘A’ Level, 1-3 AS Levels, Advanced Senior 
Certificate 
4 
2+ ‘A; Levels, 4+ AS Levels, NVQ Level 3, 
GNVQ Advanced 
5 
First Degree, NVQ Level 4, HNC, HND 6 
Higher Degree, NVQ Level 5 7 
No qualifications 8 
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C.20 Have you ceased your full time 
education? 
Yes 1 
No 2 
If Yes – At what age?  
 
ROI 1 NI 2 
 
C.21 Do you regard yourself as belonging to 
any particular religion? 
Yes 1 Go to C22 
No 2 Go to C23 
 
C.22 What religion are you? 
 C22 C23 
Catholic 1 1 
Protestant 2 2 
Other (specify) ____________ 3 3 
None - 5 
 
GO TO C24 IF ANSWERED C22 
C.23 What religion were you brought up in? 
 CODE IN GRID ABOVE 
 
C.24 POST CODE INTERVIEWER TO CODE 
       
 
C.25 HEALTH BOARD AREA:  Interviewer to 
code 
EHSSB 1 
NHSSB 2 
SHSSB 3 
WHSSB 4 
 
 
 
I certify that this interview has been 
Carried out strictly in accordance with 
your instructions and within the Code of 
Conduct of the MRS. 
Intv. Sign:  
Intv. No:    
Date of 
Interview 
   
 
 
 
 
 
 
IF AGED 15 SAY TO PARENT/RESPONSIBLE 
ADULT: 
 
Under the rules of the Market Research Society 
we are not allowed to ask children any 
questions without an adult’s permission.  May 
I have your permission to interview your child 
about lifestyles, such as alcohol, tobacco and 
drugs?  I will explain that he/she does not 
have to answer any question that he/she 
doesn’t want to. 
 
IF NECESSARY: We need to interview 15 year 
olds because it is important to understand 
changes to lifestyles over time 
 
REASSURE AS NECESSARY WITH REGARDS TO 
CONFIDENTIALITY, FOR RESEARCH PURPOSES 
ONLY ETC. 
 
HAND STANDARD LETTER TO PARENT OR 
RESPONSIBLE ADULT. 
 
PERMISSION & SIGNATURE MUST BE 
OBTAINED FROM A RESPONSIBLE ADULT 
BEFORE INTERVIEWING ANYONE AGED 15 
 
NAME AND SIGNATURE OF ADULT GIVING 
AUTHORITY FOR INTERVIEW: 
 
PRINT NAME:  
SIGNATURE:  
RELATIONSHIP TO CHILD:  
 
 
 
Interviewer record: 
Parent present during interview 1 
Parent not present during interview 2 
 
 
OFFICE USE ONLY 
Intervr. 
Checked 
Supervisor 
Checked 
Supervisor 
Accomp. 
Back- 
checked 
   Tel 1 
   Visit 2 
   Post 3 
   Date: 
 
Initials: 
 
 
NACD/DAIRU – 2002/2003 Drug Prevalence Survey – Technical Report 
Appendix I 
117 
I. Showcards - Ireland 
 
 
 
The following pages contain the full showcards used for the Population survey in Ireland in 
order of their appearance on the questionnaire. 
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225347          SHOW CARD ‘15’ 
1 Sedatives 
2 Sleeping pills 
3 Rohypnol 
4 Roofies 
5 Row rows 
6 Dalmane, Flurazepam 
7 Mogadon, (Moggies), Nitrazepam 
8 Phenobarbitone 
9 Tranquilliser 
10 Tranks 
11 Downers 
12 Benzos 
13 Roches 
14 Librium 
15 Valium, (Diazepam) 
16 Normison, (Duck eggs), Temazepam 
17 Ativan 
18 Halcion, Triazolam 
19 Anti depressants 
20 Largactil 
21 Xanax 
22 Prozac 
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225347        SHOW CARD ‘22’ 
1 Tablets 
2 Injection with a needle 
3 Other (please tell me which) 
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225347        SHOW CARD ‘23’ 
 
1 I got them on a prescription 
2 I got them from someone else I know 
3 I bought them without a prescription in a chemist 
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225347 SHOW CARD ‘24’ 
 
1 Cannabis 
2 Marijuana 
3 Dope 
4 Grass 
5 Pot 
6 Hash(ish) 
7 Ganja 
8 Shit 
9 Blow 
10 Weed 
11 Draw 
12 Puff 
13 Whacky Backy 
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225347        SHOW CARD ‘31’ 
 
1 Grass 
2 Weed 
3 Skunk 
4 Hash Oil 
5 Herb 
6 Hash 
7 Resin 
8 Other (please tell me which) 
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225347        SHOW CARD ‘32’ 
 
1 Joint 
2 Pipe 
3 Bong 
4 Eat 
5 Other (please tell me which) 
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225347        SHOW CARD ‘33’ 
 
1 Ecstasy 
2 Pills 
3 E 
4 XTC 
5 Doves 
6 Mitsubishi 
7 Shamrocks 
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225347        SHOW CARD ‘40’ 
 
1 Amphetamine 
2 Speed 
3 Billy 
4 Whizz 
5 Base 
6 Sulphate 
7 Ice 
8 Crystal 
9 Bennies 
10 Uppers 
11 Dexies 
12 Purple hearts 
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225347 SHOW CARD ‘47’ 
 
1 Crack 
2 Rock 
3 Stones 
4 Freebase 
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225347        SHOW CARD ‘54’ 
 
1 Cocaine 
2 Charlie 
3 Coke 
4 Snow 
5 Nose candy 
6 Blow 
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225347        SHOW CARD ‘61’ 
 
1 Doing a line/Snort 
2 Injection with a needle 
3 Other (please tell me which) 
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225347        SHOW CARD ‘62’ 
 
1 Heroin 
2 Smack 
3 Gear 
4 H 
5 Junk 
6 Skag 
7 Brown 
8 Horse 
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225347        SHOW CARD ‘69’ 
 
1 Smoke 
2 Injection with a needle 
3 “chasing the dragon” 
4 Other (please tell me which) 
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225347 SHOW CARD ‘70’ 
 
1 LSD 
2 Acid 
3 Trips 
4 Tabs 
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225347        SHOW CARD ‘77’ 
 
1 Solvents 
2 Glues 
3 Dry-cleaning fluids 
4 Aerosols 
5 Strippers 
6 Petrol 
7 Nail varnish remover 
8 Correction fluids 
9 Gas lighter refills 
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225347        SHOW CARD ‘84’ 
 
1 Amyl Nitrite 
2 Poppers 
3 Rush 
4 Liquid gold 
5 Locker room 
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225347        SHOW CARD ‘91’ 
 
1 Psilocybin 
2 Magic Mushrooms 
3 Mushies 
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225347        SHOW CARD ‘98’ 
 
1 Methadone 
2 Physeptone 
3 Phy 
4 Brown 
5 Green 
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225347       SHOW CARD ‘104b’ 
 
1 I got it on a prescription 
2 I got it from someone else I know 
3 I bought it without a prescription in a chemist 
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225347        SHOW CARD ‘112’ 
 
1 Opiates 
2 Opium 
3 Temgesic, (GiGis), buprenorphine 
4 Diconal, (Dike) 
5 Napps 
6 MSTs 
7 Pethidine 
8 DF118, (Dihydrocodeine) 
9 Morphine 
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225347       SHOW CARD ‘118b’ 
 
1 I got them on a prescription 
2 I got them from someone else I know 
3 I bought them without a prescription in a chemist 
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225347        SHOW CARD ‘126’ 
 
1 More as a criminal 
2 More as a patient 
3 Neither a criminal nor a patient 
4 Both a criminal and a patient 
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225347        SHOW CARD ‘127’ 
 
1 Fully agree 
2 Largely agree 
3 Neither 
4 Largely disagree 
5 Fully disagree 
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225347        SHOW CARD ‘128’ 
 
1 Do not disapprove 
2 Disapprove 
3 Strongly disapprove 
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225347        SHOW CARD ‘129’ 
 
1 No risk 
2 Slight risk 
3 Moderate risk 
4 Great risk 
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225347        SHOW CARD ‘135’ 
 
1 Yes – tried to and stopped 
2 Yes -  tried to but not stopped 
3 No 
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225347        SHOW CARD ‘136’ 
 
1 Cost 
2 Persuaded by friends/family 
3 Impact on job/friends/family 
4 No longer part of social life 
5 Concern about health/health reasons 
6 Pregnancy 
7 Less available supply 
8 Put on rehabilitation programme 
9 Did not want to take anymore 
10 Did not enjoy after effects 
11 The pros of taking did not outweigh the cons 
12 Could no longer afford it 
13 Other (please tell me which) 
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225347        SHOW CARD ‘139’ 
 
1 Yes – tried to and stopped 
2 Yes -  tried to but not stopped 
3 No 
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225347        SHOW CARD ‘140’ 
 
1 Cost 
2 Persuaded by friends/family 
3 Impact on job/friends/family 
4 No longer part of social life 
5 Concern about health/health reasons 
6 Pregnancy 
7 Less available supply 
8 Put on rehabilitation programme 
9 Did not want to take anymore 
10 Did not enjoy after effects 
11 The pros of taking did not outweigh the cons 
12 Could no longer afford it 
13 Other (please tell me which) 
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225347        SHOW CARD ‘143’ 
 
1 Yes – tried to and stopped 
2 Yes -  tried to but not stopped 
3 No 
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225347        SHOW CARD ‘144’ 
 
1 Cost 
2 Persuaded by friends/family 
3 Impact on job/friends/family 
4 No longer part of social life 
5 Concern about health/health reasons 
6 Pregnancy 
7 Less available supply 
8 Put on rehabilitation programme 
9 Did not want to take anymore 
10 Did not enjoy after effects 
11 The pros of taking did not outweigh the cons 
12 Could no longer afford it 
13 Other (please tell me which) 
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225347        SHOW CARD ‘147’ 
 
1 Yes – tried to and stopped 
2 Yes -  tried to but not stopped 
3 No 
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225347        SHOW CARD ‘148’ 
 
1 Cost 
2 Persuaded by friends/family 
3 Impact on job/friends/family 
4 No longer part of social life 
5 Concern about health/health reasons 
6 Pregnancy 
7 Less available supply 
8 Put on rehabilitation programme 
9 Did not want to take anymore 
10 Did not enjoy after effects 
11 The pros of taking did not outweigh the cons 
12 Could no longer afford it 
13 Other (please tell me which) 
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225347        SHOW CARD ‘149’ 
 
1 Given by family/friend 
2 Given by a contact I did not know personally 
3 Given by a stranger 
4 Shared amongst group of friends 
5 Bought from a friend 
6 Bought from a contact I did not know personally 
7 Bought from a stranger 
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225347        SHOW CARD ‘150’ 
1 Street/park 
2 Disco/bar/club 
3 Office/workplace 
4 School/college 
5 House of a dealer 
6 House of a friend 
7 Ordered by phone for collection/delivery 
8 Other (please tell me which) 
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225347        SHOW CARD ‘151’ 
 
1 Very easy 
2 Fairly easy 
3 Neither easy nor difficult 
4 Fairly difficult 
5 Very difficult 
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225347        SHOW CARD ‘C2’ 
 
Single (never married) 
Married 
Co-habiting 
Separated 
Divorced 
Widowed 
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225347        SHOW CARD ‘C5’ 
 
In Paid Job 
1 Working full-time 30+ hours a week 
2 Working 8-29 hours a week 
3 Working less than 8 hours a week 
No Paid Job 
4 Seeking work for the first time 
5 Unemployed (having lost or given up job) 
6 Home (domestic) duties 
7 Unable to work due to permanent illness/disability 
8 Not working (seeking work) 
9 Not working (not seeking work) 
10 On Government training/education scheme 
11 On Government employment scheme (CE, job options etc)
12 Retired 
13 Student 
14 Other (please tell me which) 
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225347        SHOW CARD ‘C9’ 
 
A Retired, gets pension from previous job 
B Unemployed, less than 2 months 
C Sick, still receiving pay or statutory pay from job 
D Widow, receiving pension from husband’s previous job 
E Divorced/separated, receiving maintenance from ex-
husband 
F- Full-time student 
G Not working, private means 
H Unemployed longer than 2 months 
I Sick – only receiving Income Support or Invalidity Benefit 
J Receiving State Pension only 
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225347        SHOW CARD ‘C12’ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A person has a disability if he/she has a physical or mental 
impairment which has a substantial and long-term adverse effect on 
his/her ability to carry out normal day to day activities.  On the basis 
of this definition, do you regard yourself as being disabled? 
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225347       SHOW CARD ‘C13’ 
 
1 No formal education 
2 Primary education 
3 Second level 
4 Lower secondary 
(Junior/Intermediate/Group Certificate, ‘O’ levels/GCSEs, 
NCVA Foundation Certificate, basic Skills Training 
Certificate or equivalent) 
5 Upper secondary 
Leaving certificate, (including Applied and Vocational 
Programmes), ‘A’ Levels NCVA       Level 1Certificate or 
equivalent) 
6 Third level 
Non degree qualification (National Certificate, Diploma 
NCEA/Institute of Technology or equivalent) 
7 Primary degree (Third level bachelor degree) 
8 Professional qualification (of degree status at least) 
9 Both a degree and a professional qualification 
10 Postgraduate certificate or diplomas 
11 Postgraduate degree or masters 
12 Doctorate (PhD) 
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J. Showcards - Northern Ireland 
 
 
 
The following pages contain the full showcards used for the Population survey in Northern 
Ireland in order of their appearance on the questionnaire. 
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220543  SHOW CARD ‘15’ 
 
1 Sedatives 
2 Sleeping pills 
3 Roofies 
4 Mogadon 
5 Moggies 
6 Phenobarbitone 
7 Tranquilliser 
8 Benzos 
9 Librium 
10 Valium 
11 Temazepam 
12 Anti depressants 
13 Rugby balls 
14 Prozac 
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220543 SHOW CARD ‘22’ 
 
1 Tablets 
2 Injection with a needle 
3 Other (please tell me which) 
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220543        SHOW CARD ‘23’ 
 
1 I got them on a prescription 
2 I got them from someone else I know 
3 I bought them without a prescription in a chemist 
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220543        SHOW CARD ‘24’ 
 
1 Cannabis 
2 Marijuana 
3 Dope 
4 Grass 
5 Pot 
6 Hash(ish) 
7 Blow 
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220543        SHOW CARD ‘31’ 
 
1 Grass 
2 Weed 
3 Skunk 
4 Hash Oil 
5 Hash 
6 Herb 
7 Resin 
8 Other (please tell me which) 
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220543        SHOW CARD ‘32’ 
 
1 Joint 
2 Pipe 
3 Bong 
4 Eat 
5 Other (please tell me which) 
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220543        SHOW CARD ‘33’ 
 
1 Ecstasy 
2 Pills 
3 E 
4 X 
5 Doves 
6 Denis the Menace 
7 MDMA 
8 New Yorkers 
9 Ecky 
10 Adam 
 
 
 
 
NACD/DAIRU – 2002/2003 Drug Prevalence Survey – Technical Report 
Appendix J 
167 
220543        SHOW CARD ‘40’ 
 
1 Amphetamine 
2 Speed 
3 Billy 
4 Whizz 
5 Ice 
6 Crystal meth 
7 Dexies 
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220543        SHOW CARD ‘46b’ 
 
1 I got them on a prescription 
2 I got them from someone else I know 
3 I bought them without a prescription in a chemist 
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220543        SHOW CARD ‘47’ 
 
1 Crack 
2 Rock 
3 Freebase 
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220543        SHOW CARD ‘54’ 
 
1 Cocaine 
2 Coke 
3 Snow 
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220543        SHOW CARD ‘61’ 
 
1 Doing a line/Snort 
2 Injection with a needle 
3 Other (please tell me which) 
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220543        SHOW CARD ‘62’ 
 
1 Heroin 
2 Smack 
3 H 
4 Skag 
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220543        SHOW CARD ‘69’ 
 
1 Smoke 
2 Injection with a needle 
3 “chasing the dragon” 
4 Other (please tell me which) 
 
 
NACD/DAIRU – 2002/2003 Drug Prevalence Survey – Technical Report 
Appendix J 
174 
220543        SHOW CARD ‘70’ 
 
1 LSD 
2 Acid 
3 Trips 
4 Tabs 
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220543        SHOW CARD ‘77’ 
 
1 Solvents 
2 Glues 
3 Dry-cleaning fluids 
4 Aerosols 
5 Strippers 
6 Petrol 
7 Nail varnish remover 
8 Correction fluids 
9 Gas lighter refills 
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220543        SHOW CARD ‘84’ 
 
1 Amyl Nitrite 
2 Poppers 
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220543        SHOW CARD ‘91’ 
 
1 Magic Mushrooms 
2 Psilocybin 
3 Mushies 
4 Liberty Caps 
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220543        SHOW CARD ‘98’ 
 
1 Methadone 
2 Physeptone 
3 Meths 
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220543       SHOW CARD ‘104b’ 
 
1 I got it on a prescription 
2 I got it from someone else I know 
3 I bought it without a prescription in a chemist 
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220543 SHOW CARD ‘105’ 
 
Nubain 
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220543 SHOW CARD ‘112’ 
 
1 
Opiates 
2 
Temgesic 
3 
Codeine 
4 
Kapake 
5 
Morphine 
6 
Opium 
7 
DF’s 
8 
Diffs 
9 
Dikes 
10 
Peach 
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220543       SHOW CARD ‘118b’ 
 
1 I got them on a prescription 
2 I got them from someone else I know 
3 I bought them without a prescription in a chemist 
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220543        SHOW CARD ‘119’ 
 
1 
Anabolic Steriods 
(This does not include steroids taken for the treatment of 
respiratory ailments e.g. Asthma, Arthritis and other 
inflammatory conditions) 
2 Iron Brew 
3 Dianabol 
4 Durabolin 
5 Stanozolol 
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220543       SHOW CARD ‘125b’ 
 
1 I got them on a prescription 
2 I got them from someone else I know 
3 I bought them without a prescription in a chemist 
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220543        SHOW CARD ‘126’ 
 
1 More as a criminal 
2 More as a patient 
3 Neither a criminal nor a patient 
4 Both a criminal and a patient 
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220543        SHOW CARD ‘127’ 
 
1 Fully agree 
2 Largely agree 
3 Neither 
4 Largely disagree 
5 Fully disagree 
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220543        SHOW CARD ‘128’ 
 
1 Do not disapprove 
2 Disapprove 
3 Strongly disapprove 
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220543        SHOW CARD ‘129’ 
 
1 No risk 
2 Slight risk 
3 Moderate risk 
4 Great risk 
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220543        SHOW CARD ‘135’ 
 
1 Yes – tried to and stopped 
2 Yes -  tried to but not stopped 
3 No 
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220543        SHOW CARD ‘136’ 
 
1 Cost 
2 Persuaded by friends/family 
3 Impact on job/friends/family 
4 No longer part of social life 
5 Concern about health/health reasons 
6 Pregnancy 
7 Less available supply 
8 Put on rehabilitation programme 
9 Did not want to take anymore 
10 Did not enjoy after effects 
11 The pros of taking did not outweigh the cons 
12 Could no longer afford it 
13 Other (please tell me which) 
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220543        SHOW CARD ‘139’ 
 
1 Yes – tried to and stopped 
2 Yes -  tried to but not stopped 
3 No 
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220543        SHOW CARD ‘140’ 
 
1 Cost 
2 Persuaded by friends/family 
3 Impact on job/friends/family 
4 No longer part of social life 
5 Concern about health/health reasons 
6 Pregnancy 
7 Less available supply 
8 Put on rehabilitation programme 
9 Did not want to take anymore 
10 Did not enjoy after effects 
11 The pros of taking did not outweigh the cons 
12 Could no longer afford it 
13 Other (please tell me which) 
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220543        SHOW CARD ‘143’ 
 
1 Yes – tried to and stopped 
2 Yes -  tried to but not stopped 
3 No 
 
NACD/DAIRU – 2002/2003 Drug Prevalence Survey – Technical Report 
Appendix J 
194 
220543        SHOW CARD ‘144’ 
 
1 Cost 
2 Persuaded by friends/family 
3 Impact on job/friends/family 
4 No longer part of social life 
5 Concern about health/health reasons 
6 Pregnancy 
7 Less available supply 
8 Put on rehabilitation programme 
9 Did not want to take anymore 
10 Did not enjoy after effects 
11 The pros of taking did not outweigh the cons 
12 Could no longer afford it 
13 Other (please tell me which) 
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220543        SHOW CARD ‘147’ 
 
1 Yes – tried to and stopped 
2 Yes -  tried to but not stopped 
3 No 
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220543        SHOW CARD ‘148’ 
 
1 Cost 
2 Persuaded by friends/family 
3 Impact on job/friends/family 
4 No longer part of social life 
5 Concern about health/health reasons 
6 Pregnancy 
7 Less available supply 
8 Put on rehabilitation programme 
9 Did not want to take anymore 
10 Did not enjoy after effects 
11 The pros of taking did not outweigh the cons 
12 Could no longer afford it 
13 Other (please tell me which) 
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220543        SHOW CARD ‘149’ 
 
1 Given by family/friend 
2 Given by a contact I did not know personally 
3 Given by a stranger 
4 Shared amongst group of friends 
5 Bought from a friend 
6 Bought from a contact I did not know personally 
7 Bought from a stranger 
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220543        SHOW CARD ‘150’ 
 
1 Street/park 
2 Disco/bar/club 
3 Office/workplace 
4 School/college 
5 House of a dealer 
6 House of a friend 
7 Ordered by phone for collection/delivery 
8 Other (please tell me which) 
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220543        SHOW CARD ‘151’ 
 
1 Very easy 
2 Fairly easy 
3 Neither easy nor difficult 
4 Fairly difficult 
5 Very difficult 
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220543        SHOW CARD ‘C2’ 
 
1 Single (never married) 
2 Married 
3 Co-habiting 
4 Separated 
5 Divorced 
6 Widowed 
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220543        SHOW CARD ‘C7’ 
 
In Paid Job 
1 Self-employed 
2 Working full-time 30 hrs+/week 
3 Working part time 
No Paid Job 
4 Unemployed and seeking work 
5 Home (domestic) duties 
6 Unable to work due to permanent illness/disability 
7 Not working (seeking work) 
8 Not working (not seeking work) 
9 On Gov. training/education scheme (Jobskills, Training for 
Work, New Deal) 
10 On Gov. employment scheme (New Deal, Workteach) 
11 Full time education 
12 Part time education 
13 Retired 
14 Other (please tell me which) 
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220543        SHOW CARD ‘C14’ 
 
A Retired, gets pension from previous job 
B Unemployed, less than 2 months 
C Sick, still receiving pay or statutory pay from job 
D Widow, receiving pension from husband’s previous 
job 
E Divorced/separated, receiving maintenance from 
ex-husband 
F Full-time student 
G Not working, private means 
H Unemployed longer than 2 months 
I Sick – only receiving Income Support or Invalidity 
Benefit 
J Receiving State Pension only 
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225078        SHOW CARD ‘C17’ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A person has a disability if he/she has a physical or mental 
impairment, which has a substantial and long-term adverse effect on 
his/her ability to carry out normal day to day activities.  On the basis 
of this definition, do you regard yourself as being disabled? 
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220543        SHOW CARD ‘C18’ 
 
1 White 
2 Chinese 
3 Irish Traveller 
4 Indian 
5 Pakistani 
6 Bangladeshi 
7 Black African 
8 Black Caribbean 
9 Black Other 
10 Mixed ethnic group 
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220543        SHOW CARD ‘C19’ 
 
1 GCSE (grades G-D), CSE (grades 2-5), NVQ Level 1, 
GNVQ Foundation 
2 1-4 CSEs (grade 1), 1-4 GCSEs (grades A-C), 1-4 ‘O’ 
Level Passes 
3 5+ CSEs (grade 1), 5+ GCSEs (grades A-C), 5+ ‘O’ 
Level passes, Senior Certificate, NVQ Level 2, GNVQ 
Intermediate 
4 1 ‘A’ Level, 1-3 AS Levels, Advanced Senior Certificate 
5 2+ ‘A; Levels, 4+ AS Levels, NVQ Level 3, GNVQ 
Advanced 
6 First Degree, NVQ Level 4, HNC, HND 
7 Higher Degree, NVQ Level 5 
8 No qualifications 
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K. Interviewer Instructions  
 
 
 
The following pages contain the interviewing instructions used for the Population survey. 
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INTERVIEWER INSTRUCTIONS 
 
POPULATION STUDY 
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225347 ROI 
220543 NI 
Background to the Study 
 
 
The European Union has an Action Plan on drugs to establish the prevalence of drug use in the 
general population of the EU member states. 
 
To enable the EU to take this forward all member countries will be carrying out population 
studies using a common methodology and basic questionnaire. 
 
  
This, the first all-Ireland study of its type, will provide data about the frequency of drug use 
(both legal and illegal) among the general population of Ireland. 
 
 
In Ireland, this research has been commissioned by the National Advisory Committee on Drugs 
(NACD) and the Drug and Alcohol Information and Research (DAIRU).  These bodies represent 
an all-Ireland front in providing data and advice to various government departments about the 
prevalence of drug use and other related aspects. 
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2. Sampling 
 
 
 
 
In this study the people to be interviewed are to be adults aged 15-64 whose normal place of 
residence is Northern Ireland/Republic of Ireland. 
 
We will interview 3,500 people in Northern Ireland and 4,100 people in the Republic of Ireland.  
Addresses have been chosen from each of the Health Boards in Northern Ireland/Republic of 
Ireland. The addresses chosen are proportionate to the populations in each Health Board, so for 
example, as there are more people living in the Eastern Health Board than in any of the other 
boards, it follows that we have more addresses here to obtain more interviews. 
 
The principle used to select individuals for interviewing is called random sampling.  This means 
that very precise instructions must be followed accurately, in order that the correct person is 
chosen for interview. 
 
Interviewing will be conducted over the next few months.  It is important that we spread the 
interviews across the time period so that any changes in the behaviour of our respondents 
during holiday periods, for example, is not over represented. 
 
We have drawn a nationally representative sample of the population (for both Northern Ireland 
and the Republic of Ireland) from the Postal Address File in Northern Ireland and the An 
Post/Ordnance Survey Geo-Directory in the Republic. 
 
These files are comprised of all addresses to which the Post Office/An Post deliver mail.  They 
are updated regularly from information collected from each postal round, so provide the most 
comprehensive sample frame available. 
 
The sample we have selected excludes large users and organisations so the vast majority of 
addresses issued to each interviewer will be private residential addresses. 
 
Each assignment will contain a specific number of addresses which should all be approached 
and an attempt made to interview the selected individual at each address, providing there is 
someone aged 15-64 living there. 
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3. When to Interview 
 
 
 
Each address has to be visited up to five times. 
 
The reason for this approach is to ensure that each address has the best possible chance of 
providing an interview. 
 
It is essential therefore to space out your calls across different days and times of day so as to 
allow people living at an address the best chance of being contacted. 
 
Ideally you should not begin work before mid-afternoon (c. 3.30pm) which will maximise your 
chances of finding someone at home. 
 
Once you have made contact with a responsible adult in the household you will follow a strict 
procedure to select the correct individual in the household to interview. 
 
You will keep a record of the number of calls and times of these calls on the Contact Record 
Sheet, explained in Chapter 4. 
 
Until you have established contact you should make your calls before 9.00pm and from Monday 
to Saturday.  Later/Sunday calls can only be made by prior appointment. 
 
You must not make subsequent calls at the same time of day, as it is likely that if the household 
is empty at 5.00pm on a Tuesday it will be on a Wednesday and Thursday too! 
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4. The Contact Record Sheet/Address List 
 
 
 
In this study you will be given particular addresses in a relatively small geographical area. 
 
It is sensible to plan your route before going out on the first day so that you can make your 
initial calls as quickly and easily as possible. 
 
When you receive each assignment, please check the addresses in case you know anyone living 
at any of them.  We do not want you to interview anyone you know.  If you find such an 
address, please code “18” as the final outcome on the contact sheet and state “Known to me”.  
Return the contact sheet with your completed assignment. 
This also applies if, when you make contact at any given address, you discover that you know 
the person/people living there. 
 
If you don’t know the area you have been given you should go out in daylight on your first day. 
 
As far as we can know, the addresses you will have been given are those of private households.  
(There may be the occasional commercial property such as a small shop but this should be the 
exception.) 
 
A private household is where a group of people (not always related) live together and whose 
food and household expenses are managed as one unit. 
 
However, sometimes more than one household is found at a single address. 
 
This could be: 
 
(1) A house has been converted into two or more flats; 
(2) Two families sharing a dwelling such as a young married couple living 
with parents but with separate catering and housekeeping arrangements 
– each is a separate household. 
(3) A group of students or other non-related individuals living together at one 
address.  These individuals form individual households, if they don’t cater 
as one unit. 
 
If you come across a multi-household you must ring the office.  Please provide all relevant 
information such as – the number or households (in the case of a flat conversion or two or 
more households at the one address) to enable us to select which one you should select your 
respondent from, list them in the following order - the person whose name is on the rent book 
or who has the mortgage (if joint holders, in age order) then those who joined the household 
next and so on.  We will select which household you should focus on from a random table, 
selection grid. 
 
Do ring as soon as you are aware of this circumstance so that we can advise you immediately. 
 
Each contact sheet has a unique address code (which will be transferred to the questionnaire 
you use to interview the selected individual). 
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Because you will need to introduce yourself and the study to the person you initially make 
contact with; the full introduction is written here, too. 
 
When you do make contact with a responsible adult in the (private) household, you will explain 
who you are and what you are doing.  Practise and learn your introduction at home, show your 
ID card and look at the person, rather than reading out the introduction.  You may be asked 
why you are at the particular address and you can explain it was chosen, at random, from the 
Postal Address File/An Post/Ordnance Survey Geo-Directory (as appropriate).  This is important 
to do if the person is concerned about how their address was obtained. 
 
If the contact is reluctant to talk to you, back off before you get an outright refusal.  Offer a 
copy of the letter from the client and say you’ll call at another time when you’re next in the 
area.  You can catch people at a bad time for them and if you don’t try to pressure them you 
may be successful next time you call. 
 
If your respondent is amenable then ask: 
 
 “How many people aged between 15-64 live here?” 
 
(a) If the answer is none then no interview can be taken here. 
 
(b) If the answer is one, me! – then take the interview there and then. 
 
(c) If the answer is one but he/she isn’t in then you should try to ascertain the best 
time to call and interview that person. 
 
(d) If the answer is two or more then you need to record their details on the contact 
sheet and select the one who has celebrated their birthday most recently.  This is 
the “last birthday rule” and is used to select individuals within a household in a 
random manner.  You must select and interview the “right” person.  To do 
otherwise introduces bias into the sample and affects the reliability of the data. 
 
It doesn’t matter in which order your contact gives you the names of all those 
aged between 15-64.  Ask what was the day and month of (all) their birthdays.  
Choose the individual who had the most recent birthday.  This has nothing to do 
with the age of respondents, only when they had their birthdays.  We don’t 
need dates of birth, only the birthdays, i.e. not 10th June 1962 only 10th June. 
 
You only need to determine the age of the selected individual. 
 
If there are twins in the household and their birthday is the most recent one then 
interview the twin born second. 
 
If two or more people in any household share the same birthday, select the 
youngest person as your respondent. 
If a member of the household has their birthday on the day that you make 
contact and carryout the selection procedure, select this person as the 
respondent who will complete the interview. 
 
If your selected respondent isn’t at home then you try to establish a good time to 
call back. 
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Each time you make a call you record the result of the call by using the codes provided for time 
of day and day of the week.  Also write on the comments line any information which will be 
useful.  For example, your initial contact has told you that her teenage son (your selected 
respondent) comes in to eat his dinner at 7.00pm and usually is out of the house for the 
evening by 8.00pm.  You’ll need to catch him about 7.30!  Write this to remind you when you’re 
planning your route for your next round of calls. 
 
You may wish to leave an appointment card if you have not succeeded in making contact after 
two visits or to remind selected respondents of when they have agreed to carry out the 
interview. 
 
If your selected individual in the household is aged 15 you need to obtain written parental 
permission before you can conduct an interview. 
 
It is a parent’s right not only to know the type of questions that you are going to ask but to 
actually sit in on the interview if they wish. 
 
Obviously with this study that would not be ideal so try to explain the subject matter in general 
terms (you may already have spoken to the parent as your contact person) and show the 
appropriate letter. 
 
If you appear very matter-of-fact about everything, the odds are that the parent will allow you 
to conduct the interview alone with the 15 year old.  If the parent wants to sit in you must 
accede. 
 
Proceed with the interview as instructed and record on the questionnaire the fact that the 
parent was present. 
 
If permission is not granted you cannot take an interview and you will record this in the final 
outcome box. 
 
If after five calls to the address on different days/different times of day you have not got an 
interview you may record the final outcome on the contact sheet and return to the office. 
 
However, you may feel that you still have a chance of getting the interview.   In that case carry 
the contact sheet and questionnaires and try when you are in the area, perhaps working on 
another project.  So long as your supervisor knows that you are holding on to that contact sheet 
this is fine. 
 
Sometimes you may not be able to carry out an interview with the selected respondent because 
they don’t speak adequate English.  If this happens we will try to find an interpreter to conduct 
the interview.  Try to establish the language spoken and tell the Field Office. 
 
You must complete the Contact Sheets accurately and conscientiously with enough detail.  We 
may need to reallocate the work to another interviewer or supervisor if response rate in the area 
is too low and a complete history of previous calls will be useful. 
 
We need to calculate the study response rate and construct a profile of non-productive or invalid 
addresses and refusals for the report to our client. 
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Included in this will be information about the type of property lived in and in the case of refusals 
the type of person who refused.  Please fill this section in accurately. 
 
If any address is non-residential, eg, a small shop or office, make no attempt to take an 
interview.   Do check however that there isn’t living accommodation above or attached to the 
business premises with the same address.  If completely non-residential, code this in the Final 
Outcome Box. 
 
In the majority of cases you will be able to complete a successful interview so don’t forget, 
 
record the name and telephone number of the selected respondent on your contact 
sheet. 
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5. Pre-Selected Progress Monitoring 
 
 
 
Your supervisor will contact you at regular intervals to see how your work is going.  Please keep 
your paperwork organised so that you can always give an up-to-date report. 
 
The basic information required for each assignment will be: 
 
• Total number of successful interviews conducted to date; 
• Total number of definite non-productives to date; 
• Total number of invalid addresses to date; 
• Number of addresses still working on. 
 
These four figures should tally with the number of addresses issued on the assignment. 
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6. The Interview 
 
 
 
We have written to Garda/Police Headquarters to advise them that this study is taking place.  
You should contact the local station in the area you are to work in to tell them when you will be 
working, car registration (if asked for) etc.  This can be in person but is acceptable by phone.   
 
Make every attempt to interview in a one-to-one setting.  This is desirable for most surveys: in 
this study it is essential. 
 
The purpose of the interview is to determine the respondent’s use of tobacco, alcohol drugs 
sometimes used as medicines and illegal drugs.  While the use of illegal drugs these days is not 
necessarily seen as something to be embarrassed about or kept quiet by those who use them, 
nevertheless, many people would not freely talk about their use of these types of drugs in front 
of members of their family. 
 
For the majority of respondents the interview will take 15 minutes or less so it is possible to 
conduct it on the doorstep.  If invited into a living room with other members of the household 
present, decline and say something like – “I don’t want to disturb them, can we do the interview 
in the hall or the kitchen or somewhere we can be private?” 
 
Reassure respondents at the beginning of the interview about confidentiality.  Their names and 
individual address will not be linked to their answers.  Indeed the only reason for taking their 
names is to check that you, the interviewer, have carried out your work accurately.  Explain as 
you usually do about backchecking and give whatever reassurance is needed as to their 
complete anonymity. 
 
Point out if you need to that their name doesn’t go on the questionnaire and that the answers of 
all the people interviewed on this study (7,600 in total) are input to a computer using codes and 
then the results are produced as statistics, tables of figures etc. 
 
You must ask all the questions as they are written, in the order that they appear and you must 
not (as in all surveys) betray any emotion or reaction to any of the answers given to your 
questions. 
 
You must appear interested in what your respondent says in order to encourage him/her to 
keep answering but please do not engage in discussion or pass any opinion about the topic of 
the study or answers you have been given. 
 
If it helps secure an interview or in response to the enquiry “What’s it for?” you may tell your 
respondent (or contact) that although everyone has an opinion about the prevalence of drug 
use in Ireland, no one actually knows how widespread it is or indeed any other real information. 
 
There have been other smaller studies about the homeless, schoolchildren etc., but never a 
study with the population.  The information gathered from this study will be used by various 
government departments to plan resources needed for education, rehabilitation etc. 
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7. The Questionnaire (and Show Cards) 
 
 
 
This is straightforward and clearly set out. 
 
Ask each section in order and follow skips as instructed.  Use the show cards where instructed.  
Their use will minimise potentially sensitive questions and answers. 
 
Each section is laid out in similar fashion, as is the type of question.  The exact words must be 
used.  Do not abbreviate questions or leave any out.  Do not assume that you know the answer 
to a particular question because of a previous answer. 
 
Where exact ages or number of days is required to be recorded and a respondent may not be 
sure, get them to give you their best estimate. 
 
For example, if you are talking to a smoker in his mid forties and he cannot remember whether 
he was 14 or 15 when he first smoked tobacco products ask him just to give you the one he 
thinks.  He needs to make the judgement not you or the editor who checks that one figure, not 
a range of figures, is in the box! 
 
Please try to get figure.  Don’t knows are not very useful to anyone. 
 
If your respondent says “no, that they have never …..” (whatever the section is asking about) 
they will be routed to the next section. 
 
At other places in the sections this routing applies.  Please become familiar with the routing 
before going out to interview. 
 
At Q.15 you introduce the show cards.  Only allow the respondent to look at the card relevant to 
the question.  The card numbers match the question numbers. 
 
Ask the question – “have you ever heard of any of these?” – showing the relevant card at the 
same time.  If ‘yes’ continue asking the questions in this section.  If none are heard of then 
code ‘no’ and go to the next section. 
 
Use the appropriate show cards and where applicable ask the respondent just to call you out the 
number(s) that applies to their answer(s). 
 
Continue for all sections. 
 
Use the link between the sections, enabling you to progress from legal drugs, tobacco, alcohol 
and drugs sometimes used as medicines to illegal drugs. 
 
Use the link before Q.126 as this section of the questionnaire moves away from collecting facts 
to collecting opinions. 
 
Note the wording of Q128. 
Not disapproving is not the same as approving and it may be helpful to emphasise the not 
disapprove slightly when reading at the question. 
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At Q.129 “five or more drinks at the weekend” means having five or more drinks on any of 
Friday, Saturday or Sunday.  It does not mean 5 drinks in total across all three days. 
  
At Q.130 “Ireland” refers to the island as a whole, Northern Ireland as well as the Republic of 
Ireland. 
 
Q.131 begins a new section where you may need to check whether or not this question is asked 
of a respondent. 
 
Questions 131/132, 133/134, 137/138, 141/142 and 145/146 ask the respondent whether they 
have taken certain things “regularly”, i.e. drunk alcohol, taken cannabis, ecstasy, cocaine and 
heroin.  In this instance “regularly” should be self defined by the respondent.  If asked what do 
you mean by or how often is “regularly”, say to the respondent that it is means whatever he/she 
considers “regularly” to mean or however often he/she considers something to be regular. 
 
To save you having to refer to the answer to a previous question several times, you must tick 
the reminder boxes on the last page of your questionnaire as you go along.  You then know 
whether or not to ask subsequent questions without having to refer back.  
 
This same procedure applies to the section that begins with Q.149. 
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8. Classification Section 
 
 
 
Having selected the “correct” individual within the household for interview and administered the 
questionnaire you then need to collect the demographic information required.  Again, if 
necessary, reassure respondents of the complete confidentiality of their answers. 
 
Some of the questions on this classification section you are well used to, others may be new to 
you. 
 
Ask all of these questions in the usual matter-of-fact way, using the classification cards as 
instructed. 
 
C1-C11 are standard on the ROI questionnaire. 
C1-C4, C11-C16 are standard on the NI questionnaire. 
 
Please familiarise yourself with the other questions, and be sure to code up answers accurately.  
 
Do remember to leave a completed thank you letter with each respondent. It is useful for 
respondents to have a contact number if they have any queries or concerns after you leave. 
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9. The Interviewer’s Role 
 
 
 
This is vital. 
 
The quality of the information collected (and reported on) depends on your skill, accuracy and 
powers of persuasion. 
 
Follow the procedures of selection correctly.  If you don’t, the validity of the sample and the 
accuracy of the results could be affected.  The sample is only representative if: 
 
1. You select the correct person; 
2. You never interview a substitute; 
3. You make every effort to contact and take an interview at every address; 
4. You use all your skill to persuade a reluctant respondent to take part. 
 
You can tell people how important this study is and that the results will be published next year.  
Assure them that their answers are wanted and are of value to the final outcome of the study.  
Again if you feel it will help, stress the fact that all information given is treated in the strictest 
confidence.  
 
If you are told by your contact or your selected respondent that he/she is too busy assure them 
that you will come back at a more convenient time. 
 
In other words, do your utmost to make contact and secure an interview with the correct 
respondent. 
 
Unlike quota studies you cannot just keep moving on until you find someone who meets your 
quota requirements. 
 
Pre-selected, random studies give much more accurate results, which is why this methodology is 
being used on this one. 
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L. Sampling Points - Ireland 
 
 
 
The following pages contain the full list of sampling points used for the Population survey in 
Ireland.  Sample points are listed in order of their county. 
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Sample 
Point 
Area Detail COUNTY HEALTH 
BOARD 
17010 CARLOW RURAL DED CARLOW SEHB 
17011 CARLOW URBAN DED CARLOW SEHB 
17013 CLONEGALL DED CARLOW SEHB 
27024 CAVAN RURAL DED CAVAN NEHB 
27065 LARAH NORTH DED CAVAN NEHB 
27092 VIRGINIA DED CAVAN NEHB 
27093 WATERLOO DED CAVAN NEHB 
37027 CLENAGH DED CLAIRE MWHB 
37042 CORROFIN DED CLAIRE MWHB 
37056 EINAGH DED CLAIRE MWHB 
37057 ENNIS RURAL DED CLAIRE MWHB 
37080 KILLALOE DED CLAIRE MWHB 
37104 KILTORAGHT DED CLAIRE MWHB 
37154 ENNIS URBAN NO 1 DED CLAIRE MWHB 
267004 BALDOYLE CO. DUBLIN ERHA 
267008 BALLINTEER-BROADFORD CO. DUBLIN ERHA 
267010 BALLINTEER-MARLEY CO. DUBLIN ERHA 
267011 BALLINTEER-MEADOWBROADS CO. DUBLIN ERHA 
267025 BLACKROCK-TEMPLEHILL CO. DUBLIN ERHA 
267028 BLANCHARDSTOWN-BLAKESTOWN CO. DUBLIN ERHA 
267029 BLANCHARDSTOWN-COOLMINE CO. DUBLIN ERHA 
267037 CABINTEELY-KILBOGGET CO. DUBLIN ERHA 
267039 CABINTEELY-POTTERY CO. DUBLIN ERHA 
267040 CASTLEKNOCK-KNOCKMAROON CO. DUBLIN ERHA 
267049 CLONDALKIN-DUNAWLEY CO. DUBLIN ERHA 
267050 CLONDALKIN-MONASTERY CO. DUBLIN ERHA 
267052 CLONDALKIN-ROWLAGH CO. DUBLIN ERHA 
267053 CLONDALKIN-VILLAGE CO. DUBLIN ERHA 
267058 CLONSKEAGH-ROEBUCK CO. DUBLIN ERHA 
267071 DUN LAOGHAIRE-MOUNTOWN CO. DUBLIN ERHA 
267072 DUN LAOGHAIRE-SALLYNOGGIN EAST CO. DUBLIN ERHA 
267080 DUNDRUM-SANDYFORD CO. DUBLIN ERHA 
267084 FIRHOUSE VILLAGE CO. DUBLIN ERHA 
267089 FOXROCK-DEANSGRANGE CO. DUBLIN ERHA 
267092 GLENCULLEN CO. DUBLIN ERHA 
267095 HOWTH CO. DUBLIN ERHA 
267096 KILLINEY NORTH CO. DUBLIN ERHA 
267100 LUCAN -ESKER CO. DUBLIN ERHA 
267103 LUCAN-ST.HELENS CO. DUBLIN ERHA 
267105 MALAHIDE EAST CO. DUBLIN ERHA 
267113 RATHFARNHAM-BALLYROAN CO. DUBLIN ERHA 
267118 RUSH CO. DUBLIN ERHA 
267119 SAGGART CO. DUBLIN ERHA 
267120 SHANKHILL-RATHMICHAEL CO. DUBLIN ERHA 
267125 STILLORGAN-KILMACUD CO. DUBLIN ERHA 
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Sample 
Point 
Area Detail COUNTY HEALTH 
BOARD 
267127 STILLORGAN-MERVILLE CO. DUBLIN ERHA 
267130 SUTTON CO. DUBLIN ERHA 
267131 SWORDS-GLASMORE CO. DUBLIN ERHA 
267133 SWORDS-LISSENHALL CO. DUBLIN ERHA 
267134 SWORDS-SEATOWN CO. DUBLIN ERHA 
267138 TALLAGHT-FETTERCAIRN CO. DUBLIN ERHA 
267139 TALLAGHT-GLENVIEW CO. DUBLIN ERHA 
267140 TALLAGHT-JOBSTOWN CO. DUBLIN ERHA 
267141 TALLAGHT-KILLINARDAN CO. DUBLIN ERHA 
267143 TALLAGHT-KILTIPPER CO. DUBLIN ERHA 
267147 TALLAGHT-SPRINGFIELD CO. DUBLIN ERHA 
267149 TEMPLEOGUE-CYPRESS CO. DUBLIN ERHA 
267154 TEMPLEOGUE-VILLAGE CO. DUBLIN ERHA 
267159 TIBRADDEN CO. DUBLIN ERHA 
268002 ARRAN QUAY B CO. DUBLIN ERHA 
268005 ARRAN QUAY E CO. DUBLIN ERHA 
268006 ASHTOWN A CO. DUBLIN ERHA 
268007 ASHTOWN B CO. DUBLIN ERHA 
268014 BALLYGALL D CO. DUBLIN ERHA 
268015 BALLYMUN A CO. DUBLIN ERHA 
268016 BALLYMUN B CO. DUBLIN ERHA 
268017 BALLYMUN C CO. DUBLIN ERHA 
268018 BALLYMUN D CO. DUBLIN ERHA 
268021 BEAUMONT A CO. DUBLIN ERHA 
268024 BEAUMONT D CO. DUBLIN ERHA 
268026 BEAUMONT F CO. DUBLIN ERHA 
268030 CABRA EAST A CO. DUBLIN ERHA 
268034 CABRA WEST B CO. DUBLIN ERHA 
268035 CABRA WEST C CO. DUBLIN ERHA 
268039 CHERRY ORCHARD B CO. DUBLIN ERHA 
268043 CLONTARF EAST C CO. DUBLIN ERHA 
268045 CLONTARF EAST E CO. DUBLIN ERHA 
268050 CLONTARF WEST E CO. DUBLIN ERHA 
268051 CRUMLIN A CO. DUBLIN ERHA 
268052 CRUMLIN B CO. DUBLIN ERHA 
268061 DRUMFINN CO. DUBLIN ERHA 
268063 FINGLAS NORTH A CO. DUBLIN ERHA 
268064 FINGLAS NORTH B CO. DUBLIN ERHA 
268072 GRANGE B CO. DUBLIN ERHA 
268073 GRANGE C CO. DUBLIN ERHA 
268076 HARMONSTOWN A CO. DUBLIN ERHA 
268077 HARMONSTOWN B CO. DUBLIN ERHA 
268078 INCHICORE A CO. DUBLIN ERHA 
268087 KILMORE D CO. DUBLIN ERHA 
268091 KIMMAGE B CO. DUBLIN ERHA 
268092 KIMMAGE C CO. DUBLIN ERHA 
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Sample 
Point 
Area Detail COUNTY HEALTH 
BOARD 
268096 MANSION HOUSE A CO. DUBLIN ERHA 
268102 MERCHANTS QUAY E CO. DUBLIN ERHA 
268103 MERCHANTS QUAY F CO. DUBLIN ERHA 
268104 MOUNTJOY A CO. DUBLIN ERHA 
268111 PEMBROKE EAST B CO. DUBLIN ERHA 
268112 PEMBROKE EAST C CO. DUBLIN ERHA 
268114 PEMBROKE EAST E CO. DUBLIN ERHA 
268117 PEMBROKE WEST C CO. DUBLIN ERHA 
268119 PRIORSWOOD C CO. DUBLIN ERHA 
268120 PRIORSWOOD D CO. DUBLIN ERHA 
268126 RAHENY-ST.ASSAM CO. DUBLIN ERHA 
268127 RATHFARNHAM CO. DUBLIN ERHA 
268128 RATHMINES EAST A CO. DUBLIN ERHA 
268133 RATHMINES WEST B CO. DUBLIN ERHA 
268135 RATHMINES WEST D CO. DUBLIN ERHA 
268143 SOUTH DOCK CO. DUBLIN ERHA 
268159 WHITEHALL C CO. DUBLIN ERHA 
47012 ARDSKEAGH DED CORK SHB 
47016 BALLINCOLLIG DED CORK SHB 
47052 BISHOPSTOWN DED CORK SHB 
47054 BLARNEY DED CORK SHB 
47055 BOHERBOY DED CORK SHB 
47064 CAHERLAG DED CORK SHB 
47066 CANDROMA DED CORK SHB 
47067 CANNAWAY DED CORK SHB 
47071 CARRIGALINE DED CORK SHB 
47074 CARRIGBOY DED CORK SHB 
47098 CLONFERT EAST DED CORK SHB 
47105 CLOYNE DED CORK SHB 
47132 DOUGLAS DED CORK SHB 
47139 DROMINA DED CORK SHB 
47140 DROMORE DED CORK SHB 
47142 DUNDERROW DED CORK SHB 
47152 FERMOY URBAN DED CORK SHB 
47169 GOWLANE DED CORK SHB 
47186 KILBROGAN DED CORK SHB 
47221 KINSALE RURAL DED CORK SHB 
47239 LISCLEARY DED CORK SHB 
47243 MACROOM URBAN DED CORK SHB 
47246 MALLOW SOUTH URBAN DED CORK SHB 
47271 MONKSTOWN URBAN DED CORK SHB 
47294 SKIBBEREEN URBAN DED CORK SHB 
48001 BALLINLOUGH A CORK SHB 
48008 BISHOPSTOWN C CORK SHB 
48009 BISHOPSTOWN E CORK SHB 
48029 GILLABBEY B CORK SHB 
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Point 
Area Detail COUNTY HEALTH 
BOARD 
48033 GLASHEEN C CORK SHB 
48042 MAHON A CORK SHB 
48045 MARDYKE CORK SHB 
48053 SHANDON B CORK SHB 
48054 SOUTH GATE A CORK SHB 
48061 THE GLEN A CORK SHB 
48069 TRAMORE B CORK SHB 
57011 BALLYMACOOL DED DONEGAL NWHB 
57018 BUNCRANA URBAN DED DONEGAL NWHB 
57036 CLOGHER DED DONEGAL NWHB 
57038 CLONLEIGH SOUTH DED DONEGAL NWHB 
57053 DONEGAL DED DONEGAL NWHB 
57073 GLENEELY DED DONEGAL NWHB 
57080 GOLAND DED DONEGAL NWHB 
57081 GORTAHORK DED DONEGAL NWHB 
57101 KINCRAIGY DED DONEGAL NWHB 
57125 NEWTOWN CUNNINGHAM DED DONEGAL NWHB 
57129 RATHMULLAN DED DONEGAL NWHB 
67017 BALLINASLOE URBAN DED GALWAY WHB 
67028 BALLYNAKILL DED GALWAY WHB 
67052 CASTLEBOY DED GALWAY WHB 
67079 DEERPARK DED GALWAY WHB 
67120 KILCROAN DED GALWAY WHB 
67134 KILLIMOR DED GALWAY WHB 
67170 LOUGHREA URBAN DED GALWAY WHB 
67173 MILLTOWN DED GALWAY WHB 
67178 MOUNTHAZEL DED GALWAY WHB 
67179 MOYCULLEN DED GALWAY WHB 
67211 TUAM RURAL DED GALWAY WHB 
68003 BARNA GALWAY WHB 
68005 CLADDAGH GALWAY WHB 
68018 SALTHILL GALWAY WHB 
68022 WELLPARK GALWAY WHB 
77041 CARRIG DED KERRY SHB 
77046 CAUSEWAY DED KERRY SHB 
77058 CURRAGHMORE DED KERRY SHB 
77065 DINGLE DED KERRY SHB 
77089 KENMARE DED KERRY SHB 
77092 KILCUMMIN DED KERRY SHB 
77101 KILLARNEY RURAL DED KERRY SHB 
77111 KILNANARE DED KERRY SHB 
77116 KINARD DED KERRY SHB 
77161 TRALEE URBAN DED KERRY SHB 
77163 TUBRID DED KERRY SHB 
87021 CARRIGEEN DED KILDARE ERHA 
87022 CASTLEDERMOT DED KILDARE ERHA 
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Point 
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87023 CELBRIDGE DED KILDARE ERHA 
87034 DROICHEAD NUA TOWN DED KILDARE ERHA 
87050 KILDARE DED KILDARE ERHA 
87064 LEIXLIP KILDARE ERHA 
87066 MAYNOOTH DED KILDARE ERHA 
87067 MONASTEREVIN DED KILDARE ERHA 
87069 MORRISTOWNBILLER DED KILDARE ERHA 
87071 NAAS URBAN DED KILDARE ERHA 
87072 NARRAGHMORE DED KILDARE ERHA 
87074 NURNEY DED KILDARE ERHA 
97029 COOLCRAHEEN DED KILKENNY SEHB 
97034 DUNMORE DED KILKENNY SEHB 
97045 GLASHARE DED KILKENNY SEHB 
97058 KILCULLIHEEN DED KILKENNY SEHB 
97063 KILKENNY RURAL DED KILKENNY SEHB 
97086 PORTNASCULLY DED KILKENNY SEHB 
107019 BORRIS-IN-OSSORY DED LAOIS MHB 
107037 CULLENAGH DED LAOIS MHB 
107047 ERRILL DED LAOIS MHB 
107072 MOUNTMELLICK URBAN DED LAOIS MHB 
107073 MOUNTRATH DED LAOIS MHB 
117039 GARADICE DED LEITRIM NWHB 
117074 SRAMORE DED LEITRIM NWHB 
127008 ARDPATRICK DED LIMERICK MWHB 
127026 BALLYSIMON DED LIMERICK MWHB 
127032 BRUREE DED LIMERICK MWHB 
127033 BULGADEN DED LIMERICK MWHB 
127042 CASTLETOWN DED LIMERICK MWHB 
127044 CLARINA DED LIMERICK MWHB 
127076 GLENBROHANE DED LIMERICK MWHB 
127105 LIMERICK NORTH RURAL DED LIMERICK MWHB 
127108 LOGHILL DED LIMERICK MWHB 
127111 MONAGAY DED LIMERICK MWHB 
127120 PATRICKS WELL DED LIMERICK MWHB 
127133 TEMPLEBREDON DED LIMERICK MWHB 
128015 DOCK B LIMERICK MWHB 
128032 RATHBANE LIMERICK MWHB 
128036 SINGLAND B LIMERICK MWHB 
128037 ST LAURENCE LIMERICK MWHB 
137005 ARDAGH WEST DED LONGFORD MHB 
137043 LONGFORD NO1 URBAN DED LONGFORD MHB 
137054 RATHCLINE DED LONGFORD MHB 
147002 ARDEE URBAN DED LOUTH NEHB 
147004 BARRONSTOWN DED LOUTH NEHB 
147008 CASTLETOWN DED LOUTH NEHB 
147020 DUNDALK URBAN 3 DED LOUTH NEHB 
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147028 LOUTH DED LOUTH NEHB 
147035 WEST GATE DED LOUTH NEHB 
157015 BALLINA RURAL DED MAYO WHB 
157033 BEKAN DED MAYO WHB 
157035 BELLAVARY DED MAYO WHB 
157048 CASTLEBAR RURAL DED MAYO WHB 
157049 CASTLEBAR URBAN DED MAYO WHB 
157097 KILLALA DED MAYO WHB 
157103 KILMOVEE DED MAYO WHB 
157124 NEALE DED MAYO WHB 
157138 SLIEVEMAHANAGH DED MAYO WHB 
167025 DONAGHMORE DED MEATH NEHB 
167026 DONAGHPATRICK DED MEATH NEHB 
167034 GRANGEGEETH DED MEATH NEHB 
167047 KILLALLON DED MEATH NEHB 
167049 KILLEAGH DED MEATH NEHB 
167065 NAVAN RURAL DED MEATH NEHB 
167076 RATHMORE DED MEATH NEHB 
167078 RATOATH MEATH NEHB 
167082 ST MARY'S DED MEATH NEHB 
167085 STAMULLIN DED MEATH NEHB 
167088 TARA DED MEATH NEHB 
177004 ANNY DED MONAGHAN NEHB 
177010 BOCKS DED MONAGHAN NEHB 
177016 CARRICKMACROSS RURAL DED MONAGHAN NEHB 
177018 CASTLEBLAYNEY URBAN DED MONAGHAN NEHB 
177052 KILMORE DED MONAGHAN NEHB 
187017 CAPPANCUR DED OFFALY MHB 
187036 EDENDERRY URBAN DED OFFALY MHB 
187043 GORTEEN DED OFFALY MHB 
187075 SCREGGAN DED OFFALY MHB 
187087 TULLAMORE URBAN DED OFFALY MHB 
197009 AUGHRIM EAST DED ROSCOMMON WHB 
197018 BALLYNAMONA DED ROSCOMMON WHB 
197027 CAMS DED ROSCOMMON WHB 
197103 STROKESTOWN DED ROSCOMMON WHB 
207028 CLOONACOOL DED SLIGO NWHB 
207038 DRUMCLIFF WEST DED SLIGO NWHB 
207041 DRUMRAT DED SLIGO NWHB 
207060 LISSADILL NORTH DED SLIGO NWHB 
207071 SLIGO WEST URBAN DED SLIGO NWHB 
217030 BORRISOKANE DED TIPPERARY MWHB 
217055 CLONMEL RURAL DED TIPPERARY SEHB 
217056 CLONMEL WEST URBAN DED TIPPERARY SEHB 
217095 KILCORAN DED TIPPERARY SEHB 
217120 LISRONAGH DED TIPPERARY SEHB 
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217129 MONSEA DED TIPPERARY MWHB 
217133 MOYNE DED TIPPERARY MWHB 
217134 MULLINAHONE DED TIPPERARY SEHB 
217136 NENAGH WEST URBAN DED TIPPERARY MWHB 
217151 RODUS DED TIPPERARY SEHB 
217176 CLONMEL EAST URBAN DED TIPPERARY SEHB 
227021 CASTLERICHARD DED WATERFORD SEHB 
227030 DRUMCANNON DED WATERFORD SEHB 
227086 TALLOW DED WATERFORD SEHB 
227090 TRAMORE DED WATERFORD SEHB 
228001 BALLYBEG NORTH WATERFORD SEHB 
228005 BALLYNAKILL WATERFORD SEHB 
228011 CLEABOY WATERFORD SEHB 
228014 FARRANSHONEEN WATERFORD SEHB 
237004 ATHLONE EAST RURAL DED WESTMEATH MHB 
237007 BALLINALACK DED WESTMEATH MHB 
237050 GREENPARK DED WESTMEATH MHB 
237058 KILBEGGAN DED WESTMEATH MHB 
237080 MULLINGAR SOUTH URBAN DED WESTMEATH MHB 
247014 BALLYHACK DED WEXFORD SEHB 
247017 BALLYLARKIN DED WEXFORD SEHB 
247030 CARNAGH DED WEXFORD SEHB 
247052 GOREY RURAL DED WEXFORD SEHB 
247064 KILGARVAN DED WEXFORD SEHB 
247078 KILPATRICK DED WEXFORD SEHB 
247091 NEW ROSS URBAN DED WEXFORD SEHB 
247117 WEXFORD RURAL DED WEXFORD SEHB 
247118 WEXFORD URBAN NO.1 DED WEXFORD SEHB 
247123 WEXFORD URBAN NO 3 DED WEXFORD SEHB 
247124 WEXFORD URBAN NO 2 DED WEXFORD SEHB 
257002 ALTIDORE DED WICKLOW ERHA 
257004 ARKLOW NO.1 URBAN DED WICKLOW ERHA 
257017 BRAY URBAN NO.3 DED WICKLOW ERHA 
257038 GLENEALY DED WICKLOW ERHA 
257051 KILMACANOGE DED WICKLOW ERHA 
257071 TINAHELY DED WICKLOW ERHA 
257077 WICKLOW RURAL DED WICKLOW ERHA 
257079 ARKLOW NO 2 URBAN DED WICKLOW ERHA 
257081 BRAY URBAN NO.2 DED WICKLOW ERHA 
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M. Sampling Points – Northern Ireland 
 
 
 
The following pages contain the full list of sampling points used for the Population survey in 
Northern Ireland.  Sample points are listed in order of their local authority. 
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Sample 
Point 
Ward Name Local Authority Health Board 
N001 GREYSTONE Antrim NHSSB 
N002 RATHENRAW Antrim NHSSB 
N004 SPRINGFARM Antrim NHSSB 
N006 FOUNTAIN HILL Antrim NHSSB 
N007 CRUMLIN Antrim NHSSB 
N008 CRANFIELD Antrim NHSSB 
N009 NEW PARK Antrim NHSSB 
N012 DRUMANAWAY Antrim NHSSB 
N015 CRANFIELD Antrim NHSSB 
N018 TEMPLEPATRICK Antrim NHSSB 
N024 STILES Antrim NHSSB 
N026 TEMPLEPATRICK Antrim NHSSB 
E046 GLEN Ards EHSSB 
E048 LOUGHRIES Ards EHSSB 
E049 COMBER SOUTH Ards EHSSB 
E050 BALLYWALTER Ards EHSSB 
E054 BALLYWALTER Ards EHSSB 
E055 DONAGHADEE SOUTH Ards EHSSB 
E056 COMBER WEST Ards EHSSB 
E057 BALLYGOWAN Ards EHSSB 
E058 KILLINCHY Ards EHSSB 
E062 WHITESPOTS Ards EHSSB 
E063 DONAGHADEE NORTH Ards EHSSB 
S032 DEMESNE Armagh SHSSB 
S034 MARKETHILL Armagh SHSSB 
S041 LAURELVALE Armagh SHSSB 
S046 RICH HILL Armagh SHSSB 
N003 DUNCLUG Ballymena NHSSB 
N013 HARRYVILLE Ballymena NHSSB 
N014 HARRYVILLE Ballymena NHSSB 
N016 GRANGE Ballymena NHSSB 
N021 ARDEEVIN Ballymena NHSSB 
N023 GALGORM Ballymena NHSSB 
N025 ARDEEVIN Ballymena NHSSB 
N027 NEWHILL Ballymoney NHSSB 
N031 FAIRHILL Ballymoney NHSSB 
N032 CARNANY Ballymoney NHSSB 
N033 BALLYHOE and CORKEY Ballymoney NHSSB 
N035 ROUTE Ballymoney NHSSB 
N039 DUNLOY Ballymoney NHSSB 
S007 GILFORD Banbridge SHSSB 
S008 BANBRIDGE WEST Banbridge SHSSB 
S011 LAWRENCETOWN Banbridge SHSSB 
S013 BANNSIDE Banbridge SHSSB 
S015 CROOB Banbridge SHSSB 
NACD/DAIRU – 2002/2003 Drug Prevalence Survey – Technical Report 
Appendix M 
231 
Sample 
Point 
Ward Name Local Authority Health Board 
S017 BANBRIDGE WEST Banbridge SHSSB 
S020 BALLYDOWN Banbridge SHSSB 
R252 SHANKILL Belfast EHSSB 
E001 FALLS Belfast EHSSB 
E002 NEW LODGE Belfast EHSSB 
E003 CRUMLIN Belfast EHSSB 
E004 UPPER SPRINGFIELD Belfast EHSSB 
E005 BEECHMOUNT Belfast EHSSB 
E006 ARDOYNE Belfast EHSSB 
E007 UPPER SPRINGFIELD Belfast EHSSB 
E008 LEGONIEL Belfast EHSSB 
E009 WOODVALE Belfast EHSSB 
E010 LEGONIEL Belfast EHSSB 
E011 THE MOUNT Belfast EHSSB 
E012 BEECHMOUNT Belfast EHSSB 
E013 WOODSTOCK Belfast EHSSB 
E014 BLACKSTAFF Belfast EHSSB 
E015 FALLS Belfast EHSSB 
E016 DUNCAIRN Belfast EHSSB 
E017 FORTWILLIAM Belfast EHSSB 
E018 GLEN ROAD Belfast EHSSB 
E019 GLEN ROAD Belfast EHSSB 
E020 DUNCAIRN Belfast EHSSB 
E021 GLEN ROAD Belfast EHSSB 
E022 BLACKSTAFF Belfast EHSSB 
E023 BELLEVUE Belfast EHSSB 
E024 SHAFTESBURY Belfast EHSSB 
E025 KNOCK Belfast EHSSB 
E026 SYDENHAM Belfast EHSSB 
E027 BELLEVUE Belfast EHSSB 
E028 SYDENHAM Belfast EHSSB 
E029 BALLYSILLAN Belfast EHSSB 
E030 LADYBROOK Belfast EHSSB 
E031 FORTWILLIAM Belfast EHSSB 
E032 BELLEVUE Belfast EHSSB 
E033 LADYBROOK Belfast EHSSB 
E034 SYDENHAM Belfast EHSSB 
E035 ORANGEFIELD Belfast EHSSB 
E036 CHERRYVALLEY Belfast EHSSB 
E037 FINAGHY Belfast EHSSB 
E038 CAVEHILL Belfast EHSSB 
E039 ROSETTA Belfast EHSSB 
E040 MALONE Belfast EHSSB 
E041 BELMOUNT Belfast EHSSB 
E042 BALLYHACKAMORE Belfast EHSSB 
E043 STRANMILLIS Belfast EHSSB 
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Sample 
Point 
Ward Name Local Authority Health Board 
E044 STRANMILLIS Belfast EHSSB 
E045 STRANMILLIS Belfast EHSSB 
N046 KILLYCROT Carrickfergus NHSSB 
N047 NORTHLAND Carrickfergus NHSSB 
N048 GORTALEE Carrickfergus NHSSB 
N049 KILLYCROT Carrickfergus NHSSB 
N050 VICTORIA Carrickfergus NHSSB 
N051 WOODBURN Carrickfergus NHSSB 
N052 BONEYBEFORE Carrickfergus NHSSB 
N053 EDEN Carrickfergus NHSSB 
E067 TULLYCARNET Castlereagh EHSSB 
E071 MINNOWBURN Castlereagh EHSSB 
E074 CARROWREAGH Castlereagh EHSSB 
E090 BEECHILL Castlereagh EHSSB 
E091 WYNCHURCH Castlereagh EHSSB 
E092 FOUR WINDS Castlereagh EHSSB 
E094 KNOCKBRACKEN Castlereagh EHSSB 
E095 WYNCHURCH Castlereagh EHSSB 
E098 HILLFOOT Castlereagh EHSSB 
N028 BALLYSALLY Coleraine NHSSB 
N029 CROSS GLEBE Coleraine NHSSB 
N030 CHURCHLAND Coleraine NHSSB 
N034 CASTLEROCK Coleraine NHSSB 
N038 WATERSIDE Coleraine NHSSB 
N040 CASTLEROCK Coleraine NHSSB 
N041 PORTSTEWART Coleraine NHSSB 
N042 THE CUTS Coleraine NHSSB 
N044 STRAND Coleraine NHSSB 
N045 PORTSTEWART Coleraine NHSSB 
N057 OLDTOWN Cookstown NHSSB 
N058 OLDTOWN Cookstown NHSSB 
N062 SANDHOLES Cookstown NHSSB 
N063 TULLAGH Cookstown NHSSB 
S001 DRUMGASK Craigavon SHSSB 
S002 CORCRAIN Craigavon SHSSB 
S003 TAVANAGH Craigavon SHSSB 
S004 TAVANAGH Craigavon SHSSB 
S005 TAGHNEVAN Craigavon SHSSB 
S006 THE BIRCHES Craigavon SHSSB 
S009 PARKLAKE Craigavon SHSSB 
S010 KILLYCOMAIN Craigavon SHSSB 
S012 BROWNSTOWN Craigavon SHSSB 
S014 BLEARY Craigavon SHSSB 
S016 KNOCKNASHANE Craigavon SHSSB 
S018 WARINGSTOWN Craigavon SHSSB 
S019 BROWNSTOWN Craigavon SHSSB 
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Sample 
Point 
Ward Name Local Authority Health Board 
W001 BRANDYWELL Derry WHSSB 
W002 CORRODY Derry WHSSB 
W003 CREVAGH and SPRINGTOWN Derry WHSSB 
W004 VICTORIA Derry WHSSB 
W005 ST. PETER'S Derry WHSSB 
W006 VICTORIA Derry WHSSB 
W007 CREVAGH and SPRINGTOWN Derry WHSSB 
W008 SHANTALLOW EAST Derry WHSSB 
W015 BANAGHER Derry WHSSB 
W017 NEW BUILDINGS Derry WHSSB 
W019 FAUGHAN Derry WHSSB 
W023 EGLINTON Derry WHSSB 
W024 BALLYNASHALLOG Derry WHSSB 
W027 ALTNAGELVIN Derry WHSSB 
W028 BALLYNASHALLOG Derry WHSSB 
E047 CATHEDRAL Down EHSSB 
E051 DRUMANESS Down EHSSB 
E052 DUNDRUM Down EHSSB 
E053 KILLOUGH Down EHSSB 
E059 SHIMNA Down EHSSB 
E060 KILMORE Down EHSSB 
E061 AUDLEYS ACRE Down EHSSB 
S022 FIVEMILETOWN Dungannon SHSSB 
S024 BALLYSAGGART Dungannon SHSSB 
S027 COALISLAND SOUTH Dungannon SHSSB 
S028 COALISLAND WEST and 
NEWMILLS 
Dungannon SHSSB 
S030 DRUMGLASS Dungannon SHSSB 
S033 FIVEMILETOWN Dungannon SHSSB 
S035 BENBURB Dungannon SHSSB 
S037 MOY Dungannon SHSSB 
S044 KILLYMEAL Dungannon SHSSB 
W031 IRVINESTOWN Fermanagh WHSSB 
W035 KESH and LISNARRICK Fermanagh WHSSB 
W036 ROSSORRY Fermanagh WHSSB 
W038 LISBELLAW Fermanagh WHSSB 
W039 CASTLECOOLE Fermanagh WHSSB 
W040 TEMPO Fermanagh WHSSB 
W041 LISBELLAW Fermanagh WHSSB 
W042 CASTLECOOLE Fermanagh WHSSB 
N005 CRAIGY HILL Larne NHSSB 
N010 CARNLOUGH Larne NHSSB 
N011 BLACKCAVE Larne NHSSB 
N017 ANTIVILLE Larne NHSSB 
N019 ISLAND MAGEE Larne NHSSB 
N020 BALLYCARRY Larne NHSSB 
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Sample 
Point 
Ward Name Local Authority Health Board 
N022 GLYNN Larne NHSSB 
W012 ENAGH Limavady WHSSB 
W016 COOLESSAN Limavady WHSSB 
W022 GLACK Limavady WHSSB 
W025 ROESIDE Limavady WHSSB 
W026 GRESTEEL Limavady WHSSB 
E064 COLLIN GLEN Lisburn EHSSB 
E065 TWINBROOK Lisburn EHSSB 
E066 COLLIN GLEN Lisburn EHSSB 
E068 HILLHALL Lisburn EHSSB 
E070 KNOCKMORE Lisburn EHSSB 
E072 TONAGH Lisburn EHSSB 
E076 LISNAGARVY Lisburn EHSSB 
E078 GLENAVY Lisburn EHSSB 
E079 BALLYMACASH Lisburn EHSSB 
E080 TONAGH Lisburn EHSSB 
E081 MOIRA Lisburn EHSSB 
E085 MAZE Lisburn EHSSB 
E086 HILLHALL Lisburn EHSSB 
N054 TOWN PARKS EAST Magherafelt NHSSB 
N055 TOWN PARKS WEST Magherafelt NHSSB 
N056 MAGHERA Magherafelt NHSSB 
N059 TOBERMORE Magherafelt NHSSB 
N060 TOWN PARKS WEST Magherafelt NHSSB 
N061 UPPERLANDS Magherafelt NHSSB 
N064 KNOCKCLOGHRIM Magherafelt NHSSB 
N036 DUNSEVERICK Moyle NHSSB 
N037 GLENAAN Moyle NHSSB 
N043 BALLYLOUGH Moyle NHSSB 
S021 LISNACREE Newry and Mourne SHSSB 
S023 CROSSMAGLEN Newry and Mourne SHSSB 
S025 DERRYMORE Newry and Mourne SHSSB 
S026 SPELGA Newry and Mourne SHSSB 
S029 MAYOBRIDGE Newry and Mourne SHSSB 
S031 FORKHILL Newry and Mourne SHSSB 
S036 LISNACREE Newry and Mourne SHSSB 
S038 ROSTREVOR Newry and Mourne SHSSB 
S039 BALLYCROSSAN Newry and Mourne SHSSB 
S040 LISNACREE Newry and Mourne SHSSB 
S042 BALLYCROSSAN Newry and Mourne SHSSB 
S043 ANNALONG Newry and Mourne SHSSB 
S045 BINNIAN Newry and Mourne SHSSB 
E069 CONLIG North Down EHSSB 
E073 SILVERSTREAM North Down EHSSB 
E075 LOUGHVIEW North Down EHSSB 
E077 CLANDEBOYE North Down EHSSB 
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Sample 
Point 
Ward Name Local Authority Health Board 
E082 CRAIGAVAD North Down EHSSB 
E083 BROADWAY North Down EHSSB 
E084 BANGOR CASTLE North Down EHSSB 
E087 BROADWAY North Down EHSSB 
E088 HOLYWOOD PRIORY North Down EHSSB 
E089 LOUGHVIEW North Down EHSSB 
E093 CLANDEBOYE North Down EHSSB 
E096 BALLYMAGEE North Down EHSSB 
E097 CRAIGAVAD North Down EHSSB 
E099 CULTRA North Down EHSSB 
W029 CAMOWEN Omagh WHSSB 
W030 LISANELLY Omagh WHSSB 
W032 LISANELLY Omagh WHSSB 
W033 TRILLICK Omagh WHSSB 
W034 GORTRUSH Omagh WHSSB 
W037 TRILLICK Omagh WHSSB 
W009 NEWTOWNSTEWART Strabane WHSSB 
W010 EAST Strabane WHSSB 
W011 SOUTH Strabane WHSSB 
W013 VICTORIA BRIDGE Strabane WHSSB 
W014 NORTH Strabane WHSSB 
W018 VICTORIA BRIDGE Strabane WHSSB 
W020 SOUTH Strabane WHSSB 
W021 PLUMBRIDGE Strabane WHSSB 
 
 
NACD/DAIRU – 2002/2003 Drug Prevalence Survey – Technical Report 
Appendix N 
236 
N. Cannabis Validation Text 
  
 
*. VERSION 2.0 - 17/01/2005. 
 
*******************************************************************************************. 
***** VALIDATION / INTERNAL CONSISTENCY OF DATA - XDRUG6.SAV *****. 
*******************************************************************************************. 
 
*******************************************************************************************. 
************************************ CANNABIS ****************************************. 
*******************************************************************************************. 
**************************************************************************************************************. 
**************************************************************************************************************. 
**************************************************************************************************************. 
**************************************************************************************************************. 
 
**** CHECK A - IF YOU HAVE NEVER HEARD OF CANNABIS (Q24=2), SKIP ALL THE QUESTIONS. 
 
TITLE 'COMPARE WITH Q24'. 
 
* ///// Creates check variable (chk_q24), and set them all to 0 (Inconsistent data - check) ///// *. 
 
COMPUTE chk_q24 = 0. 
EXECUTE. 
 
FORMAT  chk_q24 (F2.0). 
 
VARIABLE LABEL chk_q24 'Chk_q24 - If respondent has never heard of cannabis (Q24=2), skip all 
questions (they must be sysmis)'.  
 
VALUE LABELS chk_q24 
0 'Inconsistent data - check' 
1 'Pass' 
2 'Missing data Q24 (-9 Blank)' 
3 'Missing data Q24 (-1 DK)' 
4 'Check not applicable (Q24 = 1)'. 
 
* ///// Deal with all not applicables ///// *. 
 
DO IF (Q24=-9) . 
RECODE 
  chk_q24 (0=2) . 
 ELSE IF (Q24=-1) . 
 RECODE 
   chk_q24 (0=3). 
  ELSE IF (Q24=1). 
  RECODE 
    chk_q24 (0=4). 
END IF. 
EXECUTE. 
 
* ///// The main check ///// *. 
 
DO IF ((Q24=2) AND (SYSMIS(Q25)) AND (SYSMIS(Q26)) AND (SYSMIS(Q27)) AND (SYSMIS(Q28)) 
AND (SYSMIS(Q29)) AND (SYSMIS(Q30)) AND (SYSMIS(Q31A)) AND (SYSMIS(Q31B)) AND 
(SYSMIS(Q31C)) AND (SYSMIS(Q31D)) AND (SYSMIS(Q31E)) AND (SYSMIS(Q31F)) AND 
(SYSMIS(Q31G)) AND (SYSMIS(Q31H)) AND (SYSMIS(Q31I)) AND (SYSMIS(Q32A)) AND 
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(SYSMIS(Q32B)) AND (SYSMIS(Q32C)) AND (SYSMIS(Q32D)) AND (SYSMIS(Q32E)) AND 
(SYSMIS(Q32F)) AND (SYSMIS(Q151A))). 
RECODE 
  chk_q24  (0=1)  . 
END IF . 
EXECUTE . 
 
* ///// Show test results ///// *. 
 
FREQUENCIES 
  VARIABLES=chk_q24 
  /ORDER=  ANALYSIS . 
 
**************************************************************************************************************. 
**************************************************************************************************************. 
**************************************************************************************************************. 
**************************************************************************************************************. 
 
**** CHECK B - IF YOU HAVE TAKEN CANNABIS (Q26=1), YOU MUST HAVE HEARD OF IT (Q24=1). 
 
 
TITLE 'COMPARE WITH Q24, Q26'. 
 
* ///// Creates check variable (chk_q26a), and set them all to 0 (Inconsistent data - check) ///// *. 
 
COMPUTE chk_q26a = 0. 
EXECUTE. 
 
FORMAT  chk_q26a (F2.0). 
 
VARIABLE LABEL chk_q26a 'Chk_q26a  - If respondent has taken cannabis (Q26), must have heard of 
cannabis (Q24)'.  
 
VALUE LABELS chk_q26a 
1 'Pass - Q26 =1 and Q24=1' 
2 'Pass - Q26=2 and Q24=1' 
3 'Missing data in either Q26 or Q24' 
0 'Inconsistent data - check' 
99 'Check not applicable (skipped from earlier question - Q24=2)'. 
 
 
* ///// Deal with not applicables from earlier questions (working backwards) ///// *. 
 
DO IF (Q24=2) . 
RECODE 
  chk_q26a (0=99) . 
END IF. 
EXECUTE. 
 
* ///// The actual check ///// *. 
 
DO IF (Q26 = 1 AND Q24=1) . 
RECODE 
  chk_q26a  (0=1)  . 
 ELSE IF (Q26 = 2 AND Q24=1) . 
 RECODE  
   chk_q26a  (0=2)  . 
  ELSE IF (Q24=-9 OR Q24 =-1). 
  RECODE   
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   chk_q26a (0=3) . 
   ELSE IF (Q26=-9 OR Q26=-1) . 
   RECODE 
       chk_q26a  (0=3)  . 
    
END IF . 
EXECUTE . 
 
 
* ///// Show test results ///// *. 
 
FREQUENCIES 
  VARIABLES=chk_q26a 
  /ORDER=  ANALYSIS . 
 
**************************************************************************************************************. 
**************************************************************************************************************. 
**************************************************************************************************************. 
**************************************************************************************************************. 
 
 
**** CHECK C - IF YOU HAVE NEVER TAKEN CANNABIS, SKIP REMAINING QUESTIONS. 
 
TITLE 'COMPARE WITH Q24, Q26'. 
 
* ///// Creates check variable (chk_q26b), and set them all to 0 (Inconsistent data - check) ///// *. 
 
COMPUTE chk_q26b = 0. 
EXECUTE. 
 
FORMAT  chk_q26b (F2.0). 
 
VARIABLE LABEL chk_q26b 'Chk_q26b - If respondent has never taken cannabis (Q26=2), skip 
remaining questions (they must be sysmis)'.  
 
VALUE LABELS chk_q26b 
0 'Inconsistent data - check' 
1 'Pass' 
2 'Missing data Q26 (-9 Blank)' 
3 'Missing data Q26 (-1 DK)' 
4 'Check not applicable (Q26=1)' 
88 'Check n/a (skipped from earlier question - Q24=Missing)' 
99 'Check not applicable (skipped from earlier question - Q24=2)'. 
 
 
* ///// Deal with not applicables from earlier questions (working backwards) ///// *. 
 
DO IF (Q26=-9) . 
RECODE 
  chk_q26b (0=2) . 
 ELSE IF (Q26=-1) . 
 RECODE 
   chk_q26b (0=3). 
  ELSE IF (Q26=1). 
  RECODE 
    chk_q26b (0=4). 
END IF. 
EXECUTE. 
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DO IF (Q24=-9) . 
RECODE 
  chk_q26b (0=88) . 
END IF. 
EXECUTE. 
 
DO IF (Q24=2) . 
RECODE 
  chk_q26b (0=99) . 
END IF. 
EXECUTE. 
 
 
* ///// The actual check ///// *. 
 
DO IF ((Q26=2) AND (SYSMIS(Q27)) AND (SYSMIS(Q28)) AND (SYSMIS(Q29)) AND (SYSMIS(Q30)) 
AND (SYSMIS(Q31A)) AND (SYSMIS(Q31B)) AND (SYSMIS(Q31C)) AND (SYSMIS(Q31D)) AND 
(SYSMIS(Q31E)) AND (SYSMIS(Q31F)) AND (SYSMIS(Q31G)) AND (SYSMIS(Q31H)) AND 
(SYSMIS(Q31I)) AND (SYSMIS(Q32A)) AND (SYSMIS(Q32B)) AND (SYSMIS(Q32C)) AND 
(SYSMIS(Q32D)) AND (SYSMIS(Q32E)) AND (SYSMIS(Q32F)) AND (SYSMIS(Q133)) AND 
(SYSMIS(Q134)) AND (SYSMIS(Q135)) AND (SYSMIS(Q136A)) AND (SYSMIS(Q136B)) AND 
(SYSMIS(Q136C)) AND (SYSMIS(Q136D)) AND (SYSMIS(Q136E)) AND (SYSMIS(Q136F)) AND 
(SYSMIS(Q136G)) AND (SYSMIS(Q136H)) AND (SYSMIS(Q136I)) AND (SYSMIS(Q136J)) AND 
(SYSMIS(Q136K)) AND (SYSMIS(Q136L)) AND (SYSMIS(Q136M)) AND (SYSMIS(Q136N)) AND 
(SYSMIS(Q151A))). 
RECODE 
  chk_q26b  (0=1)  . 
END IF . 
EXECUTE . 
 
* ///// Show test results ///// *. 
 
FREQUENCIES 
  VARIABLES=chk_q26b 
  /ORDER=  ANALYSIS . 
 
**************************************************************************************************************. 
**************************************************************************************************************. 
**************************************************************************************************************. 
**************************************************************************************************************. 
 
**** CHECK D - IF YOU HAVE TAKEN CANNABIS (Q26=1), Q27 MUST BE ANSWERED. 
 
 
TITLE 'COMPARE WITH Q24, Q26, Q27'. 
 
 
* ///// Creates check variable (chk_q27a), and set them all to 0 (Inconsistent data - check) ///// *. 
 
COMPUTE chk_q27a = 0. 
EXECUTE. 
 
FORMAT  chk_q27a (F3.0). 
 
VARIABLE LABEL chk_q27a 'Chk_q27a - If respondent has taken cannabis (Q26=1), age first taken must 
be answered (Q27)'.  
 
VALUE LABELS chk_q27a 
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3 'Missing data Q27 (-1 DK)' 
2 'Missing data Q27 (-9 Blank)' 
1 'Pass' 
0 'Inconsistent data - check' 
88 'Check n/a (skipped from earlier question - Q24=Missing)' 
99 'Check not applicable (skipped from earlier question - Q24=2)' 
888 'Check n/a (skipped from earlier question - Q26=Missing)' 
999 'Check not applicable (skipped from earlier question - Q26=2)'. 
 
 
* ///// Deal with not applicables from earlier questions (working backwards) ///// *. 
 
 
DO IF (Q24=-9) . 
RECODE 
  chk_q27a (0=88) . 
END IF. 
EXECUTE. 
 
DO IF (Q24=2) . 
RECODE 
  chk_q27a (0=99) . 
END IF. 
EXECUTE. 
 
DO IF (Q26=-9) . 
RECODE 
  chk_q27a (0=888) . 
END IF. 
EXECUTE. 
 
DO IF (Q26=2) . 
RECODE 
  chk_q27a (0=999) . 
END IF. 
EXECUTE. 
 
 
* ///// The actual check (check the age first taken variable Q27 actually contains an answer) ///// *. 
 
 
DO IF (Q27=-9) . 
RECODE 
  chk_q27a (0=2) . 
 ELSE IF (Q27=-1) . 
 RECODE 
   chk_q27a (0=3) . 
  ELSE IF ((~SYSMIS(Q27)) AND Q26=1). 
  RECODE 
      chk_q27a  (0=1)  . 
END IF . 
EXECUTE . 
 
 
* ///// Show test results ///// *. 
 
FREQUENCIES 
  VARIABLES=chk_q27a 
  /ORDER=  ANALYSIS . 
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**************************************************************************************************************. 
**************************************************************************************************************. 
**************************************************************************************************************. 
**************************************************************************************************************. 
 
* ///// Creates check variable (chk_q27b), and set them all to 0 (Inconsistent data - check) ///// *. 
 
 
**** CHECK E - IF EVER TAKEN CANNABIS AGE FIRST TAKEN CANNABIS MUST BE LESS THAN OR 
EQUAL TO EXACT AGE. 
 
TITLE 'COMPARE WITH Q24, Q26, Q27, AGE'. 
 
* ///// Creates check variable (chk_q27b), and set them all to 0 (Inconsistent data - check) ///// *. 
 
COMPUTE chk_q27b = 0. 
EXECUTE. 
 
FORMAT  chk_q27b (F3.0). 
 
VARIABLE LABEL chk_q27b 'Chk_q27b - If respondent has ever taken cannabis (Q26=1), Age first taken 
cannabis (Q27) must be less than or equal to exact age (AGE)'.  
 
VALUE LABELS chk_q27b 
1 'Pass - Age taken regularly less than or equal to exact age' 
2 'Missing data Q27 - Age first taken dont know (-1)' 
3 'Missing data Q27 - Age first taken regularly (-9)' 
4 'Missing data Age - Exact age dont know (-1)' 
5 'Missing data Age - Exact age (-9)' 
0 'Age first taken is greater than exact age' 
88 'Check n/a (skipped from earlier question - Q24=Missing)' 
99 'Check not applicable (skipped from earlier question - Q24=2)' 
888 'Check n/a (skipped from earlier question - Q26=Missing)' 
999 'Check not applicable (skipped from earlier question - Q26=2)'. 
 
 
* ///// Deal with not applicables from earlier questions (working backwards) ///// *. 
 
 
DO IF (Q24=-9) . 
RECODE 
  chk_q27b (0=88) . 
END IF. 
EXECUTE. 
 
DO IF (Q24=2) . 
RECODE 
  chk_q27b (0=99) . 
END IF. 
EXECUTE. 
 
DO IF (Q26=-9) . 
RECODE 
  chk_q27b (0=888) . 
END IF. 
EXECUTE. 
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DO IF (Q26=2) . 
RECODE 
  chk_q27b (0=999) . 
END IF. 
EXECUTE. 
 
* ///// Deals with dont knows and missings ///// *. 
 
 
DO IF (Q27 = -1). 
RECODE 
  chk_q27b  (0=2)  . 
 ELSE IF (Q27 = -9) . 
 RECODE 
   chk_q27b (0 = 3) . 
END IF . 
EXECUTE . 
 
 
DO IF (AGE = -1). 
RECODE 
  chk_q27b  (0=4)  . 
 ELSE IF (AGE = -9) . 
 RECODE 
   chk_q27b (0 = 5) . 
END IF . 
EXECUTE . 
 
 
* ///// The actual check ///// *. 
 
DO IF (Q26=1 AND  (Q27 <= AGE)). 
RECODE 
  chk_q27b  (0=1)  . 
END IF .  
EXECUTE . 
 
 
* ///// Show test results ///// *. 
 
FREQUENCIES 
  VARIABLES=chk_q27b 
  /ORDER=  ANALYSIS . 
 
 
 
**************************************************************************************************************. 
**************************************************************************************************************. 
**************************************************************************************************************. 
**************************************************************************************************************. 
 
 
**** CHECK F - IF YOU HAVE NOT TAKEN CANNABIS IN THE PAST 12 MONTHS, SKIP REMAINING 
QUESTIONS. 
 
 
TITLE 'COMPARE WITH Q24, Q26, Q28'. 
 
* ///// Creates check variable (chk_q28a), and set them all to 0 (Inconsistent data - check) ///// *. 
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COMPUTE chk_q28a = 0. 
EXECUTE. 
 
FORMAT chk_q28a  (F3.0). 
 
VARIABLE LABEL chk_q28a 'chk_q28a - If respondent has not taken cannabis in the past 12 months 
(Q28=2), skip remaining questions (they must be sysmis)'.  
 
VALUE LABELS chk_q28a 
0 'Inconsistent data - check' 
1 'Pass' 
2 'Missing data Q28 (-9 Blank)' 
3 'Missing data Q28 (-1 DK)' 
4 'Check not applicable (Q28=1)' 
88 'Check n/a (skipped from earlier question - Q24=Missing)' 
99 'Check not applicable (skipped from earlier question - Q24=2)' 
888 'Check n/a (skipped from earlier question - Q26=Missing)' 
999 'Check not applicable (skipped from earlier question - Q26=2)'. 
 
 
* ///// Deal with all not applicables (working backwards) ///// *. 
 
DO IF (Q28=-9) . 
RECODE 
  chk_q28a (0=2) . 
 ELSE IF (Q28=-1) . 
 RECODE 
   chk_q28a (0=3). 
  ELSE IF (Q28=1). 
  RECODE 
    chk_q28a (0=4). 
END IF. 
EXECUTE. 
 
DO IF (Q24=-9) . 
RECODE 
  chk_q28a (0=88) . 
END IF. 
EXECUTE. 
 
DO IF (Q26=2) . 
RECODE 
  chk_q28a (0=999) . 
END IF. 
EXECUTE. 
 
DO IF (Q26=-9) . 
RECODE 
  chk_q28a (0=888) . 
END IF. 
EXECUTE. 
 
DO IF (Q24=2) . 
RECODE 
  chk_q28a (0=99) . 
END IF. 
EXECUTE. 
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* ///// The actual check ///// *. 
 
DO IF ((Q28=2) AND (SYSMIS(Q29)) AND (SYSMIS(Q30)) AND (SYSMIS(Q31A)) AND (SYSMIS(Q31B)) 
AND (SYSMIS(Q31C)) AND (SYSMIS(Q31D)) AND (SYSMIS(Q31E)) AND (SYSMIS(Q31F)) AND 
(SYSMIS(Q31G)) AND (SYSMIS(Q31H)) AND (SYSMIS(Q31I)) AND (SYSMIS(Q32A)) AND 
(SYSMIS(Q32B)) AND (SYSMIS(Q32C)) AND (SYSMIS(Q32D)) AND (SYSMIS(Q32E)) AND 
(SYSMIS(Q32F)) AND (SYSMIS(Q151A))). 
RECODE 
   chk_q28a (0=1)  . 
END IF . 
EXECUTE . 
 
* ///// Show test results ///// *. 
 
FREQUENCIES 
  VARIABLES=chk_q28a 
  /ORDER=  ANALYSIS . 
 
 
**************************************************************************************************************. 
**************************************************************************************************************. 
**************************************************************************************************************. 
**************************************************************************************************************. 
 
**** CHECK G - IF YOU HAVE TAKEN CANNABIS IN THE PAST 12 MONTHS, QUESTIONS MUST BE 
ANSWERED. 
 
TITLE 'COMPARE WITH Q24, Q26, Q28'. 
 
* ///// Creates check variable (chk_q28b), and set them all to 0 (Inconsistent data - check) ///// *. 
 
COMPUTE chk_q28b = 0. 
EXECUTE. 
 
FORMAT  chk_q28b (F3.0). 
 
VARIABLE LABEL chk_q28b 'Chk_q28b - If respondent has taken cannabis in the past 12 months 
(Q28=1), subsequent questions must be answered (not sysmis)'.  
 
VALUE LABELS chk_q28b 
0 'Inconsistent data - check' 
1 'Pass' 
2 'Missing data Q28 (-9 Blank)' 
3 'Missing data Q28 (-1 DK)' 
4 'Check not applicable (Q28=2)' 
88 'Check n/a (skipped from earlier question - Q24=Missing)' 
99 'Check not applicable (skipped from earlier question - Q24=2)' 
888 'Check n/a (skipped from earlier question - Q26=Missing)' 
999 'Check not applicable (skipped from earlier question - Q26=2)'. 
 
 
* ///// Deal with not applicables from earlier questions (working backwards) ///// *. 
 
DO IF (Q28=-9) . 
RECODE 
  chk_q28b (0=2) . 
 ELSE IF (Q28=-1) . 
 RECODE 
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   chk_q28b (0=3). 
  ELSE IF (Q28=2). 
  RECODE 
    chk_q28b (0=4). 
END IF. 
EXECUTE. 
 
 
DO IF (Q26=-9) . 
RECODE 
  chk_q28b (0=888) . 
END IF. 
EXECUTE. 
 
DO IF (Q26=2) . 
RECODE 
  chk_q28b (0=999) . 
END IF. 
EXECUTE. 
 
DO IF (Q24=-9) . 
RECODE 
  chk_q28b (0=888) . 
END IF. 
EXECUTE. 
 
DO IF (Q24=2) . 
RECODE 
  chk_q28b (0=99) . 
END IF. 
EXECUTE. 
 
 
* ///// The actual check ///// *. 
 
DO IF ((Q28=1) AND (~SYSMIS(Q149A)) AND (~SYSMIS(Q149B)) AND (~SYSMIS(Q149C)) AND 
(~SYSMIS(Q149D)) AND (~SYSMIS(Q149E)) AND (~SYSMIS(Q149F)) AND (~SYSMIS(Q149G)) AND 
(~SYSMIS(Q150A)) AND (~SYSMIS(Q150B)) AND (~SYSMIS(Q150C)) AND (~SYSMIS(Q150D)) AND 
(~SYSMIS(Q150E)) AND (~SYSMIS(Q150F)) AND (~SYSMIS(Q150G)) AND (~SYSMIS(Q150H)) AND 
(~SYSMIS(Q150I)) AND (~SYSMIS(Q151A))). 
RECODE 
  chk_q28b  (0=1)  . 
END IF . 
EXECUTE . 
 
* ///// Show test results ///// *. 
 
FREQUENCIES 
  VARIABLES=chk_q28b 
  /ORDER=  ANALYSIS . 
 
 
 
**************************************************************************************************************. 
**************************************************************************************************************. 
**************************************************************************************************************. 
**************************************************************************************************************. 
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**** CHECK H - IF YOU HAVE TAKEN CANNABIS IN THE PAST 30 DAYS, YOU MUST HAVE TAKEN 
IN THE PAST 12 MONTHS. 
 
 
TITLE 'COMPARE WITH Q24, Q26, Q28, Q29'. 
 
* ///// Creates check variable (chk_q29a), and set them all to 0 (Inconsistent data - check) ///// *. 
 
COMPUTE chk_q29a = 0. 
EXECUTE. 
 
FORMAT  chk_q29a (F4.0). 
 
VARIABLE LABEL chk_q29a 'Chk_q29a - If taken cannabis in past 30 days (Q29=1), must have taken in 
past 12 months (Q28=1)'.  
 
VALUE LABELS chk_q29a 
1 'Pass - Q28=1 + Q29=1' 
2 'Pass - Q28=1 + Q29=2' 
3 'Missing data - Q28 = -9' 
4 'Missing data - Q29 = -9' 
0 'Inconsistent data - check' 
88 'Check n/a (skipped from earlier question - Q24=Missing)' 
99 'Check not applicable (skipped from earlier question - Q24=2)' 
888 'Check n/a (skipped from earlier question - Q26=Missing)' 
999 'Check not applicable (skipped from earlier question - Q26=2)' 
8888 'Check n/a (skipped from earlier question - Q28=Missing)' 
9999 'Check not applicable (skipped from earlier question - Q28=2)'. 
 
 
* ///// Deal with not applicables from earlier questions (working backwards) ///// *. 
 
DO IF (Q28=-9) . 
RECODE 
  chk_q29a (0=8888) . 
END IF. 
EXECUTE. 
 
DO IF (Q28=2) . 
RECODE 
  chk_q29a (0=9999) . 
END IF. 
EXECUTE. 
 
DO IF (Q26=-9) . 
RECODE 
  chk_q29a (0=888) . 
END IF. 
EXECUTE. 
 
DO IF (Q26=2) . 
RECODE 
  chk_q29a (0=999) . 
END IF. 
EXECUTE. 
 
DO IF (Q24=-9) . 
RECODE 
  chk_q29a (0=88) . 
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END IF. 
EXECUTE. 
 
DO IF (Q24=2) . 
RECODE 
  chk_q29a (0=99) . 
END IF. 
EXECUTE. 
 
* ///// The actual check ///// *. 
 
DO IF (Q29=1 AND Q28=1). 
RECODE 
  chk_q29a  (0=1)  . 
 ELSE IF (Q29=2 AND Q28=1). 
 RECODE 
   chk_q29a  (0=2)  . 
  ELSE IF (Q28=-9) . 
  RECODE 
    chk_q29a (0=3) . 
   ELSE IF (Q29=-9) . 
   RECODE 
       chk_q29a (0=4) . 
END IF . 
EXECUTE . 
 
 
* ///// Show test results ///// *. 
 
FREQUENCIES 
  VARIABLES=chk_q29a 
  /ORDER=  ANALYSIS . 
 
 
**************************************************************************************************************. 
**************************************************************************************************************. 
**************************************************************************************************************. 
**************************************************************************************************************. 
 
 
**** CHECK I - IF YOU HAVE NOT TAKEN CANNABIS IN THE PAST 30 DAYS, SKIP REMAINING 
QUESTIONS. 
 
 
TITLE 'COMPARE WITH Q24, Q26, Q28, Q29'. 
 
* ///// Creates check variable (chk_q29b), and set them all to 0 (Inconsistent data - check) ///// *. 
 
COMPUTE chk_q29b = 0. 
EXECUTE. 
 
FORMAT chk_q29b  (F4.0). 
 
VARIABLE LABEL chk_q29b 'Chk_q29b - If respondent has not taken cannabis in the past 30 days 
(Q29=2), skip remaining questions (they must be sysmis)'.  
 
VALUE LABELS chk_q29b 
0 'Inconsistent data - check' 
1 'Pass' 
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2 'Missing data Q29 (-9 Blank)' 
3 'Missing data Q29 (-1 DK)' 
4 'Check not applicable (Q29=1)' 
88 'Check n/a (skipped from earlier question - Q24=Missing)' 
99 'Check not applicable (skipped from earlier question - Q24=2)' 
888 'Check n/a (skipped from earlier question - Q26=Missing)' 
999 'Check not applicable (skipped from earlier question - Q26=2)' 
8888 'Check n/a (skipped from earlier question - Q54=Missing)' 
9999 'Check not applicable (skipped from earlier question - Q28=2)'. 
 
 
 
 ///// Deal with all not applicables (working backwards) ///// *. 
 
 
DO IF (Q29=-9) . 
RECODE 
  chk_q29b (0=2) . 
 ELSE IF (Q29=-1) . 
 RECODE 
   chk_q29b (0=3). 
  ELSE IF (Q29=1). 
  RECODE 
    chk_q29b (0=4). 
END IF. 
EXECUTE. 
 
DO IF (Q28=-9) . 
RECODE 
  chk_q29b (0=8888) . 
END IF. 
EXECUTE. 
 
DO IF (Q28=2) . 
RECODE 
  chk_q29b (0=9999) . 
END IF. 
EXECUTE. 
 
DO IF (Q26=-9) . 
RECODE 
  chk_q29b (0=888) . 
END IF. 
EXECUTE. 
 
DO IF (Q26=2) . 
RECODE 
  chk_q29b (0=999) . 
END IF. 
EXECUTE. 
 
DO IF (Q24=-9) . 
RECODE 
  chk_q29b (0=88) . 
END IF. 
EXECUTE. 
 
DO IF (Q24=2) . 
RECODE 
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  chk_q29b (0=99) . 
END IF. 
EXECUTE. 
 
* ///// The actual check ///// *. 
 
DO IF ((Q29=2) AND (SYSMIS(Q30)) AND (SYSMIS(Q31A)) AND (SYSMIS(Q31B)) AND 
(SYSMIS(Q31C)) AND (SYSMIS(Q31D)) AND (SYSMIS(Q31E)) AND (SYSMIS(Q31F)) AND 
(SYSMIS(Q31G)) AND (SYSMIS(Q31H)) AND (SYSMIS(Q31I)) AND (SYSMIS(Q32A)) AND 
(SYSMIS(Q32B)) AND (SYSMIS(Q32C)) AND (SYSMIS(Q32D)) AND (SYSMIS(Q32E)) AND 
(SYSMIS(Q32F))). 
RECODE 
   chk_q29b (0=1)  . 
END IF . 
EXECUTE . 
 
* ///// Show test results ///// *. 
 
FREQUENCIES 
  VARIABLES=chk_q29b 
  /ORDER=  ANALYSIS . 
 
 
**************************************************************************************************************. 
**************************************************************************************************************. 
**************************************************************************************************************. 
**************************************************************************************************************. 
 
 
**** CHECK J - IF YOU HAVE TAKEN CANNABIS IN PAST 30 DAYS, HOW MANY DAYS TAKEN MUST 
BE ANSWERED. 
 
 
TITLE 'COMPARE WITH Q24, Q26, Q28, Q29, Q30'. 
 
* ///// Creates check variable (chk_q30a), and set them all to 0 (Inconsistent data - check) ///// *. 
 
COMPUTE chk_q30a = 0. 
EXECUTE. 
 
FORMAT  chk_q30a (F5.0). 
 
VARIABLE LABEL chk_q30a 'Chk_q30a - If respondent has taken cannabis in the past 30 days (Q29=1) 
number of days taken (Q30) must be answered'.  
 
VALUE LABELS chk_q30a 
3 'Missing data Q30 (-1 DK)' 
2 'Missing data Q30 (-9 Blank)' 
1 'Pass' 
0 'Inconsistent data - check' 
88 'Check n/a (skipped from earlier question - Q24=Missing)' 
99 'Check not applicable (skipped from earlier question - Q24=2)' 
888 'Check n/a (skipped from earlier question - Q26=Missing)' 
999 'Check not applicable (skipped from earlier question - Q26=2)' 
8888 'Check n/a (skipped from earlier question - Q28=Missing)' 
9999 'Check not applicable (skipped from earlier question - Q28=2)' 
88888 'Check n/a (skipped from earlier question - Q29=Missing)' 
99999 'Check not applicable (skipped from earlier question - Q29=2)'. 
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* ///// Deal with not applicables from earlier questions (working backwards) ///// *. 
 
DO IF (Q29=-9) . 
RECODE 
  chk_q30a (0=88888) . 
END IF. 
EXECUTE. 
 
DO IF (Q29=2) . 
RECODE 
  chk_q30a (0=99999) . 
END IF. 
EXECUTE. 
 
DO IF (Q28=-9) . 
RECODE 
  chk_q30a (0=8888) . 
END IF. 
EXECUTE. 
 
DO IF (Q28=2) . 
RECODE 
  chk_q30a (0=9999) . 
END IF. 
EXECUTE. 
 
DO IF (Q26=-9) . 
RECODE 
  chk_q30a (0=888) . 
END IF. 
EXECUTE. 
 
DO IF (Q26=2) . 
RECODE 
  chk_q30a (0=999) . 
END IF. 
EXECUTE. 
 
DO IF (Q24=-9) . 
RECODE 
  chk_q30a (0=88) . 
END IF. 
EXECUTE. 
 
DO IF (Q24=2) . 
RECODE 
  chk_q30a (0=99) . 
END IF. 
EXECUTE. 
 
 
* ///// The actual check (check the age first taken variable Q30 actually contains an answer) ///// *. 
 
 
DO IF (Q30=-9) . 
RECODE 
  chk_q30a (0=2) . 
 ELSE IF (Q30=-1) . 
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 RECODE 
   chk_q30a (0=3) . 
  ELSE IF ((~SYSMIS(Q30)) AND Q29=1). 
  RECODE 
      chk_q30a  (0=1)  . 
END IF . 
EXECUTE . 
 
 
* ///// Show test results ///// *. 
 
FREQUENCIES 
  VARIABLES=chk_q30a 
  /ORDER=  ANALYSIS . 
 
 
 
 
**************************************************************************************************************. 
**************************************************************************************************************. 
**************************************************************************************************************. 
**************************************************************************************************************. 
 
 
**** CHECK K - IF TAKEN CANNABIS WITHIN THE PAST 30 DAYS, NUMBER OF DAYS TAKEN MUST 
BE BETWEEN 1 AND 30. 
 
TITLE 'COMPARE WITH Q24, Q26, Q28, Q29, Q30'. 
 
* ///// Creates check variable (chk_q30b), and set them all to 0 (Inconsistent data - check) ///// *. 
 
COMPUTE chk_q30b = 0. 
EXECUTE. 
 
FORMAT  chk_q30b (F5.0). 
 
VARIABLE LABEL chk_q30b 'Chk_q30b - If respondent has taken cannabis within the past 30 days 
(Q29=1), number of days taken (Q30) must be between 1 and 30'.  
 
VALUE LABELS chk_q30b 
1 'Pass' 
2 'Missing data Q30 (-1 DK)' 
3 'Missing data Q30 (-9 Blank)' 
4 'Inconsistent data - check - Q30 less than 1' 
5 'Inconsistent data - check - Q30 greater than 30' 
0 'Inconsistent data - check' 
88 'Check n/a (skipped from earlier question - Q24=Missing)' 
99 'Check not applicable (skipped from earlier question - Q24=2)' 
888 'Check n/a (skipped from earlier question - Q26=Missing)' 
999 'Check not applicable (skipped from earlier question - Q26=2)' 
8888 'Check n/a (skipped from earlier question - Q28=Missing)' 
9999 'Check not applicable (skipped from earlier question - Q28=2)' 
88888 'Check n/a (skipped from earlier question - Q24=Missing)' 
99999 'Check not applicable (skipped from earlier question - Q29=2)'. 
 
* ///// Deal with not applicables from earlier questions (working backwards) ///// *. 
 
 
DO IF (Q29=-9) . 
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RECODE 
  chk_q30b (0=88888) . 
END IF. 
EXECUTE. 
 
DO IF (Q29=2) . 
RECODE 
  chk_q30b (0=99999) . 
END IF. 
EXECUTE. 
 
DO IF (Q28=-9) . 
RECODE 
  chk_q30b (0=8888) . 
END IF. 
EXECUTE. 
 
DO IF (Q28=2) . 
RECODE 
  chk_q30b (0=9999) . 
END IF. 
EXECUTE. 
 
DO IF (Q26=-9) . 
RECODE 
  chk_q30b (0=888) . 
END IF. 
EXECUTE. 
 
DO IF (Q26=2) . 
RECODE 
  chk_q30b (0=999) . 
END IF. 
EXECUTE. 
 
DO IF (Q24=-9) . 
RECODE 
  chk_q30b (0=88) . 
END IF. 
EXECUTE. 
 
DO IF (Q24=2) . 
RECODE 
  chk_q30b (0=99) . 
END IF. 
EXECUTE. 
 
 
* ///// The actual check ///// *. 
 
DO IF (Q30 = -9). 
RECODE 
  chk_q30b  (0=3)  . 
 ELSE IF (Q29=1 AND (Q30 >= 1 AND Q30 <=30)). 
 RECODE 
     chk_q30b  (0=1)  . 
  ELSE IF (Q29=1 AND (Q30 < 1 AND Q30 ~=-1)). 
  RECODE 
      chk_q30b  (0=4)  . 
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   ELSE IF (Q29=1 AND (Q30 > 30)). 
   RECODE 
       chk_q30b  (0=5)  . 
    ELSE IF (Q30 = -1). 
    RECODE 
        chk_q30b  (0=2)  . 
END IF . 
EXECUTE . 
 
 
* ///// Show test results ///// *. 
 
FREQUENCIES 
  VARIABLES=chk_q30b 
  /ORDER=  ANALYSIS . 
 
 
 
**************************************************************************************************************. 
**************************************************************************************************************. 
**************************************************************************************************************. 
**************************************************************************************************************. 
 
 
**** CHECK L - IF USED CANNABIS IN PAST 30 DAYS, MULTICODE VARIABLES (TYPE) MUST 
CONTAIN AT LEAST ONE ANSWER. 
 
 
TITLE 'COMPARE WITH Q24, Q26, Q28, Q29, Q31'. 
 
* ///// Creates check variable (chk_q31), and set them all to 0 (Inconsistent data - check) ///// *. 
 
COMPUTE chk_q31 = 0. 
EXECUTE. 
 
FORMAT  chk_q31 (F6.0). 
 
VARIABLE LABEL chk_q31 'Chk_q31 - MC variables TYPE (Q31) most commonly used must contain at 
least one answer'.  
 
VALUE LABELS chk_q31 
1 'Pass - at least one multicode selected' 
0 'Inconsistent data - check - No variables set to 1' 
2 'Missing data - all variables Q31' 
88 'Check n/a (skipped from earlier question - Q24=Missing)' 
99 'Check not applicable (skipped from earlier question - Q24=2)' 
888 'Check n/a (skipped from earlier question - Q26=Missing)' 
999 'Check not applicable (skipped from earlier question - Q26=2)' 
8888 'Check n/a (skipped from earlier question - Q28=Missing)' 
9999 'Check not applicable (skipped from earlier question - Q28=2)' 
88888 'Check n/a (skipped from earlier question - Q29=Missing)' 
99999 'Check not applicable (skipped from earlier question - Q29=2)'. 
 
* ///// Deal with not applicables from earlier questions (working backwards) ///// *. 
 
DO IF (Q29=-9) . 
RECODE 
  chk_q31 (0=88888) . 
END IF. 
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EXECUTE. 
 
DO IF (Q29=2) . 
RECODE 
  chk_q31 (0=99999) . 
END IF. 
EXECUTE. 
 
DO IF (Q28=-9) . 
RECODE 
  chk_q31 (0=8888) . 
END IF. 
EXECUTE. 
 
DO IF (Q28=2) . 
RECODE 
  chk_q31 (0=9999) . 
END IF. 
EXECUTE. 
 
DO IF (Q26=-9) . 
RECODE 
  chk_q31 (0=888) . 
END IF. 
EXECUTE. 
 
DO IF (Q26=2) . 
RECODE 
  chk_q31 (0=999) . 
END IF. 
EXECUTE. 
 
DO IF (Q24=-9) . 
RECODE 
  chk_q31 (0=88) . 
END IF. 
EXECUTE. 
 
DO IF (Q24=2) . 
RECODE 
  chk_q31 (0=99) . 
END IF. 
EXECUTE. 
 
 
* ///// Count number of answers given ///// *. 
 
COUNT 
  cnt_q31 = Q31A Q31B Q31C Q31D Q31E Q31F Q31G Q31H Q31I  (1)  . 
EXECUTE . 
 
FORMAT  cnt_q31 (F2.0). 
 
VARIABLE LABEL cnt_q31 'Count across Q31 - number of codes selected'.  
 
 
* ///// Deal with missing values in MC question ///// *. 
 
DO IF (Q31A = -9 AND Q31B = -9 AND Q31C = -9 AND Q31D = -9 AND Q31E = -9 AND Q31F = -9 AND 
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Q31G = -9 AND Q31H = -9 AND Q31I = -9 ). 
RECODE 
  chk_q31  (0=2)  . 
END IF . 
EXECUTE . 
 
 
* ///// Do the actual check ///// *. 
 
DO IF (Q29 =1 AND cnt_q31 >= 1). 
RECODE 
  chk_q31  (0=1)  . 
END IF . 
EXECUTE . 
 
 
* ///// Show test results ///// *. 
 
FREQUENCIES 
  VARIABLES=cnt_q31 chk_q31 
  /ORDER=  ANALYSIS . 
 
 
**************************************************************************************************************. 
**************************************************************************************************************. 
**************************************************************************************************************. 
**************************************************************************************************************. 
 
 
**** CHECK M - MULTICODE VARIABLES (METHOD USED) MUST CONTAIN AT LEAST ONE 
ANSWER. 
 
TITLE 'COMPARE WITH Q24, Q26, Q27, Q28, Q29, Q32'. 
 
* ///// Creates check variable (chk_q32a), and set them all to 0 (Inconsistent data - check) ///// *. 
 
COMPUTE chk_q32 = 0. 
EXECUTE. 
 
FORMAT  chk_q32 (F5.0). 
 
VARIABLE LABEL chk_q32 'Chk_q32 - MC variables METHOD (Q32) most commonly used must contain 
at least one answer'.  
 
VALUE LABELS chk_q32 
1 'Pass - at least one multicode selected' 
0 'Inconsistent data - check - No variables set to 1' 
2 'Missing data - all variables Q32' 
88 'Check n/a (skipped from earlier question - Q24=Missing)' 
99 'Check not applicable (skipped from earlier question - Q24=2)' 
888 'Check n/a (skipped from earlier question - Q26=Missing)' 
999 'Check not applicable (skipped from earlier question - Q26=2)' 
8888 'Check n/a (skipped from earlier question - Q28=Missing)' 
9999 'Check not applicable (skipped from earlier question - Q28=2)' 
88888 'Check n/a (skipped from earlier question - Q29=Missing)' 
99999 'Check not applicable (skipped from earlier question - Q29=2)'. 
 
 
* ///// Deal with not applicables from earlier questions (working backwards) ///// *. 
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DO IF (Q29=-9) . 
RECODE 
  chk_q32 (0=88888) . 
END IF. 
EXECUTE. 
 
DO IF (Q29=2) . 
RECODE 
  chk_q32 (0=99999) . 
END IF. 
EXECUTE. 
 
DO IF (Q28=-9) . 
RECODE 
  chk_q32 (0=8888) . 
END IF. 
EXECUTE. 
 
DO IF (Q28=2) . 
RECODE 
  chk_q32 (0=9999) . 
END IF. 
EXECUTE. 
 
DO IF (Q26=-9) . 
RECODE 
  chk_q32 (0=888) . 
END IF. 
EXECUTE. 
 
DO IF (Q26=2) . 
RECODE 
  chk_q32 (0=999) . 
END IF. 
EXECUTE. 
 
DO IF (Q24=-9) . 
RECODE 
  chk_q32 (0=88) . 
END IF. 
EXECUTE. 
 
DO IF (Q24=2) . 
RECODE 
  chk_q32 (0=99) . 
END IF. 
EXECUTE. 
 
 
* ///// Count number of answers given ///// *. 
 
COUNT 
  cnt_q32 = Q32A Q32B Q32C Q32D Q32E Q32F (1)  . 
EXECUTE . 
 
FORMAT  cnt_q32 (F2.0). 
 
VARIABLE LABEL cnt_q32 'Count across q32 - number of codes selected'.  
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* ///// Deal with missing values in MC question ///// *. 
 
DO IF (Q32A = -9 AND Q32B = -9 AND Q32C = -9 AND Q32D = -9 AND Q32E = -9 AND Q32F = -9). 
RECODE 
  chk_q32  (0=2)  . 
END IF . 
EXECUTE . 
 
* ///// Do the actual check ///// *. 
 
DO IF (Q29=1 AND cnt_q32 >= 1). 
RECODE 
  chk_q32  (0=1)  . 
END IF . 
EXECUTE . 
 
 
* ///// Show test results ///// *. 
 
FREQUENCIES 
  VARIABLES=cnt_q32 chk_q32 
  /ORDER=  ANALYSIS . 
 
**************************************************************************************************************. 
**************************************************************************************************************. 
**************************************************************************************************************. 
**************************************************************************************************************. 
 
 
**** CHECK N - EVER TAKEN CANNABIS - EVER TAKEN REGULARLY MUST BE ANSWERED. 
 
TITLE 'COMPARE WITH Q24, Q26, Q133, Q134, AGE'. 
 
* ///// Creates check variable (chk_q133a), and set them all to 0 (Inconsistent data - check) ///// *. 
 
COMPUTE chk_q133a = 0. 
EXECUTE. 
 
FORMAT  chk_q133a (F3.0). 
 
VARIABLE LABEL chk_q133a 'Chk_q133a - If respondent has ever taken cannabis (Q26), ask have they 
ever taken cannabis regularly (Q133)'.  
 
VALUE LABELS chk_q133a 
1 'Pass - Q133 = Yes (and Q26=1)' 
2 'Pass - Q133 = No (and Q26=2)' 
3 'Missing data Q133' 
4 'Missing data Q134' 
0 'Inconsistent data - check' 
88 'Check n/a (skipped from earlier question - Q24=Missing)' 
99 'Check not applicable (skipped from earlier question - Q24=2)' 
888 'Check n/a (skipped from earlier question - Q26=Missing)' 
999 'Check not applicable (skipped from earlier question - Q26=2)'. 
 
 
* ///// Deal with not applicables from earlier questions (working backwards) ///// *. 
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DO IF (Q26=-9) . 
RECODE 
  chk_q133a (0=888) . 
END IF. 
EXECUTE. 
 
DO IF (Q26=2) . 
RECODE 
  chk_q133a (0=999) . 
END IF. 
EXECUTE. 
 
DO IF (Q24=-9) . 
RECODE 
  chk_q133a (0=88) . 
END IF. 
EXECUTE. 
 
DO IF (Q24=2) . 
RECODE 
  chk_q133a (0=99) . 
END IF. 
EXECUTE. 
 
 
* ///// Do the actual check ///// *. 
 
DO IF (Q26 = 1 AND Q133=1). 
RECODE 
  chk_q133a  (0=1)  . 
 ELSE IF (Q26 =1 AND Q133=2) . 
 RECODE 
   chk_q133a (0=2) . 
  ELSE IF (Q133=-9 OR Q133=-1) . 
  RECODE 
     chk_q133a (0=3). 
   ELSE IF (Q134=-9 OR Q134=-1) . 
   RECODE 
     chk_q133a (0=4). 
END IF . 
EXECUTE  
 
 
* ///// Show test results ///// *. 
 
FREQUENCIES 
  VARIABLES=chk_q133a 
  /ORDER=  ANALYSIS . 
 
 
**************************************************************************************************************. 
**************************************************************************************************************. 
**************************************************************************************************************. 
**************************************************************************************************************. 
 
 
**** CHECK O - IF IF EVER TAKEN CANNABIS REGULARLY, AGE STARTED TAKING REGULARLY 
MUST BE ANSWERED. 
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TITLE 'COMPARE WITH Q24, Q26, Q27, Q133, 134'. 
 
* ///// Creates check variable (chkq133b), and set them all to 0 (Inconsistent data - check) ///// *. 
 
COMPUTE chkq133b = 0. 
EXECUTE. 
 
FORMAT  chkq133b (F3.0). 
 
VARIABLE LABEL chkq133b 'Chkq133b - If respondent has taken cannabis regularly (Q133=1), age 
started taking cannabis regularly must be answered (Q134)'.  
 
VALUE LABELS chkq133b 
1 'Pass' 
2 'Missing data Q133 (-9 Blank)' 
3 'Missing data Q133 (-1 DK)' 
4 'Missing data Q134 (-9 Blank)' 
5 'Missing data Q134 (-1 DK)' 
0 'Inconsistent data - check' 
88 'Check n/a (skipped from earlier question - Q24=Missing)' 
99 'Check not applicable (skipped from earlier question - Q24=2)' 
888 'Check n/a (skipped from earlier question - Q26=Missing)' 
999 'Check not applicable (skipped from earlier question - Q26=2)' 
8888 'Check n/a (skipped from earlier question - Q133=Missing)' 
9999 'Check not n/a (skipped from earlier question - Q133=2)'. 
 
* ///// Deal with not applicables from earlier questions (working backwards) ///// *. 
 
DO IF (Q133=-9) . 
RECODE 
  chkq133b (0=8888) . 
END IF. 
EXECUTE. 
 
DO IF (Q133=2) . 
RECODE 
  chkq133b (0=9999) . 
END IF. 
EXECUTE. 
 
DO IF (Q26=-9) . 
RECODE 
  chkq133b (0=888) . 
END IF. 
EXECUTE. 
 
DO IF (Q26=2) . 
RECODE 
  chkq133b (0=999) . 
END IF. 
EXECUTE. 
 
DO IF (Q24=-9) . 
RECODE 
  chkq133b (0=88) . 
END IF. 
EXECUTE. 
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DO IF (Q24=2) . 
RECODE 
  chkq133b (0=99) . 
END IF. 
EXECUTE. 
 
 
* ///// The actual check (check the age first taken variable Q134 actually contains an answer) ///// *. 
 
DO IF (Q133=-9) . 
RECODE 
  chkq133b (0=2) . 
 ELSE IF (Q133=-1) . 
 RECODE 
  chkq133b (0=3) . 
  ELSE IF (Q134=-9) . 
  RECODE 
    chkq133b (0=4) . 
   ELSE IF (Q134=-1) . 
   RECODE 
     chkq133b (0=5) . 
  ELSE IF ((~SYSMIS(Q134)) AND Q133=1). 
  RECODE 
   chkq133b (0=1) . 
END IF. 
EXECUTE. 
 
 
* ///// Show test results ///// *. 
 
FREQUENCIES 
  VARIABLES=chkq133b 
  /ORDER=  ANALYSIS . 
 
 
 
**************************************************************************************************************. 
**************************************************************************************************************. 
**************************************************************************************************************. 
**************************************************************************************************************. 
 
 
**** CHECK P - IF YOU HAVE NOT TAKEN CANNABIS IN THE PAST 30 DAYS, SKIP REMAINING 
QUESTIONS. 
 
TITLE 'COMPARE WITH Q24, Q26, Q27, Q133, 134'. 
 
* ///// Creates check variable (chk_q133c), and set them all to 0 (Inconsistent data - check) ///// *. 
 
COMPUTE chk_q133c = 0. 
EXECUTE. 
 
FORMAT chk_q133c  (F3.0). 
 
VARIABLE LABEL chk_q133c 'Chk_q133c - If respondent has not taken cannabis regularly (Q133=2), 
skip remaining questions (they must be sysmis)'.  
 
VALUE LABELS chk_q133c 
0 'Inconsistent data - check' 
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1 'Pass' 
2 'Missing data Q133 (-9 Blank)' 
3 'Missing data Q133 (-1 DK)' 
4 'Check not applicable (Q133=1)' 
88 'Check n/a (skipped from earlier question - Q24=Missing)' 
99 'Check not applicable (skipped from earlier question - Q24=2)' 
888 'Check n/a (skipped from earlier question - Q26=Missing)' 
999 'Check not applicable (skipped from earlier question - Q26=2)'. 
 
 
* ///// Deal with all not applicables (working backwards) ///// *. 
 
 
DO IF (Q133=-9) . 
RECODE 
  chk_q133c (0=2) . 
 ELSE IF (Q133=-1) . 
 RECODE 
   chk_q133c (0=3). 
  ELSE IF (Q133=1). 
  RECODE 
    chk_q133c (0=4). 
END IF. 
EXECUTE. 
 
DO IF (Q26=-9) . 
RECODE 
  chk_q133c (0=888) . 
END IF. 
EXECUTE. 
 
DO IF (Q26=2) . 
RECODE 
  chk_q133c (0=999) . 
END IF. 
EXECUTE. 
 
DO IF (Q24=-9) . 
RECODE 
  chk_q133c (0=88) . 
END IF. 
EXECUTE. 
 
DO IF (Q24=2) . 
RECODE 
  chk_q133c (0=99) . 
END IF. 
EXECUTE. 
 
 
* ///// The actual check ///// *. 
 
DO IF ((Q133=2) AND (SYSMIS(Q134)) AND (SYSMIS(Q135)) AND (SYSMIS(Q136A)) AND 
(SYSMIS(Q136B)) AND (SYSMIS(Q136C)) AND (SYSMIS(Q136D)) AND (SYSMIS(Q136E)) AND 
(SYSMIS(Q136F)) AND (SYSMIS(Q136G)) AND (SYSMIS(Q136H)) AND (SYSMIS(Q136I)) AND 
(SYSMIS(Q136J)) AND (SYSMIS(Q136K)) AND (SYSMIS(Q136L)) AND (SYSMIS(Q136M)) AND 
(SYSMIS(Q136N))). 
RECODE 
   chk_q133c (0=1)  . 
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END IF . 
EXECUTE . 
 
* ///// Show test results ///// *. 
 
FREQUENCIES 
  VARIABLES=chk_q133c 
  /ORDER=  ANALYSIS . 
 
 
 
**************************************************************************************************************. 
**************************************************************************************************************. 
**************************************************************************************************************. 
**************************************************************************************************************. 
 
 
 
**** CHECK Q - IF EVER TAKEN CANNABIS REGULARLY AGE STARTED TAKING REGULARLY 
MUST BE LESS THAN OR EQUAL TO EXACT AGE. 
 
TITLE 'COMPARE WITH Q24, Q26, Q133, Q134, AGE'. 
 
* ///// Creates check variable (chkq134a), and set them all to 0 (Inconsistent data - check) ///// *. 
 
COMPUTE chkq134a = 0. 
EXECUTE. 
 
FORMAT  chkq134a (F9.0). 
 
VARIABLE LABEL chkq134a 'Chkq134a - If respondent has ever taken cannabis (Q133=1), age started 
taking cannabis regularly (Q134) must less than or equal to exact age (AGE)'.  
 
VALUE LABELS chkq134a 
1 'Pass - Age taking regularly less than exact age' 
2 'Missing data - Q134 (-1 DK)' 
3 'Missing data - Q134 (-9 Blank)' 
4 'Missing data - AGE (-1 DK)' 
5 'Missing data - AGE (-9 Blank)' 
0 'Age first taken is greater than exact age' 
88 'Check n/a (skipped from earlier question - Q24=Missing)' 
99 'Check not applicable (skipped from earlier question - Q24=2)' 
888 'Check n/a (skipped from earlier question - Q26=Missing)' 
999 'Check not applicable (skipped from earlier question - Q26=2)' 
888888 'Check n/a (skipped from earlier question - Q133=Missing)' 
999999 'Check not applicable (skipped from earlier quest - Q133=2)'. 
 
* ///// Deal with not applicables from earlier questions (working backwards) ///// *. 
 
DO IF (Q133=-9) . 
RECODE 
  chkq134a (0=888888) . 
END IF. 
EXECUTE. 
 
DO IF (Q133=2) . 
RECODE 
  chkq134a (0=999999) . 
END IF. 
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EXECUTE. 
 
DO IF (Q26=-9) . 
RECODE 
  chkq134a (0=888) . 
END IF. 
EXECUTE. 
 
DO IF (Q26=2) . 
RECODE 
  chkq134a (0=999) . 
END IF. 
EXECUTE. 
 
DO IF (Q24=-9) . 
RECODE 
  chkq134a (0=88) . 
END IF. 
EXECUTE. 
 
DO IF (Q24=2) . 
RECODE 
  chkq134a (0=99) . 
END IF. 
EXECUTE. 
 
 
* ///// Deals with dont knows and missings ///// *. 
 
DO IF (Q134 = -1). 
RECODE 
  chkq134a  (0=2)  . 
 ELSE IF (Q134 = -9) . 
 RECODE 
   chkq134a (0 = 3) . 
END IF . 
EXECUTE . 
 
 
DO IF (AGE = -1). 
RECODE 
  chkq134a  (0=4)  . 
 ELSE IF (AGE = -9) . 
 RECODE 
   chkq134a (0 = 5) . 
END IF . 
EXECUTE . 
 
 
* ///// The actual check ///// *. 
 
DO IF (Q133=1 AND Q134 <= AGE). 
RECODE 
  chkq134a  (0=1)  . 
END IF .  
EXECUTE . 
 
 
* ///// Show test results ///// *. 
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FREQUENCIES 
  VARIABLES=chkq134a 
  /ORDER=  ANALYSIS . 
 
 
**************************************************************************************************************. 
**************************************************************************************************************. 
**************************************************************************************************************. 
**************************************************************************************************************. 
 
 
**** CHECK R - IF EVER TAKEN CANNABIS REGULARLY, AGE STARTED TAKING REGULARLY 
MUST BE GREATER THAN OR EQUAL TO AGE FIRST TAKEN. 
 
 
TITLE 'COMPARE WITH Q24, Q26, Q27, Q133, Q134'. 
 
* ///// Creates check variable (chkq134b), and set them all to 0 (Inconsistent data - check) ///// *. 
 
COMPUTE chkq134b = 0. 
EXECUTE. 
 
FORMAT  chkq134b (F9.0). 
 
VARIABLE LABEL chkq134b 'Chkq134b - If respondent has ever taken cannabis (Q133=1), age started 
taking cannabis regularly (Q134) must be greater than or equal to age cannabis first taken (Q27)'.  
 
VALUE LABELS chkq134b 
1 'Pass - Age taken regularly greater than age first taken' 
2 'Missing data Q134 (-1)' 
3 'Missing data Q134 (-9)' 
4 'Missing data Q27 (-1)' 
5 'Missing data Q27 (-9)' 
0 'Age first taken is greater than age regularly taken' 
88 'Check n/a (skipped from earlier question - Q24=Missing)' 
99 'Check not applicable (skipped from earlier question - Q24=2)' 
888 'Check n/a (skipped from earlier question - Q26=Missing)' 
999 'Check not applicable (skipped from earlier question - Q26=2)' 
888888 'Check n/a (skipped from earlier question - Q133=Missing)' 
999999 'Check not applicable (skipped from earlier quest - Q133=2)'. 
 
* ///// Deal with not applicables from earlier questions (working backwards) ///// *. 
 
DO IF (Q133=-9) . 
RECODE 
  chkq134b (0=888888) . 
END IF. 
EXECUTE. 
 
DO IF (Q133=2) . 
RECODE 
  chkq134b (0=999999) . 
END IF. 
EXECUTE. 
 
DO IF (Q26=-9) . 
RECODE 
  chkq134b (0=888) . 
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END IF. 
EXECUTE. 
 
DO IF (Q26=2) . 
RECODE 
  chkq134b (0=999) . 
END IF. 
EXECUTE. 
 
DO IF (Q24=-9) . 
RECODE 
  chkq134b (0=88) . 
END IF. 
EXECUTE. 
 
DO IF (Q24=2) . 
RECODE 
  chkq134b (0=99) . 
END IF. 
EXECUTE. 
 
 
* ///// Deals with dont knows and missings ///// *. 
 
 
DO IF (Q134 = -1). 
RECODE 
  chkq134b  (0=2)  . 
 ELSE IF (Q134 = -9) . 
 RECODE 
   chkq134b (0 = 3) . 
END IF . 
EXECUTE . 
 
 
DO IF (Q27 = -1). 
RECODE 
  chkq134b  (0=4)  . 
 ELSE IF (Q27 = -9) . 
 RECODE 
   chkq134b (0 = 5) . 
END IF . 
EXECUTE . 
 
 
* ///// The actual check ///// *. 
 
DO IF (Q133=1 AND Q134 >= Q27). 
RECODE 
  chkq134b  (0=1)  . 
END IF .  
EXECUTE . 
 
 
* ///// Show test results ///// *. 
 
FREQUENCIES 
  VARIABLES=chkq134b 
  /ORDER=  ANALYSIS . 
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**************************************************************************************************************. 
**************************************************************************************************************. 
**************************************************************************************************************. 
**************************************************************************************************************. 
 
**** CHECK S - IF YOU HAVE TAKEN CANNABIS, "EVER TRIED TO STOP" MUST BE ANSWERED. 
 
 
TITLE 'COMPARE WITH Q24, Q26, Q133, Q135'. 
 
* ///// Creates check variable (chk_q135), and set them all to 0 (Inconsistent data - check) ///// *. 
 
COMPUTE chk_q135 = 0. 
EXECUTE. 
 
FORMAT  chk_q135 (F9.0). 
 
VARIABLE LABEL chk_q135 'Chk_q135 - If respondent has taken cannabis regularly (Q133=1), ever tried 
to stop (Q135) must be answered'.  
 
VALUE LABELS chk_q135 
1 'Pass' 
2 'Missing data Q135 (-9 Blank)' 
3 'Missing data Q135 (-1 DK)' 
0 'Inconsistent data - check' 
88 'Check n/a (skipped from earlier question - Q24=Missing)' 
99 'Check not applicable (skipped from earlier question - Q24=2)' 
888 'Check n/a (skipped from earlier question - Q26=Missing)' 
999 'Check not applicable (skipped from earlier question - Q26=2)' 
888888 'Check n/a (skipped from earlier question - Q133=Missing)' 
999999 'Check not applicable (skipped from earlier quest - Q133=2)'. 
 
 
* ///// Deal with not applicables from earlier questions (working backwards) ///// *. 
 
DO IF (Q133=-9) . 
RECODE 
  chk_q135 (0=888888) . 
END IF. 
EXECUTE. 
 
DO IF (Q133=2) . 
RECODE 
  chk_q135 (0=999999) . 
END IF. 
EXECUTE. 
 
DO IF (Q26=-9) . 
RECODE 
  chk_q135 (0=888) . 
END IF. 
EXECUTE. 
 
DO IF (Q26=2) . 
RECODE 
  chk_q135 (0=999) . 
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END IF. 
EXECUTE. 
 
DO IF (Q24=-9) . 
RECODE 
  chk_q135 (0=88) . 
END IF. 
EXECUTE. 
 
DO IF (Q24=2) . 
RECODE 
  chk_q135 (0=99) . 
END IF. 
EXECUTE. 
 
 
* ///// The actual check (check the age first taken variable Q135 actually contains answer) ///// *. 
 
DO IF (Q135=-9) . 
RECODE 
  chk_q135 (0=2) . 
 ELSE IF (Q135=-1) . 
 RECODE 
   chk_q135 (0=3) . 
  ELSE IF ((~SYSMIS(Q135)) AND Q133=1). 
  RECODE 
      chk_q135  (0=1)  . 
END IF . 
EXECUTE . 
 
 
* ///// Show test results ///// *. 
 
FREQUENCIES 
  VARIABLES=chk_q135 
  /ORDER=  ANALYSIS . 
 
 
 
 
**************************************************************************************************************. 
**************************************************************************************************************. 
**************************************************************************************************************. 
**************************************************************************************************************. 
 
 
**** CHECK T - IF EVER TRIED TO GIVE UP CANNABIS WHAT WAS THE REASON MUST CONTAIN 
AT LEAST ONE ANSWER. 
 
TITLE 'COMPARE WITH Q24, Q26, Q133, Q135, Q136'. 
 
* Creates check variable (chk_q136), and set them all to 0 (Inconsistent data - check). 
 
COMPUTE chk_q136 = 0. 
EXECUTE. 
 
FORMAT  chk_q136 (F9.0). 
 
VARIABLE LABEL chk_q136 'Chk_q136 - If respondent has ever tried to give up cannabis (Q135=1), MC 
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variables REASON (Q136) must contain at least one answer'.  
 
VALUE LABELS chk_q136 
2 'Missing data - all variables Q136' 
1 'Pass - at least one multicode selected' 
0 'Inconsistent data - check - No variables set to 1' 
88 'Check n/a (skipped from earlier question - Q24=Missing)' 
99 'Check not applicable (skipped from earlier question - Q24=2)' 
888 'Check n/a (skipped from earlier question - Q26=Missing)' 
999 'Check not applicable (skipped from earlier question - Q26=2)' 
888888 'Check n/a (skipped from earlier question - Q133=Missing)' 
999999 'Check not applicable (skipped from earlier quest - Q133=2)' 
8888888 'Check n/a (skipped from earlier question - Q135=Missing)' 
9999999 'Check N/A (skipped from earlier quest - Q135=2 OR 3)'. 
 
 
* ///// Deal with not applicables from earlier questions (working backwards) ///// *. 
 
 
DO IF (Q135=-9) . 
RECODE 
  chk_q136 (0=8888888) . 
END IF. 
EXECUTE. 
 
DO IF (Q135=2 OR Q135=3) . 
RECODE 
  chk_q136 (0=9999999) . 
END IF. 
EXECUTE. 
 
DO IF (Q133=-9) . 
RECODE 
  chk_q136 (0=888888) . 
END IF. 
EXECUTE. 
 
DO IF (Q133=2) . 
RECODE 
  chk_q136 (0=999999) . 
END IF. 
EXECUTE. 
 
DO IF (Q26=-9) . 
RECODE 
  chk_q136 (0=888) . 
END IF. 
EXECUTE. 
 
DO IF (Q26=2) . 
RECODE 
  chk_q136 (0=999) . 
END IF. 
EXECUTE. 
 
DO IF (Q24=-9) . 
RECODE 
  chk_q136 (0=88) . 
END IF. 
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EXECUTE. 
 
DO IF (Q24=2) . 
RECODE 
  chk_q136 (0=99) . 
END IF. 
EXECUTE. 
 
 
* ///// Count number of answers given ///// *. 
 
COUNT 
  cnt_q136 = Q136A Q136B Q136C Q136D Q136E Q136F Q136G Q136H Q136I Q136J Q136K Q136L 
Q136M Q136N (1)  . 
EXECUTE . 
 
FORMAT  cnt_q136 (F2.0). 
 
VARIABLE LABEL cnt_q136 'Count across Q136 - number of codes selected'.  
 
 
* ///// Deal with missing values in MC question ///// *. 
 
DO IF (Q136A = -9 AND Q136B = -9 AND Q136C = -9 AND Q136D = -9 AND Q136E = -9 AND Q136F = -
9 AND Q136G = -9 AND Q136H = -9 AND Q136I = -9 AND Q136J = -9 AND Q136K = -9 AND Q136L = -9 
AND Q136M = -9 AND Q136N = -9). 
RECODE 
  chk_q136  (0=2)  . 
END IF . 
EXECUTE . 
 
* ///// Do the actual check ///// *. 
 
DO IF (Q135 =1 AND cnt_q136 >= 1). 
RECODE 
  chk_q136  (0=1)  . 
END IF . 
EXECUTE . 
 
 
* ///// Show test results ///// *. 
 
FREQUENCIES 
  VARIABLES=cnt_q136 chk_q136 
  /ORDER=  ANALYSIS . 
 
 
**************************************************************************************************************. 
**************************************************************************************************************. 
**************************************************************************************************************. 
**************************************************************************************************************. 
 
 
**** CHECK U - IF USED CANNABIS IN THE PAST 12 MONTHS, HOW DID YOU GET THE DRUGS MC 
VARIABLES MUST CONTAIN ANSWER. 
 
TITLE 'COMPARE WITH Q24, Q26, Q28, Q149'. 
 
* Creates check variable (chk_q149), and set them all to 0 (Inconsistent data - check). 
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COMPUTE chk_q149 = 0. 
EXECUTE. 
 
FORMAT  chk_q149 (F4.0). 
 
VARIABLE LABEL chk_q149 'Chk_q149 - If respondent has taken cannabis during the past 12 months 
(Q28=1), MC variables GET DRUGS (Q149) must contain at least one answer'.  
 
VALUE LABELS chk_q149 
2 'Missing data - all variables Q149' 
1 'Pass - at least one multicode selected' 
0 'Inconsistent data - check - No variables set to 1' 
88 'Check n/a (skipped from earlier question - Q24=Missing)' 
99 'Check not applicable (skipped from earlier question - Q24=2)' 
888 'Check n/a (skipped from earlier question - Q26=Missing)' 
999 'Check not applicable (skipped from earlier question - Q26=2)' 
8888 'Check n/a (skipped from earlier question - Q28=Missing)' 
9999 'Check not applicable (skipped from earlier question - Q28=2)' 
 
 
* ///// Deal with not applicables from earlier questions (working backwards) ///// *. 
 
DO IF (Q28=-9) . 
RECODE 
  chk_q149 (0=8888) . 
END IF. 
EXECUTE. 
 
DO IF (Q28=2) . 
RECODE 
  chk_q149 (0=9999) . 
END IF. 
EXECUTE. 
 
DO IF (Q26=-9) . 
RECODE 
  chk_q149 (0=888) . 
END IF. 
EXECUTE. 
 
DO IF (Q26=2) . 
RECODE 
  chk_q149 (0=999) . 
END IF. 
EXECUTE. 
 
DO IF (Q24=-9) . 
RECODE 
  chk_q149 (0=88) . 
END IF. 
EXECUTE. 
 
DO IF (Q24=2) . 
RECODE 
  chk_q149 (0=99) . 
END IF. 
EXECUTE. 
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* ///// Count number of answers given ///// *. 
 
COUNT 
  cnt_q149 = Q149A Q149B Q149C Q149D Q149E Q149F Q149G (1)  . 
EXECUTE . 
 
FORMAT  cnt_q149 (F2.0). 
 
VARIABLE LABEL cnt_q149 'Count across Q149 - number of codes selected'.  
 
 
* ///// Deal with missing values in MC question ///// *. 
 
DO IF (Q149A = -9 AND Q149B = -9 AND Q149C = -9 AND Q149D = -9 AND Q149E = -9 AND Q149F = -
9 AND Q149G = -9). 
RECODE 
  chk_q149  (0=2)  . 
END IF . 
EXECUTE . 
 
* ///// Do the actual check ///// *. 
 
DO IF (Q28=1 AND cnt_q149 >= 1). 
RECODE 
  chk_q149  (0=1)  . 
END IF . 
EXECUTE . 
 
 
* ///// Show test results ///// *. 
 
FREQUENCIES 
  VARIABLES=cnt_q149 chk_q149 
  /ORDER=  ANALYSIS . 
 
 
**************************************************************************************************************. 
**************************************************************************************************************. 
**************************************************************************************************************. 
**************************************************************************************************************. 
 
 
**** CHECK V - IF USED CANNABIS IN THE PAST 12 MONTHS, WHERE DID YOU GET THE DRUGS 
MC VARIABLES MUST CONTAIN ANSWER. 
 
TITLE 'COMPARE WITH Q24, Q26, Q28, Q150'. 
 
* Creates check variable (chk_q150), and set them all to 0 (Inconsistent data - check). 
 
COMPUTE chk_q150 = 0. 
EXECUTE. 
 
FORMAT  chk_q150 (F4.0). 
 
VARIABLE LABEL chk_q150 'Chk_q150 - If respondent has taken cannabis during the past 12 months 
(Q28=1), MC variables WHERE get drugs (Q150) must contain at least one answer'.  
 
VALUE LABELS chk_q150 
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1 'Pass - at least one multicode selected' 
2 'Missing data - all variables Q150' 
0 'Inconsistent data - check - No variables set to 1' 
88 'Check n/a (skipped from earlier question - Q24=Missing)' 
99 'Check not applicable (skipped from earlier question - Q24=2)' 
888 'Check n/a (skipped from earlier question - Q26=Missing)' 
999 'Check not applicable (skipped from earlier question - Q26=2)' 
8888 'Check n/a (skipped from earlier question - Q28=Missing)' 
9999 'Check not applicable (skipped from earlier question - Q28=2)' 
 
 
* ///// Deal with not applicables from earlier questions (working backwards) ///// *. 
 
DO IF (Q28=-9) . 
RECODE 
  chk_q150 (0=8888) . 
END IF. 
EXECUTE. 
 
DO IF (Q28=2) . 
RECODE 
  chk_q150 (0=9999) . 
END IF. 
EXECUTE. 
 
DO IF (Q26=-9) . 
RECODE 
  chk_q150 (0=888) . 
END IF. 
EXECUTE. 
 
DO IF (Q26=2) . 
RECODE 
  chk_q150 (0=999) . 
END IF. 
EXECUTE. 
 
DO IF (Q24=-9) . 
RECODE 
  chk_q150 (0=88) . 
END IF. 
EXECUTE. 
 
DO IF (Q24=2) . 
RECODE 
  chk_q150 (0=99) . 
END IF. 
EXECUTE. 
 
 
* ///// Count number of answers given ///// *. 
 
COUNT 
  cnt_q150 = Q150A Q150B Q150C Q150D Q150E Q150F Q150G Q150H Q150I (1)  . 
EXECUTE . 
 
FORMAT  cnt_q150 (F2.0). 
 
VARIABLE LABEL cnt_q150 'Count across Q150 - number of codes selected'.  
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* ///// Deal with missing values in MC question ///// *. 
 
DO IF (Q150A = -9 AND Q150B = -9 AND Q150C = -9 AND Q150D = -9 AND Q150E = -9 AND Q150F = -
9 AND Q150G = -9 AND Q150H = -9 AND Q150I = -9). 
RECODE 
  chk_q150  (0=2)  . 
END IF . 
EXECUTE . 
 
 
* ///// Do the actual check ///// *. 
 
DO IF (Q28=1 AND cnt_q150 >= 1). 
RECODE 
  chk_q150  (0=1)  . 
END IF . 
EXECUTE . 
 
 
* ///// Show test results ///// *. 
 
FREQUENCIES 
  VARIABLES=cnt_q150 chk_q150 
  /ORDER=  ANALYSIS . 
 
 
**************************************************************************************************************. 
**************************************************************************************************************. 
**************************************************************************************************************. 
**************************************************************************************************************. 
 
 
**** CHECK W - IF USED CANNABIS IN THE PAST 12 MONTHS, HOW EASY IS IT TO GET? 
 
TITLE 'COMPARE WITH Q24, Q26, Q28, Q151A'. 
 
* ///// Creates check variable (chkq151), and set them all to 0 (Inconsistent data - check) ///// *. 
 
COMPUTE chkq151a = 0. 
EXECUTE. 
 
FORMAT  chkq151a (F4.0). 
 
VARIABLE LABEL chkq151a 'Chkq151a - If respondent has taken cannabis in the past 12 months 
(Q28=1), how easy is it to get? (Q151A)'.  
 
Value Labels chkq151a 
1 'Pass' 
2 'Missing data Q151A (-9 Blank)' 
3 'Missing data Q151A (-1 DK)' 
0 'Inconsistent data - check' 
88 'Check n/a (skipped from earlier question - Q24=Missing)' 
99 'Check not applicable (skipped from earlier question - Q24=2)' 
888 'Check n/a (skipped from earlier question - Q26=Missing)' 
999 'Check not applicable (skipped from earlier question - Q26=2)' 
8888 'Check n/a (skipped from earlier question - Q28=Missing)' 
9999 'Check not applicable (skipped from earlier question - Q28=2)'. 
NACD/DAIRU – 2002/2003 Drug Prevalence Survey – Technical Report 
Appendix N 
274 
 
 
* ///// Deal with not applicables from earlier questions (working backwards) ///// *. 
 
DO IF (Q28=-9) . 
RECODE 
  chkq151a (0=8888) . 
END IF. 
EXECUTE. 
 
DO IF (Q28=2) . 
RECODE 
  chkq151a (0=9999) . 
END IF. 
EXECUTE. 
 
DO IF (Q26=-9) . 
RECODE 
  chkq151a (0=888) . 
END IF. 
EXECUTE. 
 
DO IF (Q26=2) . 
RECODE 
  chkq151a (0=999) . 
END IF. 
EXECUTE. 
 
DO IF (Q24=-9) . 
RECODE 
  chkq151a (0=88) . 
END IF. 
EXECUTE. 
 
DO IF (Q24=2) . 
RECODE 
  chkq151a (0=99) . 
END IF. 
EXECUTE. 
 
 
* ///// The actual check (check the age first taken variable (Q151) actually contains an answer) ///// *. 
 
DO IF (Q151a=-9) . 
RECODE 
  chkq151a (0=2) . 
 ELSE IF (Q151a=-1) . 
 RECODE 
   chkq151a (0=3) . 
  ELSE IF ((~SYSMIS(Q151a)) AND Q28=1). 
  RECODE 
      chkq151a  (0=1)  . 
END IF . 
EXECUTE . 
 
 
* ///// Show test results ///// *. 
 
FREQUENCIES 
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  VARIABLES=chkq151a 
  /ORDER=  ANALYSIS . 
 
 
 
 
 
 
 
